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Rare diseases, when considered as a whole, affect up to 7% of the population, which 
would represent 3.5 million individuals in the United Kingdom alone. However, while 
“personalised medicine” is now yielding remarkable results using recent sequencing 
technologies in terms of diagnosing genetic conditions, we have made much less 
headway in translating this patient information into therapies and effective treatments. 
Even with recent calls for greater research into personalised treatments for those 
affected by a rare disease, progress in this area is still severely lacking, in part due to 
the astronomical cost and time involved in bringing treatments to the clinic. 
Gene correction using the recently-described genome editing technology 
CRISPR/Cas9, which allows precise editing of DNA, offers an exciting new avenue 
of treatment, if not cure, for rare diseases; up to 80% of which have a genetic 
component. This system allows the researcher to target any locus in the genome for 
cleavage with a short guide-RNA, as long as it precedes a highly ubiquitous NGG 
sequence motif. If a repair sequence is then also provided, such as a wild-type copy of 
the mutated gene, it can be incorporated by homology-directed repair (HDR), leading 
to gene correction. As both guide-RNA and repair template are easily generated, whilst 
the machinery for editing and delivery remain the same, this system could usher in the 
era of ‘personalised medicine’ and offer hope to those with rare genetic diseases. 
However, currently it is difficult to test the efficacy of CRISPR/Cas9 for gene 
correction, especially in vivo. 
Therefore, in my PhD I have developed a novel fluorescent reporter system which 
provides a rapid, visual read-out of both non-homologous end joining (NHEJ) and 
homology-directed repair (HDR) driven by CRISPR/Cas9. This system is built upon 
a cassette which is stably and heterozygously integrated into a ubiquitously expressed 
locus in the mouse genome. This cassette contains a strong hybrid promoter driving 
expression of membrane-tagged tdTomato, followed by a strong stop sequence, and 
then membrane-tagged EGFP. Unedited, this system drives strong expression of 
membrane-tdTomato in all cell types in the embryo and adult mouse. However, 
following the addition of CRISPR/Cas9 components, and upon cleavage, the tdTomato 
is rapidly excised, resulting via NHEJ either in cells without fluorescence (due to 
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imperfect deletions) or with membrane-EGFP. If a repair template containing nuclear 
tagged-EGFP is also supplied, the editing machinery may then use the precise HDR 
pathway, which results in a rapid transition from membrane-tdTomato to nuclear-
EGFP. Thereby this system allows the kinetics of editing to be visualised in real time 
and allows simple scoring of the proportion of cells which have been edited by NHEJ 
or corrected by HDR. It therefore provides a simple, fast and scalable manner to 
optimise reagents and protocols for gene correction by CRISPR/Cas9, especially 
compared to sequencing approaches, and will prove broadly useful to many 
researchers in the field.  
Further to this, I have shown that methods which lead to gene correction in our reporter 
system are also able to partially repair mutations found in the disease-causing gene, 
Zmynd10; which is implicated in the respiratory disorder primary ciliary dyskinesia 
(PCD), for which there is no effective treatment. PCD is an autosomal-recessive rare 
disorder affecting motile cilia (MIM:244400), which results in impaired mucociliary 
clearance leading to neonatal respiratory distress and recurrent airway infections, often 
progressing to lung failure. Clinically, PCD is a chronic airway disease, similar to CF, 
with progressive deterioration of lung function and lower airway bacterial 
colonization. However, unlike CF which is monogenic, over 40 genes are known to 
cause PCD. The high genetic heterogeneity of this rare disease makes it well suited to 






While “personalised medicine” has recently come into its own and allowed clinicians 
to provide many patients suffering from rare genetic conditions with a diagnosis, we 
have made much less headway in translating this information into therapies and 
successful therapeutics. In the case of the rare respiratory disease primary ciliary 
dyskinesia (PCD), genetic mutations have been identified in nearly 40 genes and yet 
there is still no effective treatment for this debilitating condition; mostly due to the 
astronomical cost in bringing therapies to clinic. PCD patients suffer from a lifelong, 
severe and progressive lung disorder, which urgently requires the development of an 
effective and aggressive intervention. The recent game-changer for rare human genetic 
disease is the possibility of gene correction using targeted “molecular scissors” which 
allow precise and efficient editing of our DNA sequence. This powerful technology 
can accurately cut out the disease-causing sequence of DNA and paste a correct copy 
in its place. If this occurs in the right cell types, this technology offers the possibility 
of a cure for genetic diseases like PCD. The biggest obstacles to making this a reality 
are (a) targeted delivery of this machinery and (b) making it more efficient at repair.  
To fast-track solutions to these problems, I have developed a fluorescent reporter 
mouse model that allows us to sensitively visualise gene-correction events within our 
bodies. Using this model we can quickly and accurately see under the microscope 
which cells we have corrected and how many. In this way, it will allow researchers to 
rapidly optimise approaches for gene correction in a live model, which was previously 
impossible. Furthermore, I have optimised a toolkit containing several types of gene 
editing reagents which can be delivered to any cell type in the body; which can 
themselves be grown in culture outside the reporter mouse. Using this reporter, I have 
determined that (1) the motile-ciliated cell types which are affected in PCD can be 
edited; (2) that the editing we see by fluorescence is an accurate read-out of changes 
in the DNA sequence and (3) that the reporter provides a rapid read-out of these genetic 
changes. Furthermore, I have also tested whether these gene-editing tools can be 
improved by adding small molecules which alter DNA repair pathways. 
As a result of my thesis work, the lab is ready to test these optimised reagents in live 
reporter mice and their embryos, with the ultimate goal of using the tools to correct 
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the defects found in mice with PCD. It is our hope that our corrective gene-editing 
strategy for PCD would intervene early to limit the damage caused by recurrent 
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Chapter 1 Introduction - The Therapeutic Application of 
Genome Editing for Rare Genetic Respiratory Diseases 
1.1 Rare Diseases 
Rare diseases are defined by their limited life-time prevalence in a population, with 
various international bodies outlining their own parameters for classification. In the 
United States, for example, a disease is considered rare when it affects less than 
200,000 individuals (U.S. Food and Drug Administration 2017), whereas in the 
European Union (EU), a rare disease is seen to affect less than 1 in 2,000 citizens 
(European Organisation for Rare Diseases 2005). Despite this variation, as over 5,800 
rare diseases are currently listed on the web portal Orphanet (www.orpha.net/, 
accessed 05/02/2018), considered as a whole, they will come to affect a large 
proportion of the population. Indeed, in the EU in 2005, it was estimated 
approximately 30 million individuals suffered from a rare disease, or 6 to 8% of the 
total population (European Organisation for Rare Diseases 2005). 
Patients suffering from a rare disease are disadvantaged compared to sufferers of more 
common conditions in several ways. Firstly, there is often a significant delay between 
a patient initially presenting to a medical practitioner and them receiving a correct 
diagnosis, often on the scale of years. This is partly due to a lack of knowledge and 
awareness, but also since the presence of many of these conditions can only be 
confirmed after genetic testing (Pogue, Cavalcanti et al. 2018). Indeed, up to 80% of 
rare diseases are believed to have a genetic component (European Organisation for 
Rare Diseases 2005), and 3573 genes are listed as associated with rare diseases on 
Orphanet (www.orpha.net/, accessed 08/02/2018). Recent advances in sequencing 
technologies have partially improved diagnoses for patients but have also lead to a 
substantial increase in the number of genes implicated each year. Even with a correct 
diagnosis, given the rarity of each condition, there may be very few physicians 
available with the skills to treat the condition of interest (Pogue, Cavalcanti et al. 
2018).  Treatment options are then further limited as pharmaceutical companies are 
generally unwilling to invest in rare disease drug development, due to the high costs 
and small market size involved. Currently, 400 drugs are licensed in the US for treating 
33 
 
rare conditions, covering only 5% of the rare disease burden (Zhao and Wei 2017), 
and each of these treatments is often prohibitively expensive (European Organisation 
for Rare Diseases 2005). 
Given the severely limited therapeutic options for rare diseases, governmental bodies 
have rallied behind improved access to current treatments and the development of 
novel therapeutics (Gammie, Lu et al. 2015). In particular, the United Kingdom (UK) 
has published a comprehensive strategy for rare diseases. This strategy sets ten goals 
which are to be achieved by 2020, including the establishment of specialised clinical 
centres for care, the promotion of research into rare diseases, including collaboration 
with the NHS (National Health Service), and the rapid translation of advances in 
understanding through novel infrastructure.  Furthermore, this strategy recognises the 
impact next-generation sequencing (NGS) technologies will have on reducing the cost 
of genetic diagnosis, and in identifying novel causative genes. As such, it recommends 
the adoption of NGS into mainstream diagnosis pathways by 2020 (UK Department 
of Health 2013). 
1.2 Next-Generation Sequencing and Genetic Diagnosis 
Prior to the development of NGS technologies, genetic diagnosis was performed on a 
gene-by-gene basis using Sanger sequencing, affording a very limited power of 
detection, especially for conditions associated with multiple genes. However, with 
advancements in sequencing capacities, it became possible to simultaneously sequence 
several disease-causing genes in a ‘gene panel’, and then later perform whole exome 
sequencing (WES) relatively inexpensively (Caspar, Dubacher et al. 2017), with the 
potential to detect 85% of known disease-causing mutations (Choi, Scholl et al. 2009). 
However, the current gold-standard for diagnosis is whole genome sequencing (WGS), 
which has been shown to more accurately detect copy number variations (CNVs), 
indels and single nucleotide variants (SNVs) (Soden, Saunders et al. 2014, Meienberg, 
Bruggmann et al. 2016, Stavropoulos, Merico et al. 2016), as well as affording the 
possibility of detecting mutations in non-exonic, regulatory regions. While the average 
price of WGS is still relatively high, it is rapidly falling and expected to be below 
$5,000 per patient by 2020, although advancements in data analysis will need to be 
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made to prevent this becoming a time and cost limitation (Weymann, Laskin et al. 
2017). 
Currently, the majority of WES and WGS tests are carried out using short-read 
sequencing (SRS) techniques. In SRS, the input DNA is randomly sheared into 100-
400bp fragments followed by adapter ligation and massively parallel sequencing. The 
current market leader in this field is Illumina, with Ion Torrent (Thermo Fisher) being 
a significant competitor (Caspar, Dubacher et al. 2017), both using variations of a 
‘sequencing by synthesis’ approach (Goodwin, McPherson et al. 2016). In Illumina 
sequencing, reversible terminators are employed to allow the sequential addition of 
single, fluorescently-tagged nucleotides which can be detected by laser illumination. 
Following detection, the fluorescent dyes are removed, creating a new 3’-OH and 
allowing the addition of the next tagged nucleotide. In repeating these steps, a whole 
fragment can be sequenced with high accuracy (Figure 1.1A) (Ambardar, Gupta et al. 
2016). In Ion Torrent sequencing, adapter-ligated fragments are fixed in micro-wells 
and then nucleotide species are sequentially washed over the wells. Upon 
incorporation of a base, an H+ ion is released resulting in a change in pH which is 
detected by a complementary metal-oxide semiconductor (CMOS) and an ion-
sensitive field-effect transistor (ISFET) device (Figure 1.1B) (Goodwin, McPherson 
et al. 2016). One disadvantage of this approach is its imprecision in quantifying the 
number of bases in homopolymer stretches, based on the intensity of the pH signal, 
leading to a characteristic error profile (Ambardar, Gupta et al. 2016). 
More recently, third-generation, or long-read sequencing (LRS), approaches have been 
described which may overcome the issues SRS has in detecting variants in repetitive 
regions, due to the challenge of short read alignment (Caspar, Dubacher et al. 2017). 
There are currently two main players in the LRS field, PacBio with their single-
molecule real-time sequencing (SMRT) approach, and Oxford Nanopore Technologies 
with single-molecule nanopore sequencing. In SMRT, a high-fidelity DNA 
polymerase is immobilised in a zero-mode waveguide (ZMW), a microscopic pore 
which allows the visualisation of individual fluorescent nucleotides. The DNA 
polymerase is then specifically illuminated, allowing detection of fluorescently-
labelled nucleotides as they are incorporated (Figure 1.2A) (Ambardar, Gupta et al. 
2016). This method can produce reads of up to 10kb, although with an ~10% error rate 
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(Nagarajan and Pop 2013). The alternative platform, the Oxford Nanopore MinION, 
makes use of a proprietary DNA helicase which ‘feeds’ single-stranded DNA through 
a proprietary protein pore which is fixed in a polymer membrane. A current is passed 
through the membrane, and as each base travels through the pore its unique shape 
creates a characteristic disturbance in the current which can be recorded (Ambardar, 
Gupta et al. 2016) (Figure 1.2B). Currently, MinION reads have a similar length 
distribution and slightly higher error rate than SMRT reads (Lu, Giordano et al. 2016), 
although MinION sequencing is significantly easier to perform, with minimal sample 
preparation and the only equipment required being a USB-sized device (Ambardar, 
Gupta et al. 2016). Planned future updates to the MinION system should significantly 
reduce the error rate and increase throughput (Next Gen Seek 2016), which may 
potentially lead to a paradigm shift in NGS, allowing WGS in the space of a few hours 




Figure 1.1 (on previous page): Comparison of short-read sequencing technologies 
from Illumina and Thermo Fisher (Ion Torrent). A) Illumina: Templates are 
hybridised to slides and then amplified. Primers and DNA polymerase are added to the 
flow cell. Terminally blocked, fluorescently-labelled nucleotides are then added, 
resulting in the incorporation of a single base. Unincorporated bases are removed by 
washing and the slide is illuminated. The fluorescent dye is then cleaved, regenerating 
the 3’-OH and allowing the addition of another terminally blocked nucleotide in the 
next cycle. B) Ion Torrent: Templates are PCR amplified on beads, which are placed 
individually into micro-wells. Nucleotide species are sequentially added to the wells. 
Upon base incorporation, the H+ release results in a change in pH which is detected by 
an integrated complementary metal-oxide semiconductor (CMOS) and an ion-
sensitive field-effect transistor (ISFET) device. Adapted from Goodwin, McPherson 
et al. (2016). 
 
Figure 1.2: Comparison of long-read sequencing (LRS) technologies. A) SMRT 
sequencing: 1) fluorescently-tagged nucleotides are added to the ZMW; 2) the DNA 
polymerase immobilises the incorporated base in the detection volume; 3) the attached 
fluorescent dye is released upon phosphate chain cleavage; and 4–5) the process is 
repeated. Taken from Clinical Lab Products (2017). B) Nanopore sequencing: The 
unwinding enzyme passes the single-stranded DNA through a protein pore in a charged 
membrane. Disturbances in the membrane caused by the translocation of nucleotides 




1.3 Gene Therapy 
With the advancements in NGS technologies, we will continue to detect ever greater 
numbers of disease-causing mutations. Gene therapy, using various vectors to transfer 
a wild-type copy of a mutated gene into affected cells, offers the potential to 
permanently functionally correct mutations that do not have a dominant-negative 
effect, as opposed to drug treatments which require repeated dosing (Dunbar, High et 
al. 2018). Furthermore, a gene therapy approach will be applicable to all mutations 
found in a gene, whereas the efficacy of drugs will likely depend on the exact mutation.  
As nucleic acids are anionic polymers, they cannot interact with negatively charged 
plasma membranes, and as such require synthetic vectors to allow delivery into cells 
(Mottais, Le Gall et al. 2017). A substantial amount of research has therefore been 
dedicated to identifying and optimising delivery vectors for gene therapy, with the 
ideal vector often depending on the gene and tissue of interest. As the subject of this 
thesis is rare respiratory diseases, I shall focus on gene therapy of the lung. 
Much of the work done on gene delivery to the pulmonary epithelium has been 
focussed on the rare, autosomal-recessive disease cystic fibrosis (CF), which is caused 
by mutations in a single gene, the cystic fibrosis transmembrane conductance regulator 
(CFTR). Defects in the chloride channel CFTR lead to the production of thick, sticky 
mucus in the airways and obstructive lung disease which is fatal in ~80% of cases, 
with an average life expectancy of 37 years (Cutting 2014). Recent clinical trials have 
demonstrated success using the liposome GL67A and plasmid pGM169 in delivering 
CFTR to the airways, although the improvement in lung function was very modest 
(Alton, Armstrong et al. 2015). The airways have a complex, branching structure, and 
in order to reach the cell layer, therapeutics also have to penetrate a layer of mucus 
and the periciliary layer (PCL) (Figure 1.3). Furthermore, in a disease state such as 
cystic fibrosis, the mucus layer is substantially thickened, and may contain interacting 
particles such as cellular debris, DNA and bacteria, which will all reduce efficiencies 
(Mottais, Le Gall et al. 2017). Therefore, it may be necessary to move to a viral vector 
approach to achieve high transgene expression, exploiting the natural ability of viruses 





Figure 1.3: Diagrammatic representation of the human airway, showing the 
branching structure present. Within the airway, target cells are covered by the 
airway surface liquid. Taken from Mottais, Le Gall et al. (2017).  
The two virus types which currently show the most promise in gene therapy of the 
lung are lentivirus, specifically the HIV-1 strain, and adeno-associated virus (AAV). 
Lentiviral vectors have a packaging capacity of ~8kb, are able to transduce non-
dividing cells, and provide efficient transgene expression (Castellani and Conese 
2010). Furthermore, adaptations to produce self-inactivating (SIN), or replication-
incompetent lentiviral vectors, have made them largely bio-safe (Miyoshi, Blömer et 
al. 1998, Zufferey, Dull et al. 1998).  Unfortunately, whilst their safety profile is good, 
most pseudotypes display a limited ability to transduce a fully differentiated 
epithelium, unless agents that disrupt tight-junctions are simultaneously applied 
(Castellani and Conese 2010), although they may be effective in a neonatal or fetal 
context (Buckley, Howe et al. 2008). To overcome this barrier, it has been shown that 
efficient transduction of the respiratory epithelium via the apical side without 
conditioning can be achieved by pseudotyping the Simian Immunodeficiency Virus 
(SIV) with  envelope proteins (F and HN) from Sendai virus to produce F/HN-SIV 
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(Mitomo, Griesenbach et al. 2010, Griesenbach, Inoue et al. 2012). Importantly, F/HN-
SIV was shown to be permissive to repeat administration in the mouse, with increased 
expression depending on dose (approximately twice that of the non-viral formulation) 
and no discernible toxicity. Furthermore, it gave persistent expression in human lung 
slices and airway epithelial cells (Griesenbach, Inoue et al. 2012). This vector has 
thence been shown to drive expression in ~15% of the target epithelial cells in mouse 
(c.f. with the 5-10% correction believed to be required to reverse the CF defect 
(Castellani and Conese 2010)), with no apparent effect from pre-existing immunity, 
and therefore has recently been recommended for progression into human trials (Alton, 
Beekman et al. 2017).  
Alongside lentivirus, much current research is directed at the use of AAV vectors. 
AAV is naturally non-pathogenic in humans, replication-defective and largely non-
integrating, which makes it attractive for gene therapy approaches, although one 
drawback is its small packaging capacity, at ~4.7kb, which limits its use for larger 
genes (Dunbar, High et al. 2018). However, as demonstrated with CFTR (Zhang, 
Wang et al. 1998, Wang, Fischer et al. 1999), it may be possible to produce truncated 
versions of genes which still drive high expression levels. AAV exists in nine naturally 
occurring serotypes, of which AAV6 has been shown to drive the highest levels of 
transgene expression in the murine respiratory epithelium and normal human primary 
bronchial epithelial cells (NHBE) (Kurosaki, Uchibori et al. 2017). Moreover, AAV 
genomes and capsid proteins can be recombined; the combination AAV2/5 (AAV2 
genome and AAV5 capsid proteins) has been discovered to also drive high levels of 
expression in human intestinal organoids and the mouse lung (Vidović, Carlon et al. 
2015). Further increases may be seen in efficiencies by directed evolution of the capsid 
proteins, as has shown promise in the CF pig (Sus domesticus) (Steines, Dickey et al. 
2016). Alternatively, the AAV genome can also be packaged in other capsids, such as 
that of human bocavirus type 1 (HBoV1). The HBoV1 capsid offers a larger packaging 
capacity of ~5.5kb, while also efficiently transducing the human airway epithelium via 
the apical membrane (Yan, Feng et al. 2017). However, work still needs to be done in 
translating these recent advances clinically for the treatment of diseases such as CF 
(Guggino and Cebotaru 2017). 
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1.4 Gene Correction by Site-Specific Nucleases 
As an alternative to the above gene therapy by gene transfer approaches, the discovery 
and characterisation of several site-specific nucleases (SSNs) has afforded the novel 
possibility of directly correcting mutated genes in situ, eliminating the chance of 
insertional mutagenesis and leaving a gene which will be controlled by its native 
promoters and enhancers. In addition, this approach may show particular promise in 
treating diseases caused by dominant negative mutations, such as HTT in Huntington’s 
disease, which are un-targetable by gene addition, due to the efficiency at which these 
tools can ‘knock-out’ their target genes (Cox, Platt et al. 2015). Furthermore, it 
circumvents the limited packaging capacities of viral vectors, allowing the targeting 
of genes, and diseases, which were previously unfeasible. 
SSNs are targeted to a specific sequence in the genome, whereupon their nuclease 
domains create a double-strand break (DSB). This DSB is generally repaired by one 
of two major cellular DSB repair pathways; non-homologous end joining (NHEJ) or 
homology-directed repair (HDR). NHEJ is template-independent and error-prone, 
allowing the creation of mutations and ‘knock-outs’, whereas HDR depends on the 
presence of a repair template and can elicit precise, bespoke changes (Cox, Platt et al. 




Figure 1.4: The application of site-specific nucleases for therapeutic genome 
editing. A) An SSN is targeted to a disease-causing gene/mutation, where it creates a 
DSB. This DSB is repaired by NHEJ, resulting in the formation of an indel and the 
production of a non-functional/degraded protein. B) An insertion is targeted on either 
side by two SSNs, resulting in cleavage which removes the fragment and the resulting 
locus is repaired by NHEJ. C) If a corrective repair template is supplied alongside an 
SSN, it may be incorporated by the HDR pathway resulting in the production of a 
correct gene copy (‘gene correction’). Adapted from Cox, Platt et al. (2015). 
The first SSN system described was based on the use of an array of zinc-fingers (ZnFs), 
a common DNA-triplet-binding motif found in eukaryotes, which was linked to the 
bacterial endonuclease FokI to create zinc-finger nucleases (ZFNs). While ZFNs were 
specific and efficacious, their uptake was limited due to the requirement to re-engineer 
and validate each array, a costly and time-consuming process. Following ZFNs, a new 
modality emerged upon the discovery of transcription activator-like effectors 
(TALEs). TALEs are formed of 33-35bp repetitive DNA-binding domains which each 
recognise a single nucleotide. Unlike ZFNs, the DNA-binding domains of TALEs are 
modular and can be easily combined to target any sequence in the genome. 
Furthermore, a nuclease can be attached to the TALE to form a TALEN, allowing 
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directed cleavage. As both approaches can be designed to require a significant amount 
of homologous sequence (>30bp) for cleavage, they are highly specific in the human 
genome (Gaj, Gersbach et al. 2013) (Figure 1.5). Furthermore, both ZFNs and 
TALENs have shown promise in clinical translation.  ZNFs have recently been used 
to render CD4 T cells resistant to HIV infection by mutating its receptor CCR5. On 
infusion of CD4 T cells back into patients, levels of HIV dropped and in one case 
became undetectable (Tebas, Stein et al. 2014). TALENs have been employed in a 
similar ex vivo approach, and used to autologously edit T cells to express a chimeric 
antigen receptor (CAR) against the leukaemia antigen CD19. Upon re-infusion into 
two patients, marked remissions were observed (Qasim, Zhan et al. 2017). However, 
the therapeutic application of SSN-mediated genome editing is still in its infancy. 
 
Figure 1.5: Diagrammatic representation of zinc-finger nuclease (ZFN) and 
TALEN dimers bound to DNA. A) ZFNs: left and right zinc-finger proteins (ZFPs) 
are designed to target a 5-7bp sequence recognised by the FokI cleavage domain. B) 
33-35bp TALE repeats bind in a base-specific manner due to two repeat-variable di-
residues (RVDs). Left and right TALEN target sites are separated by a spacer sequence 
(12-20bp). RVD compositions are indicated. Adapted from Gaj, Gersbach et al. 
(2013). 
1.5 The CRISPR/Cas9 System 
While ZFNs and TALENs have shown promise in therapeutic genome editing, their 
use has been rapidly superseded by the recently-described CRISPR/Cas9 system for 
genome editing. CRISPR, short for clustered regularly interspaced short palindromic 
repeats, was originally used to describe functionally obscure repetitive arrays which 
were found in the genomes of most prokaryotes. These arrays were invariably found 
to associate with four CRISPR-associated, or Cas proteins, which were absent in 
CRISPR-negative species (Jansen, Embden et al. 2002). Later, it was found that these 
arrays contained invasive DNA sequences termed ‘spacers’ (Bolotin, Quinquis et al. 
2005, Mojica, Diez-Villasenor et al. 2005), that these spacers could be gained upon 
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phage adaptation (Pourcel, Salvignol et al. 2005, Barrangou, Fremaux et al. 2007), and 
that they were required, together with the Cas proteins, for phage resistance 
(Barrangou, Fremaux et al. 2007). Therein, the CRISPR/Cas system was found to be 
a form of prokaryotic immune system. Soon after, it was found that DNA is the target 
of CRISPR/Cas (Marraffini and Sontheimer 2008), that target sites are always 
followed by a conserved protospacer adjacent motif (PAM) (Mojica, Diez-Villasenor 
et al. 2009) and that Cas9 is an endonuclease which cleaves DNA precisely 3nt from 
the 5’ end of the PAM (Garneau, Dupuis et al. 2010). 
Today, many different CRISPR/Cas systems have been described, although the best 
characterised is the CRISPR/Cas9 system from Streptococcus pyogenes (spCas9). It 
was shown that the non-coding CRISPR RNAs (crRNAs) required by spCas9 for 
cleavage could be combined into a (single) guide-RNA (sgRNA/gRNA), and that these 
gRNAs could be employed to direct Cas9 cleavage in vitro (Jinek, Chylinski et al. 
2012). Soon after this discovery, two groups demonstrated that this system could be 
adapted for efficient, RNA-guided genome editing in mammalian cells (Cong, Ran et 
al. 2013, Mali, Yang et al. 2013), and that all the components necessary for editing 
could be delivered effectively on a single plasmid, with the only requirement being to 
clone in a specific 20bp ‘target sequence’ (Mali, Yang et al. 2013, Ran, Hsu et al. 
2013). The ease-of-use and low cost of this system, combined with its comparable or 
higher efficiency than TALENs (Cong, Ran et al. 2013, Mali, Yang et al. 2013), has 
led to an explosion of publications in the genome editing field in recent years (Stella 
and Montoya 2016). 
1.5.1 Off-Target Editing with the CRISPR/Cas9 System 
The CRISPR/Cas9 system functions similarly to ZFNs and TALENs, in that it creates 
a DSB which is repaired by the cellular machinery, resulting in NHEJ or HDR (Figure 
1.4). However, unlike the other two systems, Cas9 creates a DSB on binding only one 
strand with a 20nt target sequence (Figure 1.6A), of which it initially appeared only 8-
12bp was required for cleavage (Jinek, Chylinski et al. 2012, Cong, Ran et al. 2013). 
This would afford much less specificity than is seen with ZFNs or TALENs, raising 
fears of off-target cleavage and mutagenesis. Subsequently, a high rate of off-target 
mutagenesis was indeed detected in human cells with spCas9 (Fu, Foden et al. 2013, 
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Hsu, Scott et al. 2013). To address this issue, a ‘nickase’ version of Cas9 (Cas9n) was 
developed (Cong, Ran et al. 2013) which needs to be targeted to two adjacent target 
sites to produce a DSB (Figure 1.6B). This approach was found to offer similar 
on-target editing efficiencies to wild-type Cas9, in terms of NHEJ and HDR, with 50- 
to 1000-fold reduced off-target mutagenesis (Ran, Hsu et al. 2013). However, this 
approach also severely limits the number of potential on-target sites in the genome. 
Recently, a significant amount of research has been carried out to address the issue of 
off-target mutagenesis. Several online tools have been developed to bioinformatically 
predict off-target sites in the genome, such as GuideScan (Perez, Pritykin et al. 2017), 
CRISPOR (Haeussler, Schönig et al. 2016) and Cas-OFFinder (Bae, Park et al. 2014), 
allowing guides with likely off-targets to be avoided. Furthermore, a wide array of 
sequencing approaches have been performed to attempt to quantitate and characterise 
the off-target profile of Cas9, including targeted sequencing based on off-target 
predictions (Fu, Foden et al. 2013, Hsu, Scott et al. 2013), ChIP-seq to sequence 
regions bound by Cas9  (Duan, Lu et al. 2014, Kuscu, Arslan et al. 2014, Wu, Scott et 
al. 2014, O'Geen, Henry et al. 2015), whole genome sequencing  (Smith, Gore et al. 
2014, Veres, Gosis et al. 2014), and ‘unbiased’ approaches for mapping and 
sequencing DSBs (Crosetto, Mitra et al. 2013, Tsai, Zheng et al. 2014, Kim, Bae et al. 
2015). Whilst varied, generally these efforts have shown that the rates of off-target 
mutagenesis driven by Cas9 are substantially lower than feared with most guides 
(Duan, Lu et al. 2014, Smith, Gore et al. 2014, Veres, Gosis et al. 2014, Wu, Scott et 
al. 2014, Kim, Bae et al. 2015, O'Geen, Henry et al. 2015), and that recent algorithms 
allow accurate prediction of off-target sites with mutation rates over 0.1% (Bae, Park 
et al. 2014, Haeussler, Schönig et al. 2016). Moreover, a highly sensitive sequencing 
tool failed to detect mutations in the vast majority of off-target sites with 4 or greater 




Figure 1.6: Schematic representation of the wild-type Cas9 (A) and Cas9-nickase 
‘double nicking’ (B) strategies for editing DNA. A) Cas9: a single 20bp guide-RNA 
(sgRNA) directs double strand cleavage by the Cas9 endonuclease, 3 bases 5’ of the 
PAM (pink arrowheads). B) Cas9n double nicking: 20nt target sites are chosen on both 
strands, separated by a 0-20bp offset. Nicking at both sites by Cas9n leads to the 
creation of a DSB with 5’ overhangs. Adapted from Ran, Hsu et al. (2013). 
Whist the rates of off-target mutagenesis are therefore very low, and essentially 
negligible in the context of a molecular biology lab (Veres, Gosis et al. 2014), even 
very infrequent events must be avoided in a clinical setting, where mutations risk 
leading to oncogenesis. Several strategies have been employed to reduce the frequency 
of off-target mutagenesis. Promising results have been reported with the use of 
truncated gRNAs, less than 20nt long, in providing a several-fold increase in targeting 
specificity (depending on the locus) with similar on-target editing (Fu, Sander et al. 
2014, Tsai, Zheng et al. 2014, Zhang, Li et al. 2016). Furthermore, the Cas9 nuclease 
has been engineered to produce several higher specificity variants (Bolukbasi, Gupta 
et al. 2015, Slaymaker, Gao et al. 2015, Kleinstiver, Pattanayak et al. 2016, Chen, 
Dagdas et al. 2017), the most recent of which, evoCas9, being reported to increase 
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specificity 79-fold while maintaining 90% on-target efficiency (Casini, Olivieri et al. 
2018). In addition, on-target specificity can be improved simply by titrating the 
quantity of Cas9 (Ran, Hsu et al. 2013), by limiting the duration of exposure through 
an inducible system (Cao, Wu et al. 2016) or by direct delivery of Cas9/gRNA 
complexes to cells which are degraded within 24 hours (DeWitt, Corn et al. 2017). 
Moreover, it is likely that these approaches could be combined, resulting in a system 
which is highly specific and with a very limited risk of off-target effects. 
1.5.2 On-Target Editing with the CRISPR/Cas9 System 
As with off-target editing, much work has been done in elucidating the factors which 
lead to high on-target editing efficiencies. A study by Doench, Hartenian et al. (2014), 
in which they screened a pool of gRNAs for their bi-allelic knock-out ability, revealed 
that gRNAs which target the coding sequence, especially the exact exon-intron 
boundary, are highly favoured. Furthermore, they found specific nucleotide 
preferences within the protospacer, PAM and PAM-proximal sequences (Figure 1.7). 
 
Figure 1.7: Nucleotide preference varies along the guide, PAM and adjacent 
sequences. Graph shows the p-values of observing a guide with a percent-rank activity 
of >0.8 at every position, based on 1,841 gRNAs targeting the CDS of 9 mouse genes. 
P-values were calculated from the binomial distribution from all coding-sequence 
targeting guides employed. Taken from Doench, Hartenian et al. (2014). 
Besides sequence, it is hypothesised that chromatin context may play an important role 
in determining guide activities. Chromatin exists in two broad states, euchromatin and 
heterochromatin. Euchromatin is open, accessible for transcription and associated with 
active genes, whereas heterochromatin is densely packed and inaccessible (Watts 
2016). Studies have found that editing by CRISPR/Cas9 is impeded in a 
heterochromatic context  (Chen, Rinsma et al. 2016, Jensen, Floe et al. 2017), and that 
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NHEJ may be more affected than HDR (Chen, Liu et al. 2017). Furthermore, all 
mammalian DNA is packaged in nucleosomes, with some regions being more 
nucleosome-dense than others. A significant correlation has been observed between 
higher nucleosome-density and reduced binding of Cas9, although the effects of this 
may be locus specific due to the potential for nucleosome remodelling (Horlbeck, 
Witkowsky et al. 2016, Isaac, Jiang et al. 2016). Interestingly, an inactive, ‘dead’ 
version of Cas9 (dCas9) has been shown to induce an open chromatin state (Barkal, 
Srinivasan et al. 2016), a feature which may also find therapeutic application. 
1.5.3 Delivery Vectors for CRISPR/Cas9-Mediated Genome Editing In 
Vivo 
Whilst many simple and effective methods exist for employing the Cas9 system in cell 
culture systems (Luo and Saltzman 2000), especially plasmid (Ran, Hsu et al. 2013) 
and RNP transfection (DeWitt, Corn et al. 2017), achieving in vivo genome editing in 
a tissue of interest is a more complex task. A range of approaches can be deployed, the 
most simple of which being hydrodynamic injection of plasmid DNA, which has 
shown success in targeting several tissues in rodents, in particular hepatocytes (Suda 
and Liu 2007). Using CRISPR/Cas9 plasmids, this approach has been used to suppress 
hepatitis B virus (HBV) in mice (Lin, Yang et al. 2014, Ramanan, Shlomai et al. 2015, 
Zhen, Hua et al. 2015), although currently the method is not translatable to humans 
due to the risk of adverse cardiac events (Suda and Liu 2007).  
An alternative method, also commonly employed in animal models, involves the direct 
injection of Cas9 mRNA and gRNA (with or without repair template) into oocytes or 
zygotes, and has shown high efficiencies in the mouse (Li, Qiu et al. 2013, Wang, 
Yang et al. 2013), rat (Li, Qiu et al. 2013) and zebrafish (Hruscha, Krawitz et al. 2013, 
Hwang, Fu et al. 2013), amongst other systems. Interestingly, a proof-of-principle 
report used this technique to correct a mouse model with a dominant mutation that 
causes cataracts (Wu, Liang et al. 2013). Alternatively, Cas9 ribonucleoprotein 
complexes (RNPs) can be delivered by injection (Sung, Kim et al. 2014), or 
electroporation (Chen, Lee et al. 2016), with similarly high efficiencies. However, 
germline targeting in humans remains the subject of intense ethical debate, although 
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controversial reports are already emerging of gene correction in human zygotes (Ma, 
Marti-Gutierrez et al. 2017, Tang, Zeng et al. 2017). 
For gene correction approaches to prove successful in humans outside of the embryo, 
it may be necessary to move to a viral delivery approach, as with conventional gene 
therapy (Lau and Suh 2017). AAV vectors are also considered to be the most 
promising for CRISPR/Cas9 gene editing, although due to the ~4.2kb size of spCas9, 
it has been necessary to employ minimal promoters and poly-adenylation signals to 
stay within packaging limits (Senís, Fatouros et al. 2014). Alternatively, a recent study 
took advantage of the split-intein protein trans-splicing technique (Li, Sun et al. 2008), 
to deliver the spCas9 gene on two separate AAV vectors, freeing >2kb on each vector 
for additional elements and retaining high efficiencies (Chew, Tabebordbar et al. 
2016). Recently, several smaller spCas9 alternatives have been described (Mir, Edraki 
et al. 2018), the most notable of which being Staphylococcus aureus Cas9 (saCas9), 
which is smaller in size (~3.2kb) but has a more restrictive PAM sequence (Friedland, 
Baral et al. 2015). SpCas9 and saCas9 AAV-based methods have already demonstrated 
success in several tissues of the mouse, including muscle (Nelson, Hakim et al. 2016, 
Amoasii, Long et al. 2017, Bengtsson, Hall et al. 2017), heart (Xie, Zhang et al. 2016, 
Amoasii, Long et al. 2017, El Refaey, Xu et al. 2017, Ishizu, Higo et al. 2017) and 
retina (Yu, Mookherjee et al. 2017). 
In addition, it is necessary to consider the format of delivery of the repair template. 
Whilst single-stranded oligonucleotides (ssODNs) may be effective in eliciting small 
changes in tissues amenable to HDR such as the embryo (Hwang, Fu et al. 2013, Wang, 
Yang et al. 2013, Wu, Liang et al. 2013), larger templates such as plasmids may be 
required for longer insertions (Yang, Wang et al. 2013). In tissues less amenable to 
HDR, more efficient repair templates may be required. Minicircle plasmid derivatives 
may offer greater repair efficiencies, potentially due to their lack of bacterial sequences 
which can elicit an immune response (Kay, He et al. 2010). Furthermore, the inability 
of the immune system to readily detect minicircles may increase their residency times 
and allow them to be repeatedly dosed (Munye, Tagalakis et al. 2016), leading to 
higher total rates of HDR. Alternatively, AAV itself appears to have an innate ability 
to stimulate HDR, along with a high packaging capacity (Gaj, Epstein et al. 2015), 
although repeated dosing may not be possible (Beck, Jones et al. 1999, Chirmule, Xiao 
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et al. 2000). Interestingly, a ten-fold increase in HDR has been noted when using an 
RNP-Cas9 and AAV repair approach over a dual plasmid strategy in a HEK293T 
reporter cell line (Gaj, Staahl et al. 2017). 
1.6 Double-Strand Break Repair Mechanisms 
Once a double-strand break has been created by an SSN, the resulting editing outcome 
is largely decided by the cellular machinery. In mammalian cells there are two major 
DSB repair pathways, NHEJ and homologous recombination (HR, employed for 
HDR), and several minor repair pathways, the most important for SSN-mediated 
mutagenesis being microhomology-mediated end-joining (MMEJ) and single-strand 
annealing (SSA) (Figure 1.8A). The choice of repair pathway depends to a large extent 
on the cell’s position in the cell cycle (Figure 1.8B). As there is no endogenous repair 
template available in mammalian cells outside of S/G2 phase (when replicated DNA 
is present), mammalian cells largely rely on the template independent, error-prone 
NHEJ pathway to repair DSBs, which are common and can arise due to various factors 
such as oxidative damage and ionising radiation (Lieber 2010).  
In NHEJ, upon DSB creation, the proteins Ku70/Ku80 bind the free ends forming 
Ku-DNA complexes (Figure 1.8A i) (Franco, Murphy et al. 2008). These Ku-DNA 
complexes are able to recruit nuclease, polymerase and ligase in any order, resulting 
in a large range of potential indels (Lieber 2008). Further cleavage is mediated by the 
DNA–protein kinase catalytic subunit (DNA-PKcs) which binds to Ku-DNA and 
activates the endo/exonuclease Artemis (Franco, Murphy et al. 2008). In addition, the 
template-independent DNA polymerase mu, as well as DNA polymerase lambda, are 
able to bind Ku-DNA via their BRCT (BRCA1 C terminus) domains. Lastly, the 
complex XLF-XRCC4-DNA ligase IV is required to ligate the free ends (Ahnesorg, 
Smith et al. 2006), whether or not cleavage or extension has occurred. DNA ligase IV 
is non-specific and able to ligate incompatible ends across substantial gaps. 
During the S and G2 phases of the cell cycle, the alternative repair pathways, HR, 
MMEJ and SSA become available. All three pathways depend on an initial 5’ to 3’ 
resection event mediated by CtIP/MRE11-RAD50-NBS1 (MRN) (Kakarougkas and 
Jeggo 2014, Seol, Shim et al. 2017), a complex which is regulated during the cell cycle 
by the presence of cyclin-dependent kinase (CDK) (Sfeir and Symington 2015). 
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Following resection, if there are small (~2-20bp) regions of homology present, the 
MMEJ pathway (Figure 1.8A ii) may be employed to repair the break, whereas larger 
regions of homology invoke the HR pathway, including the SSA pathway (Figure 1.8A 
iii) for resolving larger repeats (>14bp). Both MMEJ and SSA are highly mutagenic, 
resulting in deletions (MMEJ & SSA) and insertions (MMEJ) (Sfeir and Symington 
2015). They consist of a similar process, including annealing, flap trimming, DNA 
synthesis and ligation, however MMEJ appears not to require the ssDNA-binding 
proteins RAD51/RAD52 or Ku70/Ku80 for repair (McVey and Lee 2008, Sfeir and 
Symington 2015). MMEJ instead appears to require replication protein A (RPA) for 
ssDNA-binding, and indeed the transition in occupancy of ssDNA ends between RPA 
and RAD52 at ~14bp appears to mediate the choice of repair pathway between MMEJ 
and SSA (Sfeir and Symington 2015). 
In HR the ssDNA tail is also rapidly bound by RPA, however, unlike in MMEJ, RPA 
is then displaced by RAD51 in a BRCA2-dependent process. If no nearby 
intrachromatid homology is found, RAD51 then directs strand invasion of the 
homologous region of the sister chromatid and formation of a D-loop (Figure 1.8A iv) 
(Kakarougkas and Jeggo 2014). Following this initial formation of a D-loop, several 
different pathways can be employed to repair the break, including synthesis-dependent 
strand annealing (SDSA) and double-strand break repair (DSBR) (Li and Heyer 2008), 
the mechanisms governing which are poorly understood in mammalian (human) cells, 
but likely involve the interplay of several proteins and protein complexes 
(Kowalczykowski 2015). It is probable the relative frequency of MMEJ/SSA versus 
non-SSA HR is dependent on the presence of the sister chromatid for repair within a 
time-frame following DSB formation, as end-resection by CtIP/MRN can proceed 
automatically in S/G2 (Bhargava, Onyango et al. 2016).  
Given this high complexity, the exact pathway employed following SSN-mediated 
cleavage will likely depend on several factors, including the nature of the locus and 
the nature of the repair template, if supplied. However, it must also be noted that Ku70 
and Ku80 are still active during S/G2 and compete with CtIP for DNA binding, 
resulting in greater utilisation of the NHEJ pathway in mammalian cells even during 




Figure 1.8: Schematic of the major repair pathways in mammalian cells, and their 
activity in the cell cycle. A) i) non-homologous end joining (NHEJ), yellow ovals 
indicate Ku-DNA and associated proteins; ii) micro-homology mediated end joining 
(MMEJ); iii) single-strand annealing (SSA); iv) double-strand break repair (DSBR), 
yellow stars indicate potential mutagenesis introduced by low-fidelity DNA synthesis. 
Light blue boxes indicate regions of homology. Sister chromatids are distinguished by 
colour. Dashed lines indicate newly-synthesised DNA. Adapted from Seol, Shim et al. 
(2017). B) Diagrammatic representation of the activity of each repair pathway in 
relation to the cell cycle. Adapted from Suzuki and Izpisua Belmonte (2018). 
1.6.1 Small Molecule Enhancement of HDR 
Given that the desired outcome of gene correction in mammalian cells will depend on 
the action of the infrequently-employed HR pathway, several studies have been 
performed to identify small molecules which can improve rates of HDR. As HR is 
active during S/G2 phases, trials have shown that small molecules which block the cell 
cycle in one of these phases can improve HDR. Nocodazole and ABT-751 (ABT) both 
block cells at the G2/M transition and have been shown to produce a 3-5 fold increase 
in HDR in hPSCs and iPSCs (Yang, Scavuzzo et al. 2016). Another study confirmed 
the increase in HDR on nocodazole treatment in HEK293T cells, human primary 
neonatal fibroblasts and human embryonic stem cells, and also found a similar if 
reduced effect with aphidicolin, which blocks in early S phase (Lin, Staahl et al. 2014). 
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Alternatively, small molecules have been identified which can perturb the NHEJ and 
HR pathways, leading to increases in HDR. SCR7 (pyrazine), an inhibitor of DNA 
ligase IV (Srivastava, Nambiar et al. 2012), has proven effective in a large array of cell 
lines (Chu, Weber et al. 2015, Maruyama, Dougan et al. 2015, Gkotzamanidou, Terpos 
et al. 2016, Li, Zhang et al. 2017, Shao, Ren et al. 2017, Hu, Shi et al. 2018), as has 
the DNA-PKcs inhibitor NU-7441 in HEK293 cells, MEFs and iPSCs (Robert, 
Barbeau et al. 2015, Zhang, Li et al. 2017). Alternatively, the HR-stimulator RS-1 
(RAD51-stimulatory compound 1) also appears effective in HEK293A, U2OS and 
rabbit embryos (Pinder, Salsman et al. 2015, Song, Yang et al. 2016). Interestingly, 
two other compounds have also been discovered through screens to increase rates of 
HDR, through unexplained mechanisms, namely L-755,507 in many cell types (Yu, 
Liu et al. 2015, Li, Zhang et al. 2017) and BFA in mouse ES cells and iPSCs (Yu, Liu 
et al. 2015, Zhang, Li et al. 2017). 
1.6.2 Alternatives to HDR 
As these small molecule treatments may not be applicable in all cell types, especially 
in vivo and therapeutically, recently a new method has emerged which takes advantage 
of the NHEJ pathway to introduce a corrected fragment. Termed 
homology-independent targeted integration (HITI), it requires simultaneous Cas9-
directed cleavage of an exogenous plasmid and the genomic target locus (Suzuki, 
Tsunekawa et al. 2016). The genomic target site is added in reverse direction to the 
plasmid/minicircle such that only correct insertion of the fragment will abolish further 
cleavage, leading to the production of virtually no clones with insertions in the reverse 
direction (Figure 1.9). Notably, this technique achieved several-fold higher rates of 
knock-in (KI) than an HDR donor, up to 60% in HEK293 cells. Critically, using AAV 
delivery in mice, they achieved KI rates of 3.5% in the brain following injection of the 
visual cortex, and KI rates of 4.2%, 3.4% and 10.0% in the liver, heart and quadriceps 
muscle respectively after systemic injection. Furthermore, they demonstrated this 
method can deliver substantial improvements in a rat model of retinitis pigmentosa 
(RP) following subretinal injections 3 weeks after birth (Suzuki, Tsunekawa et al. 
2016). This targeted integration approach for gene therapy should partially address 
fears associated with insertional mutagenesis and afford somewhat better regulation of 
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the inserted gene, which could be introduced into its native locus, although, compared 
with HDR, care must be taken not to disrupt or introduce regulatory elements.  
 
Figure 1.9: Schematic representation of the homology-independent targeted 
integration (HITI) system. Blue rectangles depict gRNA binding sites and blue 
triangles their associated PAM sites. Correct insertion of the gene of interest (GOI) 
results in the disruption of the target site, whereas reverse integration does not, leading 
to re-cleavage. Taken from Riken Center for Developmental Biology (2017). 
Alternatively, novel Cas9 fusion proteins have recently been produced which allow 
‘base editing’ within a defined window, typically 5nt, following Cas9 binding to DNA. 
Taking advantage of the rat cytidine deaminase APOBEC1 to elicit a C to T change 
(Komor, Kim et al. 2016), or a highly engineered RNA adenosine deaminase to elicit 
an A to G change (Gaudelli, Komor et al. 2017), these ‘base editors’ allow efficient 
(~35-50%) and targeted conversion of point mutations which are causative of human 
disease, with low rates of indel mutations (~0.1-1.1%, Komor, Kim et al. (2016), 
Gaudelli, Komor et al. (2017). They therefore provide an attractive alternative to HDR 
and HITI where only single base-pair changes are required. One concern with this base 
editing strategy is the unwanted, and potentially deleterious, conversion of 
surrounding bases, however, recent work has shown that these proteins can be 
engineered to have narrower editing windows (Kim, Komor et al. 2017), alleviating 
these concerns if a nearby gRNA target sequence is present. 
1.7 Project Rationale and Aims 
As explained in the preceding sections, the ease and precision of genome editing 
afforded by the CRISPR/Cas9 system opens an exciting new therapeutic avenue for 
the treatment, and potentially cure, of many genetic diseases. By creating bespoke 
guides and repair templates, which can be delivered alongside universal editing 
machinery using standardised protocols and delivery vectors, this ‘modular’ approach 
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allows truly personalised genetic medicine. With improved genetic diagnosis 
facilitated by the advancement of next-generation sequencing (NGS) technologies, we 
have the opportunity to develop tailored gene therapies for many rare genetic diseases, 
which would not have previously been deemed economically viable targets. However, 
for this to be a feasible therapeutic option, two significant hurdles must be overcome: 
a) improving delivery of the CRISPR components to the somatic tissues of 
interest in vivo; and 
b) biasing editing events in the targeted cells towards repair and gene 
correction. 
When I began my PhD, genome editing events were being monitored at a 
sequence-based level, creating a bottleneck in determining which editing events are 
occurring in which cell types. No suitable methods were available which would allow 
us to systematically address these two issues, therefore we identified the need to 
develop a system which: 
1) allows rapid and robust scoring of CRISPR-mediated events, particularly 
rates of NHEJ and HDR; 
2) is functional in vivo; 
3) is functional in all cell types; and 
4) is functional throughout the cell cycle. 
 
In order to achieve this, we decided to repurpose a mouse fluorescent-based reporter 
model of Cre-mediated recombination, noting the similarities between this system and 
deletions instigated by CRISPR/Cas9, as well as the speed and ease of detecting 
changes in fluorescence as a read-out via microscopy and flow cytometry (FC) or 
FACS (fluorescence-activated cell sorting). This model will be discussed further in 
Chapters 3 and 4. Furthermore, we wished to validate the applicability of results 
generated with our reporter system to other, disease-causing loci. To do so, as a proof-
of-principle, I began with a mouse model of the rare, genetic, respiratory disease 




Chapter 2 Materials and Methods 
2.1 Design of CRISPR Guide-RNAs 
Guides were designed against the desired target sequences using an array of well-
known online tools and were chosen based on their high scores, indicating high 
efficiency and specificity, across the three tools used. These tools are located at 
http://crispr.mit.edu/ (Zhang Lab 2017), http://zifit.partners.org/ZiFiT/ (Sander, 
Zaback et al. 2007, Sander, Maeder et al. 2010, Hwang, Fu et al. 2013, Zinc Finger 
Consortium 2017) and https://www.atum.bio/eCommerce/cas9/input (ATUM 2018), 
the latter formerly being known as DNA2.0. Guides were designed to cut as close to 
the desired targets as possible, that being the -7bp deletion in Zmynd10 or the loxP 
sites in the mTmG cassette, although guides which exactly overlapped these regions 
were not found. In the case of the mTmG system, the two guides used were both 
designed by another member of the lab, Peter Budd, whereas the three guides for 
Zmynd10 were chosen by myself. 
2.1.1 mTmG Locus 
As stated above, the two guides designed against the loxP sequence in the mTmG 
system were both designed by Peter Budd using DNA2.0 (now ATUM), MIT CRISPR 
Design and further checked using ZiFit. The design of the guides takes advantage of 
the fact that there is 62bp of identical sequence surrounding both loxP sites, as based 




Figure 2.1: A BLASTn alignment of 100bp 5’ and 3’ of both loxP sites reveals 
62bp of identical sequence. Here, the loxP sites are highlighted in green. Nucleotide 
positions are relative to the entire Rosa26 mTmG Sequence which can be accessed at 













In this 62bp of identical sequence, DNA2.0 identified three potential guide-RNAs, 
whereas MIT CRISPR Design identified four, however the top two guides identified 
by both are the same: 
 
Figure 2.2: Screen capture of the DNA2.0 online software indicating the three 
potential guides against the loxP region identified. Accessed on 10/02/2015. 
 
 
Figure 2.3: Screen capture of the MIT CRISPR Design online software indicating 




Based on this, the following two guides were chosen to target the locus: 






LoxP#1 CGAAGTTATATTAAGGGTTC CGG 83 51 55 
LoxP#2 GTATGCTATACGAAGTTATT AGG 79 100 15 
Table 2.1: Guide-RNAs chosen to target the loxP region in the mTmG mice. 
 
These two guides target either side of the loxP site on opposite strands, in case cleavage 
proceeds more efficiently on one strand than the other: 
 
Here, the target site is highlighted in yellow with the PAM highlighted in blue. 
2.1.2 Zmynd10 Locus 
Guides targeting the -7bp deletion locus in the Zmynd10 mice were chosen using the 
same procedure as for the mTmG guides. A 100bp sequence surrounding the deletion 
was put into MIT CRISPR Design, DNA2.0 and ZiFit: 
 
Figure 2.4: DNA and protein sequence of the region surrounding the -7bp 







Each program produced several possible guides targeting this region, unfortunately 
none of the guides were specific to the -7bp deletion mutant and so will also cleave 
the wild-type allele: 
 
Figure 2.5: Output from the MIT CRISPR Design tool for the Zmynd10 -7bp 
deletion locus, showing several potential guides identified. Grey bars are predicted 
guides relative to the input sequence. No guides specific to the -7bp deletion mutant.  
Guide prediction was therefore repeated with a larger input sequence spanning 300bp 
around the deletion. Again, each program produced several possible guides. From this 
output three guides were chosen, one on the forward strand and two on the reverse 
strand, based on the guides’ rankings and their proximity to the deletion: 




Z10 R GAAGCACCGAGAGGGCTTTC AGG 73 Summary: Off by 0 
= 1; Off by 1 = 0; 
Off by 2 = 0; Off 
by 3 = 6 
Z10 R2 GATGTAGCGAAGCACCGAGA GGG 86 Summary: Off by 0 
= 1; Off by 1 = 0; 
Off by 2 = 0; Off 
by 3 = 5 
Z10 F GATATCCCTGAAAGCCCTCT CGG 63 Summary: Off by 0 
= 1; Off by 1 = 0; 
Off by 2 = 1; Off 
by 3 = 10 




Figure 2.6: Location of the chosen guides against Zmynd10 in relation to the 
deletion. 
2.2 Processing of CRISPR gRNAs 
Following design, oligonucleotides were ordered from Sigma-Aldrich to allow cloning 
into several commonly used Cas9/gRNA expression plasmids, as per the protocol in 
Ran, Hsu et al. (2013). Oligonucleotides were synthesised for both strands following 
this general template, where N indicates the target site: 
 
5’ - CACCGNNNNNNNNNNNNNNNNNNNN - 3’ 








Once received, oligonucleotides were resuspended in NF-H2O (nuclease-free water) 
to a stock concentration of 100µM. The initial G allows efficient transcription from 
the U6 promoter, while the added overhangs allow cloning into a BbsI-digested 
expression vector (Figure 2.7). 
 
Figure 2.7: Cloning guides into an expression vector. Top and bottom 
oligonucleotides are first annealed. Subsequently, the added overhangs then allow 
ligation into a BbsI-digested expression vector, which inserts the guide downstream of 
the U6 promoter, and immediately upstream of the rest of the sgRNA scaffold. Taken 
from Ran, Hsu et al. (2013). 
2.2.1 Construction of Expression Plasmids 
The oligonucleotides were cloned into the expression plasmids, which are listed at the 
end of this section, following the protocol in ‘Genome engineering using the CRISPR-
Cas9 system’ by Ran, Hsu et al. (2013). 
Briefly, the top and bottom oligonucleotides were phosphorylated and annealed using 
T4 PNK (polynucleotide kinase); incubating at 37°C for 30 minutes, then 95°C for 5 
minutes, and then cooling to 25°C at 2.5°C min-1 (note: this is half the speed of the 






Following this, the annealed oligonucleotides were diluted 1:200 in ddH2O and then 
ligated into the BbsI-digested vectors in a reaction with the following components: 
Component Amount (µl) 
Expression Plasmid (100ng/µl) 1.0 
Diluted oligo duplex 2.0 
Tango buffer, 10x 2.0 
DTT, 10mM 1.0 
ATP, 10mM 1.0 
FastDigest BbsI 1.0 




This reaction was incubated for a total of 1 hour, in a programme which consisted of 
six ten-minute cycles of 37°C for 5 minutes, followed by 21°C for 5 minutes, to allow 
digestion and annealing to take place. 
Alternatively, when FastDigest BbsI (Thermo Fisher) was not available, the 
expression plasmid was first digested with BbsI (NEB) for one hour at 37°C, and then 
phosphorylated with SAP (shrimp alkaline phosphatase) at 37°C for 30 minutes. 
Following this, the annealed, diluted oligonucleotides were ligated into the 
BbsI-digested plasmid with T4 ligase overnight at 16°C. 
The ligation product was then treated with PlasmidSafe ATP-dependent exonuclease 
(Lucigen) at 37°C for 30 minutes to remove any remaining linearized DNA, and then 
incubated at 70°C for 30 minutes to deactivate any remaining enzymes. Following 
PlasmidSafe treatment, the plasmid could be stored at -20°C prior to being transformed 
into DH5α Subcloning Efficiency Escherichia coli (E. coli) (Thermo Fisher) as per the 





2.2.2 List of Plasmids Used 
All Cas9 expression plasmids used were a gift from Feng Zhang (Ran, Hsu et al. 2013), 
and are available on Addgene (https://www.addgene.org). The plasmid stocks used to 
perform the cloning reactions in Section 2.2.1 were prepared and sequence- verified 
by Peter Budd. 
2.2.2.1 pX330 (Addgene plasmid #42230) 
The ‘basic’ sgRNA, Cas9 expression plasmid which contains no selection cassette: 
 
Figure 2.8: Diagrammatic representation of the pX330 expression plasmid. Taken 
from Addgene, https://www.addgene.org/42230/, accessed on 03/01/2018. A gift from 






2.2.2.2 pX458 (Addgene plasmid #48138) 
A derivative of pX330 which contains an EGFP reporter following Cas9: 
 
Figure 2.9: Diagrammatic representation of the pX458 expression plasmid. Taken 
from Addgene, https://www.addgene.org/48138/, accessed on 03/01/2018. A gift from 








2.2.2.3 pX459 V2.0 (Addgene plasmid #62988) 
A derivative of pX330 which contains a puromycin resistance cassette following Cas9: 
 
Figure 2.10: Diagrammatic representation of the pX459 v2.0 expression plasmid. 
Taken from Addgene, https://www.addgene.org/62988/, accessed on 03/01/2018. A 
gift from Feng Zhang (Ran, Hsu et al. 2013). 
 
As the original version of this plasmid was not used, the name ‘pX459’ in this thesis 






2.2.2.4 pmaxGFP (Lonza) 
The GFP expression vector pmaxGFP was included in the P4 Primary Cell 
4D-Nucleofector X Kit L (Lonza, catalogue number: V4XP-4024), and was used for 
several optimisation experiments. 
 







2.2.3 Preparation of sgRNAs for Ribonucleoprotein (RNP) Delivery 
As an alternative approach to a plasmid-based expression system, direct delivery of 
the Cas9 protein complexed to the sgRNA was also attempted. The design and 
synthesis of these complexes was based on the user guide supplied with the GeneArt 
Platinum Cas9 Nuclease (catalogue number B25641) from Thermo Fisher Scientific 
(2015). 
The initial gRNA DNA template was generated using the GeneArt Precision gRNA 
Synthesis Kit, also from Thermo Fisher (catalogue number A29377), based on the 
manufacturer’s instructions (Thermo Fisher Scientific 2016). Primers were designed 
to insert the target sequence between the T7 promoter and crRNA/tracrRNA as so: 
 
Figure 2.12: Schematic of primer design for the production of the gRNA DNA 
template sequence, for later in vitro transcription to produce a sgRNA. Adapted 
from Thermo Fisher Scientific (2016). 
The primers were then ordered from Sigma-Aldrich. Once received they were 
resuspended in NF-H2O to make a stock solution at 10µM, and a working solution at 
0.3µM. Following this, a PCR assembly reaction was set up as so: 
Phusion High-Fidelity PCR Master Mix (2x) (NEB, cat. no. M0531S) 12.5µl 
Tracr Fragment + T7 Primer Mix      1.00µl 
0.3µM Target F1/R1 oligonucleotide mix     1.00µl 
NF-H2O         10.5µl 
Total          25.00µl 
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A PCR was then performed to amplify the gRNA DNA template with the following 
cycling parameters: 
Temperature Time Number of Cycles 







72°C 1min 1x 
4°C hold 1x 
 
After this, an in vitro transcription (IVT) reaction was set up with the following 
components and incubated at 37°C for 2 hours: 
NTP Mix (100mM of each dNTP)      8µl 
gRNA DNA Template        6µl 
5X TranscriptAid Reaction Buffer      4µl 
TrascriptAid Enzyme Mix       2µl 
Total          20µl   
Once the IVT reaction was complete, 1µl of DNase I was added to the reaction mix 
and it was again incubated at 37°C for 15 minutes. The in vitro transcribed gRNA was 
then purified as per the manufacturer’s instructions using the kit components and 
eluted in NF-H2O. Purified sgRNAs were then stored at -80°C before being analysed. 
2.2.3.1 RNA Purity Analysis 
Following purification, all sgRNAs were denatured at 70°C for 2 minutes and analysed 
on an Agilent 2100 Bionalayzer, using a nanogram sensitivity eukaryote total RNA 
assay, to check their purity and the size and concentration of the product. If a single 
product of the correct size was present, the sgRNA was diluted to 240ng/µl in NF-H2O 
and aliquoted for future use. All aliquots were stored at -80°C. 
2.3 Bacterial Work 
Once guides had been cloned into the sgRNA/Cas9 expression plasmids as detailed in 
Section 2.2.1, the resulting PlasmidSafe-treated ligation mixes were then transformed 
into E. coli. 
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2.3.1 Transformation of Plasmids 
Subcloning Efficiency DH5α Competent E. coli (Thermo Fisher, catalogue number: 
18265017) were used for the transformation of all the plasmids in this thesis. 
Transformations were performed as per the manufacturer’s instructions, adding 2µl of 
the PlasmidSafe-treated products from 2.2.1 to each 50µl aliquot of E. coli. Following 
transformation, several different volumes were plated on ampicillin-containing LB-
plates (Luria Bertani-plates) to ensure there were well-spaced colonies, and plates were 
incubated overnight at 37°C. The next day, if transformation had been successful, 
plates were stored at 4°C if they were not immediately used in the following steps. 
2.3.2 Isolation of Plasmids 
2.3.2.1 Colony Re-spreading 
If transformation was successful, and several well-spaced colonies were found the next 
day, two or three of these colonies were then re-spread on new ampicillin LB-plates. 
This was done to reduce the risk of accidentally picking up two overlapping colonies 
and to remove any non-antibiotic resistant bacteria which may be on the plate. 
To do this, a single colony was stabbed with a pipette tip, which was then inserted into 
a 1.5ml microcentrifuge tube with 1ml LB. Using a Gilson pipette, the contents of the 
tip were then aspirated in and out several times to disperse the bacteria into the LB. 
Following this, 1µl was taken from the tube and added to another microcentrifuge tube 
with 1ml LB to create a 1 in 1000 dilution, this was then vortexed briefly. 10µl of this 
1 in 1000 dilution was then spread out on an ampicillin-containing LB-plate. 
Generally, this would give 10-50 well-spaced colonies the next day. If successful, the 
resulting plates were then stored at 4°C if they were not immediately used for mini-
preps. 
2.3.2.2 Mini-preps 
Mini-preps were performed using a QIAprep Spin Miniprep Kit (QIAGEN, catalogue 
number: 27106) as per the manufacturer’s instructions. A re-spread colony from the 
preceding step was inoculated into 3ml of LB + ampicillin in a 15ml Falcon tube, 
which was then placed at 37°C overnight in a shaking incubator. The next morning, 
2ml of the bacterial cultures was harvested by centrifugation and the manufacturer’s 
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protocol was followed to extract total DNA, eluting in either NF-H2O or TE buffer. 
The remaining culture was stored at 4°C for potential future use. The purity and 
concentration of the eluted DNA was then checked using a Nanodrop 
spectrophotometer (Section 2.4.3). If satisfactory, the plasmids were sent for 
sequencing using the U6 Forward primer, which will reveal if the guide sequence has 
been correctly inserted (Section 2.9): 
U6 Forward Primer  GAGGGCCTATTTCCCATGATTCC 
2.3.2.3 Maxi-preps 
If sequencing indicated the correct insertion of the guides into the expression plasmids, 
a maxi-prep was then performed. Firstly, 100µl of the stored outgrowth from the mini-
prep was inoculated into 100ml of LB + ampicillin in a 1 litre conical flask. This was 
then incubated with vigorous shaking overnight at 37°C. Following this, the bacterial 
culture was harvested by centrifugation and the plasmids were extracted using a 
QIAGEN Plasmid Maxi Kit (QIAGEN, catalogue number: 12163), following the 
manufacturer’s instructions. In the final step, plasmids were eluted in 250µl of TE 
buffer and the concentration and purity of the preparation was checked on a Nanodrop 
spectrophotometer (Section 2.4.3). All plasmids were then stored at 4°C for future use. 
2.4 DNA Manipulation 
2.4.1 DNA Extraction 
2.4.1.1 DNA Extraction from Cells 
DNA was extracted from cells, generally in a 6-well plate, using Quick Lysis Buffer 
(QLB, Section 2.22.3). Firstly, the media was aspirated from the wells and the cells 
were rinsed in PBS. Following this, 250µl QLB + 10µl Proteinase K was added to each 
of the wells (quantities were scaled up or down for different well sizes). The plates 
were then placed at 55°C for between 2 and 16 hours. If the QLB had then evaporated, 
the contents of the well were resuspended in extra QLB + Proteinase K and transferred 
to a 1.5ml microcentrifuge tube. This was then centrifuged at maximum speed 
(>14,000 x g) at room temperature for 5 minutes. Following this, the supernatant was 
transferred to a new tube and 250µl isopropanol was added. The tube was then 
vortexed briefly and incubated at room temperature for 30 minutes. Subsequently, the 
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tube was centrifuged at maximum speed at room temperature for 30 minutes. The 
supernatant was removed from the tube and the DNA pellet was washed in 70% 
ethanol. Excess ethanol was carefully removed from the tube and the pellet was then 
left to dry at room temperature for approximately 20 minutes. The DNA pellet was 
then resuspended in 100µl TE buffer and the concentration and purity of the DNA 
extraction was checked on a Nanodrop spectrophotometer (Section 2.4.3). 
2.4.1.2 DNA Extraction from Mouse Ear Punches and Tail Tips 
Ear punches were taken from mice at weaning for genotyping, or alternatively tail tips 
during dissections, and collected in a microcentrifuge tube. To quickly extract DNA 
from these tissue samples, 100µl of buffer 25mM NaOH/0.2mM EDTA was added to 
each tube and they were then incubated at 95°C for 20 minutes. Following this, 100µl 
of 40mM Tris-HCl was added to each tube, which was then vortexed. The extracted 
DNA could then be checked on a Nanodrop spectrophotometer (Section 2.4.3), 
although generally 2µl was used in the following genotyping PCR (Section 2.6). 
2.4.1.3 DNA Extraction from Gel Slices 
To isolate a single band of interest from an agarose gel (Section 2.7), generally after a 
PCR reaction, the gel was first visualised under a UV transilluminator. The desired 
band was then quickly and accurately excised using a clean scalpel and placed into a 
microcentrifuge tube. Following this, DNA was extracted from the gel slice using a 
QIAquick Gel Extraction Kit (QIAGEN, catalogue number: 28706), as per the 
manufacturer’s instructions. In the final step, DNA was eluted in 30µl of TE buffer 
and then either checked on a Nanodrop spectrophotometer (Section 2.4.3) or visually 
verified on another agarose gel (Section 2.7). 
2.4.2 DNA Purification 
To isolate DNA and remove contaminants such as enzymes and dNTPs from a PCR 
reaction, or to change DNA between buffers, a DNA purification was performed. All 
DNA purifications were carried out using a QIAquick PCR Purification Kit (QIAGEN, 
catalogue number: 28106) as per the manufacturer’s instructions. In the final step, 
DNA was eluted in an appropriate volume of TE buffer, or alternatively NF-H2O. 
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2.4.3 DNA Quantification 
To check concentration and purity, DNA samples were analysed on a NanoDrop1000 
spectrophotometer (Thermo Fisher). Concentration was gauged by the absorbance at 
260nm, while purity was gauged by the ratio of absorbances at 260nm/280nm. A 
sample was considered pure if it had an A260/A280 of 1.8 or greater. 
2.4.4 DNA Digestion 
2.4.4.1 Restriction Enzyme Digests 
The only restriction enzyme digest performed in this thesis used MlucI, purchased 
from New England Biolabs (catalogue number: R0538S), for genotyping the Zmynd10 
-7bp deletion mutants. To perform the restriction enzyme digest, 15µl of the 
genotyping PCR product (Section 2.5.2) was taken. To the PCR product, 0.5µl of 
MlucI was added, along with 3µl of 10x CutSmart buffer (NEB) and NF-H2O up to a 
total volume of 30µl. The PCR product was digested at 37°C for 30 minutes, and the 
digestion products were then analysed on a 2% agarose gel (Section 2.7). 
2.4.4.2 Surveyor Assay 
Surveyor assays were carried out using the Surveyor Mutation Detection Kit (IDT 
DNA, catalogue number: 706020), as per the manufacturer’s instructions. Prior to this, 
PCR products were purified (Section 2.4.2) and resuspended in Surveyor buffer +   
NF-H2O (Section 2.22.1) for optimal results.  
2.5 Primer Design 
All primers were designed using the Primer3 online tool (Koressaar and Remm 2007, 
Untergasser, Cutcutache et al. 2012), available at http://primer3.ut.ee/, using the 
relevant mis-priming library, i.e. rodent. Furthermore, all primers were checked for 
specificity in the mouse genome using the UCSC in silico PCR 
(http://rohsdb.cmb.usc.edu/GBshape/cgi-bin/hgPcr), and in the sequence of interest 
using BLAST (https://www.ncbi.nlm.nih.gov/BLAST/) (where the sequence would 




2.5.1 mTmG Sequencing Primers 
Six primers were designed to sequence across the mTmG locus: 
Primer 1   -  ACGTGCTGGTTATTGTGCTG 
Primer 2   -  TACCTTCACGTGGCCATTCT 
Primer 3   -  CTTGGGCTGCAGGTCGAG 
Primer 4   -  GTCTTGTAGTTGCCGTCGTC 
Primer 5  -   CCATGTTGTTGTCCTCGGAG 
Primer 6  -   TGATGAATGGGAGCAGTGGT 
These primers were used in the following combinations: 
 Primer 1 + Primer 5  - 914bp 
 Primer 6 + Primer 2  - 917bp 
 Primer 3 + Primer 4  - 538bp 
 Primer 1 + Primer 4  - 3017bp 
Further details of the sequencing experiment are in Chapter 4. 
2.5.2 mTmG Promoter Sequencing Primers 
Two sets of primers, three primers in total, were designed for sequencing across the 
promoter region; one forward primer and two reverse primers, one in tdTomato and 
one in EGFP. 
Tomato primers (927bp): 
mTmG_Tomato_Promoter_Seq_Left - CCTCCCCGAGTTGCTGAG 
mTmG_Tomato_Promoter_Seq_Right - CTTGGAGCCGTACATGAAC 
EGFP primers (931bp): 
mTmG_EGFP_Promoter_Seq_Left - CCTCCCCGAGTTGCTGAG 




2.5.3 Zmynd10 Genotyping Primers 
Two primers were used for the genotyping of Zmynd10 -7bp deletion mutants, these 
were both designed by Dr. Girish Mali. 
  766 - CCAGGACAGTACCCCTATGC 
  767 - AGGTAGGGTAGAAGGGTGGT 
2.5.4 Zmynd10 Ion Torrent Primers 
A series of barcoded forward primers were designed to amplify the Zmynd10 samples 




































































Table 2.3: Zmynd10 Ion Torrent sequencing primers. 
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These use IonXpress barcodes and adapter sequences (Thermo Fisher). All samples 
were amplified with the same reverse primer: 
Pr 767_trP1  - 
 CCTCTCTATGGGCAGTCGGTGATAGGTAGGGTAGAAGGGTGGT 
2.5.5 Zmynd10 Sequencing Primers 
Four primers were designed to sequence across a larger region surrounding the 
Zmynd10 -7bp deletion locus in our mouse lines, to check for variants: 
Set 1  (521bp): 
 
Z10_SEQ_1  - CTGTCTCTCCCTCTCAGCC 
Z10_SEQ_2  - GCAGTCTGTGATGTAGCGAA 
 
Set 2  (589bp): 
 
Z10_SEQ_3  - AGCTACGGTTTCCTGGACTT 
Z10_SEQ_4  - ACGTCAGAACAAGGTGGAGT 
 
2.6 Polymerase Chain Reaction 
The polymerase chain reaction (PCR) was used to amplify DNA, using the primers 
mentioned in the previous section (Section 2.5). All reactions were either performed 
with Taq polymerase, DreamTaq Green PCR Master Mix (Thermo Fisher, catalogue 
number: K1081), or a proof-reading polymerase, Phusion High-Fidelity DNA 
Polymerase (Thermo Fisher, catalogue number: F530S). Generally, Taq polymerase 
was used for simple genotyping experiments, whereas Phusion polymerase was used 








2.6.1 PCR Reaction Compositions 
For Zmynd10 genotyping, DreamTaq Green PCR Master Mix was used: 
DreamTaq Green PCR Master Mix  15.0µl 
NF-H2O     11.5µl 
Forward Primer (10µM)   0.75µl 
Reverse Primer (10µM)   0.75µl 
Template     2.00µl 
Total      30.0µl 
 
For Zmynd10 Ion Torrent (Thermo Fisher) sequencing, Phusion HF Master Mix 
(Thermo Fisher, catalogue number: M0531S) was used: 
2xPhusion HF Master Mix   10.0µl 
NF-H2O     5.40µl 
Forward Primer (10µM)   1.00µl 
Reverse Primer (10µM)   1.00µl 
DMSO      0.60µl 
Template     2.00µl 
Total      20.0µl 
 
For mTmG sequencing experiments, Phusion Hot Start II DNA Polymerase (Thermo 
Fisher, catalogue number: F549L) was used. This was used in combination with 









For primer sets 1 + 5, 6 + 2 and 3 + 4 the following composition was used: 
NF-H2O     24.5µl  
Phusion HF Buffer    10.0µl 
Betaine (5.0M)    9.00µl   
10mM dNTPs     1.00µl 
Phusion Hot Start II DNA Polymerase 0.50µl    
Forward Primer (10µM)   2.00µl   
Reverse Primer (10µM)   2.00µl   
Template DNA    1.00µl 
Total      50.0µl  
 
Whereas for primer set 1 + 4, as well as the promoter sequencing primers, the 
following composition was used: 
NF-H2O     18.5µl 
Betaine (5.0M)    15.0µl   
Phusion GC Buffer    10.0µl   
10mM dNTPs     1.00µl 
Phusion Hot Start II DNA Polymerase 0.50µl    
Forward Primer (10µM)   2.00µl   
Reverse Primer (10µM)   2.00µl   
Template DNA    1.00µl 







2.6.2 Cycling Parameters 
Cycling parameters were optimised for each PCR reaction, and as such annealing 
temperatures and extension times were adjusted to suit each set of primers. 
Furthermore, cycle numbers were optimised for different samples to achieve optimal 
yields with no non-specific bands. However, general cycling parameters for each of 
the DNA polymerases is included below. 
DreamTaq Green PCR Master Mix (Zmynd10 genotyping): 
Step Temperature (°C) Time Number of Cycles 
Initial Denaturation 95 1-3 min 1 
Denaturation 95 30s  
 
25-40 
Annealing Tm - 5 30s 
Extension 72 1min/Kb 
Final Extension 72 5-15 min 1 
 
Phusion HF Master Mix (Zmynd10 Ion Torrent sequencing): 
Step Temperature (°C) Time Number of Cycles 
Initial Denaturation 98 1 min 1 
Denaturation 98 10s  
 
40 
Annealing 61.5 22s 
Extension 72 30s 










Phusion Hot Start II (mTmG sequencing): 
Step Temperature (°C) Time Number of Cycles 
Initial Denaturation 98 1 min 1 
Denaturation 98 10s  
 
10 
Annealing 75 – 65 / 74 - 64 15s 
Extension 72 30s/Kb 
Denaturation 98 10s  
 
29-32 
Annealing 65 / 64 15s 
Extension 72 30s/Kb 
Final Extension 72 5 mins 1 
 
In relation to the mTmG sequencing primers, for primer set 1 + 4 an annealing 
temperature of 65°C was used along with an extension time of 1 minute 35 seconds, 
in a total of 34 cycles. For the other three primer sets an annealing temperature of 64°C 
was used along with an extension time of 25 seconds, in a total of 39 or 42 cycles. 
2.7 Agarose Gel Electrophoresis 
DNA was separated by size using agarose gel electrophoresis. Agarose gels were made 
to a concentration of 1.5% or 2% using Hi-Pure Low EEO agarose (BioGene, 
catalogue number 300-300) dissolved in TBE buffer. To visualise the DNA molecules 
in the gel, ethidium bromide (EtBr) was added to the agarose at a concentration of 
0.5µg/ml. Once prepared, the melted agarose was poured into gel trays with a comb to 
form wells. DNA was mixed with Orange G Loading Dye (Section 2.22.1) prior to 
loading, unless the PCR master mix already contained a loading dye. To mark the sizes 
of the migrating bands, 5µl of 1 Kb Plus DNA Ladder (Thermo Fisher, catalogue 
number: 10787018) was added to the side wells. A voltage of 50-150V was then 
applied to the gel in an electrophoresis gel tank to mobilise the nucleic acids. After one 
to two hours, depending on the size of the expected DNA fragment(s), the gel was 





TOPO-Cloning was performed using the TOPO TA Cloning Kit for Sequencing, and 
One Shot TOP10 Chemically Competent E. coli (Thermo Fisher, catalogue number: 
K457540) per the manufacturer’s instructions (https://assets.thermofisher.com/TFS-
Assets/LSG/manuals/topotaseq_man.pdf).  
LB-ampicillin agar plates were spread with X-Gal (20mg/ml) and 100mM IPTG (to 
allow screening of colonies) and left to dry for 1 hour prior to plating the transformed 
bacteria. The following day, white or light blue colonies, which should harbour the 
correct insert, were taken for outgrowth and sequencing. Colonies were stabbed with 
a pipette tip and added to 1ml of LB + ampicillin in a 96-well plate. These plates were 
left overnight in a 37°C incubator with vigorous shaking. The following day, the plates 
were submitted to the IGMM technical services who performed plasmid extractions 
and sequencing (Section 2.9) with the M13 Forward and M13 Reverse primers: 
M13 Forward - GTAAAACGACGGCCAG 
M13 Reverse  - CAGGAAACAGCTATGAC 
2.9 Sanger Sequencing & Analysis 
All DNA sequencing was performed by the IGMM technical services department on 
an Applied Biosystems 3130 (4-capillary) Genetic Analyzer or a 48-capillary 3730 
DNA Analyzer (Both Thermo Fisher). When received, sequencing traces were visually 
inspected using the FinchTV 1.4 software (Geospiza Inc.) and further analysed if 
necessary using alignment tools such as SnapGene (GSL Biotech LLC) and BLAST 
(NCBI NLM, https://blast.ncbi.nlm.nih.gov/Blast.cgi). 
2.10 Mouse Embryonic Fibroblast Work 
2.10.1 Generation of Mouse Embryonic Fibroblasts 
Mouse embryonic fibroblasts (MEFs) were generated from mice embryos between the 
stages of embryonic day (E) 11.5 to E13.5. Briefly, gestational sacs were removed 
from the uterus and placed into PBS. The embryos were then dissected out of their 
gestational sacs, and the red organs and heads of the embryos were further removed. 
A small tissue sample was generally taken for genotyping and placed in QLB for DNA 
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Extraction (Section 2.4.1.2). Each embryo was then placed into a single well of a 6-
well plate, containing 2ml Trypsin/Versene, and cut using forceps into several small 
pieces. Plates were left at room temperature in a tissue culture hood for an hour to 
allow cells to dissociate. Following this, 3ml of MEF growth media was added to each 
well and the contents were transferred to a 15ml Falcon tube. Falcon tubes were 
centrifuged at 150 x g for 5 minutes to pellet the cells. Pellets were then resuspended 
in 10ml of MEF growth media and transferred to a T75 flask. The following day, any 
debris was removed by changing the media. At 90% confluency cells were split 1 in 
3. MEF cells were considered ready to use once they had reached passage number 3, 
as at this point other cell types will have detached.   
2.10.2 Culture Conditions 
MEFs were maintained in a 37°C, 5% CO2, humidified, normoxic incubator in MEF 
growth media. At 90% confluency non-immortalised MEFs were rinsed in PBS and 
split with Trypsin/Versene (Section 2.22.3) 1 in 3 into a new flask. Immortalised MEFs 
were split 1 in 10. 
2.10.3 Mycoplasma Testing & Liquid Nitrogen Storage 
All MEF cultures were tested for mycoplasma at P3 and prior to beginning 
experiments. Furthermore, all cultures were tested prior to being cryostored. All 
cultures used were mycoplasma negative. 
Generally, non-immortalised MEF cultures were initially expanded and then 
cryostored once they had reached confluency at P2 stage. Immortalised MEF lines 
were cryostored immediately following the immortalisation protocol (Section 2.10.4), 
or sporadically as necessary. To do this, flasks were rinsed in PBS and cells were 
detached with Trypsin/Versene (Section 2.22.3). Detached cells were centrifuged at 
150 x g for 5 minutes and pellets were resuspended in 1ml MEF freezing media 
(Section 2.22.3) in a cryotube. Cryotubes were immediately put on dry ice and then 
stored at -80°C prior to liquid nitrogen storage. 
2.10.4 Immortalisation Protocol 
MEFs were transfected at an early stage, i.e. P3, with an immortalisation plasmid 
containing an SV40 cassette and a puromycin resistance cassette. This immortalisation 
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plasmid, pJKN114, was a gift from the lab of Andrew Jackson. MEFs were transfected 
using the Neon system (Section 2.12.1). A non-transfected control well was also 
prepared. Twenty-four hours later, media was replaced with MEF growth media + 
3µg/ml puromycin. Wells were left until all cells in the control well had detached, 
generally 3 or 4 days. The puromycin-containing media was removed and wells were 
rinsed in PBS. Antibiotic-free MEF growth media (Section 2.22.3) was added and 
wells were allowed to recover for several days. Upon recovery, cells were tested for 
mycoplasma and either frozen down (Section 2.10.3) or expanded for use in future 
experiments. 
2.11 Mouse Ependymal Cell Work 
2.11.1 Generation of Mouse Ependymal Cells 
To generate ependymal cells, mice at E18.5 were killed by decapitation and their heads 
were received. Brains were then manually dissected out into Hank’s solution (Section 
2.22.3), and from brains the ventricular cups were removed. Ventricular cups, 
separated by genotype and/or mouse, were placed into appropriately sized wells and 
manually cut into pieces. TrypLE Express (Thermo Fisher, catalogue number: 
12605010) was added to digest the pieces and plate(s) were incubated at 37°C, 5% 
CO2 for 60 minutes. Digestion was stopped with the addition of an equal amount of 
ependymal growth medium (Section 2.22.3). Cell suspensions were then centrifuged 
for 5 minutes at 150 x g. Cell pellets were resuspended in ependymal growth medium 
and placed in poly-L-lysine coated wells or flasks. Ependymal progenitor cells were 
allowed to proliferate until confluence, generally ~5 days, during which time debris 
and detached cells were regularly removed by washing in 1x PBS and replacing the 
ependymal growth media. 
2.11.2 Culture Conditions & Differentiation 
Ependymal progenitor cells and ependymal cells were both maintained in a 
humidified, normoxic, 5% CO2, 37°C incubator. Upon confluency, progenitor cells 
were washed in 1x PBS, and serum-starved in ependymal serum starvation media (1% 




2.12 Primary Cell Transfection & Transduction 
2.12.1 Neon System 
The Neon Transfection System (Thermo Fisher, catalogue number: MPK5000) was 
employed for both MEF and ependymal cell transfections, using both 10µl and 100µl 
electroporation kits (catalogue numbers MPK1096 and MPK10096 respectively), and 
identical electroporation parameters. Mixes for transfection were scaled up or down as 
necessary between the two tip sizes.  
2.12.1.1 Protocol for Neon Plasmid Transfection (MEFs) 
Prior to transfection, MEF growth media was added to the wells of a plastic- or glass-
bottomed plate as necessary, and small molecules (Section 2.14) were added if 
required. Plates were then left at 37°C for later use. Buffer R and buffer E2 (100µl 
electroporation kit, Thermo Fisher) were allowed to warm to room temperature.  
MEFs were rinsed in PBS and detached with Trypsin/Versene. An equal volume of 
MEF growth media was then added to the flask(s) and the contents were transferred to 
a 15ml Falcon tube, which was centrifuged at 150 x g for 5 minutes. Cell pellets were 
resuspended in 10ml PBS, and 100µl of this suspension was then diluted 1 in 2 in 
100µl of PBS. Using this final dilution, a cell count was taken using a Scepter 2.0 Cell 
Counter (Merck). Generally, 0.5x105 cells were used per 10µl transfection, or 5x105 
cells per 100µl transfection, and an excess was always prepared. Based on the cell 
count, an appropriate volume of cells in PBS was centrifuged at 150 x g for 5 minutes. 
During centrifugation, transfection mixes were prepared in microcentrifuge tubes. In 
all experiments, 1000ng of Cas9 expression plasmid and 1000ng of repair 
plasmid/minicircle (if included) were used per 1x105 cells (up to a total of 2000ng), 
unless otherwise noted. If an ssODN repair template was included, 1µl of ssODN at 
10µM concentration was used per 2x105 cells. Following centrifugation, the 
supernatant was removed and the pellet was resuspended in an appropriate volume of 
Buffer R to bring the final volume to 10µl or 100µl per transfection, taking account of 




For transfection, a Neon tube (Thermo Fisher) was placed in the Neon Transfection 
System and 3ml of Buffer E2 was added. The cell-DNA mixture was taken up into the 
Neon electroporation tip and electroporated with the following parameters: voltage 
1350V, width 30ms and pulses 1, unless otherwise noted. Following electroporation, 
cells were immediately returned to MEF growth media (Section 2.22.3). Neon tips and 
Neon tubes were changed between samples, however, when transfecting the same 
sample they were reused up to 5 times. Following electroporation, plates were 
incubated at 37°C, 5% CO2 overnight and the following day the media was replaced. 
2.12.1.2 Protocol for Neon Plasmid Transfection (Ependymal Cells) 
Prior to transfection, ependymal growth media was added to the wells of laminin-
coated plastic- or glass-bottomed plates as necessary, and small molecules (Section 
2.14) were added if required. Plates were left at 37°C for later use. Furthermore, buffer 
R and buffer E (100µl electroporation kit, Thermo Fisher) were allowed to warm to 
room temperature. 
Upon confluency, ependymal progenitor cells were rinsed in PBS and detached with 
TrypLE Express (Thermo Fisher Scientific, catalogue number: 12605010). An equal 
volume of growth media was added, and the cell suspension was centrifuged at 150 x 
g for 5 minutes. The supernatant was removed and the cell pellet was resuspended in 
PBS. A cell count was taken using a Scepter 2.0 Cell Counter (Merck). 1.5x105 cells 
were electroporated per well of a 24-well plate. Based on this, an appropriate volume 
of cell suspension was transferred to a fresh Falcon tube and centrifuged at 150 x g for 
5 minutes. During centrifugation, plasmids and repair templates were aliquoted into 
microcentrifuge tubes; 500ng of plasmid per transfection, and if included, 0.75µl of 
ssODN at 10µM per transfection.  
Following centrifugation, cell pellets were resuspended in an appropriate volume of 
buffer R to bring the total volume to 10µl per reaction, and cells were mixed with the 
DNA. DNA-cell solutions were taken up into 10µl Neon tips, and electroporated with 
the following parameters: 1300V, 20ms, 2 pulses. Electroporated cells were 
immediately returned to growth media. Plates were then returned to the incubator. 




2.12.1.3 Protocol for Neon RNP Transfection (MEFs) 
The protocol for RNP Transfection of MEFs was adapted from the section 
‘Transfection of HEK293 FT cells using the Neon Transfection System’ in the User 
Guide for the GeneArt Platinum Cas9 Nuclease (catalogue number B25641) from 
Thermo Fisher Scientific (2015). The only alterations are the potential inclusion of a 
repair template in step 2, and that electroporation was performed using the parameters 
optimised for MEFs (1350V, 30ms width, 1 pulse) in step 11. 
2.12.2 4D-Nucleofector System 
Transfections with the 4D-Nucleofector System (Lonza) were performed using the P4 
Primary Cell 4D-Nucleofector® X Kit L (catalogue number: V4XP-4024) and the 
following protocol, adapted from the manufacturer’s supplied protocol for MEFs 
(available at http://bio.lonza.com/go/op/335). 
The supplied nucleofector solution was allowed to warm to room temperature. MEF 
growth media (Section 2.22.3) was added to the required number of wells in a six well 
plate, which was returned to a 37°C incubator. MEFs were dissociated with 
Trypsin/Versene (Section 2.22.3), and an equal volume of MEF growth media was 
added. The cell suspension was centrifuged at 150 x g for 5 minutes, the supernatant 
removed, and the pellet resuspended in 10ml of PBS. The cell suspension was diluted 
1 in 2 in PBS and a cell count was performed using a Scepter 2.0 Cell Counter (Merck). 
Based on the cell count, an appropriate volume of the cell suspension (containing 
0.5x105 cells per well required) was transferred to a Falcon tube. This was centrifuged 
at 150 x g for 5 minutes. 
Following centrifugation, the supernatant was removed and the pellet was resuspended 
in 100µl Buffer P4 (Lonza). The cell suspension was then transferred to the 
nucleocuvette vessel(s). The desired substrates (e.g. plasmid DNA) were added to the 
nucleocuvettes with gentle mixing. 0.5µg of plasmid was used per 1x105 cells along 
with 0.5µl of 10µM ssODN repair template. Nucleocuvettes were gently tapped to 
settle the contents and nucleofected using programme CZ-167 in the X-Unit of the 
4D-Nucleofector System. Following nucleofection, nucelocuvettes were incubated at 
room temperature for 10 minutes. Subsequently, 500µl of growth media was added to 
the nucleocuvette and cells were gently resuspended. An appropriately sized aliquot 
86 
 
of cells was transferred to the required number of wells of a 6-well plate, and plates 
were returned to a humidified incubator at 37°C, 5% CO2, 3% O2. 
2.12.3 jetPRIME Transfection 
jetPRIME (Polyplus transfection, catalogue number: 114-07) transfections were 
performed as per the manufacturer’s instructions (https://www.polyplus-
transfection.com/wp-content/uploads/2015/08/Short-Protocol-jetPRIME-DNA-
vF.pdf). Briefly, for each well of a 6-well plate, DNA was mixed with jetPRIME 
reagent at a 1:2 ratio and 200µl of jetPRIME buffer was added. This mixture was 
vortexed and centrifuged briefly, then incubated at room temperature for 10 minutes. 
Subsequently, the transfection mix was added to the cells in 2ml of MEF growth 
media. Twenty-four hours later, media was replaced. 
2.12.4 Viral Transduction 
The reagents used for viral transduction of mTmG MEFs, along with the following 
protocol, were both received from Dr. Peter Tennant. Lentivirus was generated by Pam 
Brown (Shared University Research Facilities, University of Edinburgh), while adeno-
associated virus (AAV) was generated by Christina McClure (Centre for Integrative 
Physiology, University of Edinburgh). 
On day one, MEFs were seeded into a 24-well plate at a density of 1x105 cells per well. 
The next day wells were generally 80-90% confluent. A fresh stock of polybrene was 
made in PBS to a concentration of 5mg/ml. Polybrene mix was added to MEF growth 
media (Section 2.22.3), 2µl per ml, and 1ml polybrene-media mix was then transferred 
per reaction to a 1.5ml microcentrifuge tube. To this, 4µl of lentivirus and/or 4µl of 
AAV repair template was added per tube and 500µl was transferred to each well of the 
24-well plate. Plates were then returned to a humidified incubator at 37°C, 5% CO2, 
3% O2 for 4 hours. Subsequently, each well was washed with PBS and 500µl of fresh 
growth media was added. Three days later, this transduction protocol was repeated. 




2.13 Repair Template Design 
Repair templates were all designed manually, either by myself, Dr. Pleasantine Mill or 
Dr. Peter Tennant. ssODN ‘ultramers’ were ordered from Integrated DNA 
Technologies (IDT), plasmids were ordered from Thermo Fisher, and minicircles were 
created in-house by Dr. Peter Tennant, containing the repair plasmid sequence minus 
the bacterial backbone. 
2.13.1 mTmG Repair Templates 
For the mTmG system, three different ssODNs (NLS EGFP 1-3) were designed by Dr. 
Pleasantine Mill, alongside three different plasmids (Figure 3.4). The minicircle used 
in later experiments contains the repair sequence in H2Bv2. 
2.13.2 Zmynd10 Repair Templates 
For the Zmynd10 repair experiments only ssODNs were used, which all contained the 
wild-type reference sequence from Ensembl (ENSMUST00000010188). ssODNs 
were designed specifically for each of the three guides used (Figure 5.3). 
2.14 Small Molecule Enhancers of HDR 
Small molecules were added to media immediately prior to transfection. All molecules 
were received in powdered form and resuspended in DMSO to a stock concentration 
recommended by the manufacturer. The stock solutions were separated into several 
aliquots and stored at -80°C. The 6 small molecules used were: 
Brefeldin A (Cambridge BioScience, catalogue number: B012-5mg),  
L-755,507 (Cambridge BioScience, catalogue number: 18629-5 mg-CAY), 
Mirin (Cambridge BioScience, catalogue number: 13208-5 mg-CAY), 
NU-7441 (Cambridge BioScience, catalogue number: 14881-5 mg-CAY), 
SCR7 (XcessBio, catalogue number: M60082-2s) and 
RS-1 (Cambridge BioScience, catalogue number: B1118-5) 
Note: In 2016, Tocris indicated (https://resources.tocris.com/pdfs/archive/5342.pdf) 
that the correct identity of the molecule being used as SCR7, and which was received 
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from XcessBio, is SCR7 pyrazine. Nevertheless, it is SCR7 pyrazine which was shown 
to increase rates of HDR. In this thesis, ‘SCR7’ is taken to refer to SCR7 pyrazine 
exclusively. 
2.15 Confocal Imaging 
Imaging experiments were performed using different platforms depending on the aims 
of the experiment. Thirty minutes prior to most experiments, one drop of NucBlue 
Live ReadyProbes Reagent (Thermo Fisher, catalogue number: R37605) was added to 
stain nuclei. All confocal imaging experiments were carried out in glass-bottomed 
plates. 
Platforms used include Nikon A1R and A1 confocal microscopes, Dragonfly spinning 
disk confocal (Andor) and Celldiscoverer 7 (Zeiss). The most up-to-date software 
recommended by the manufacturer was used to operate the microscopes and acquire 
images during each experiment. Lasers/LEDs were set up to visualise the tdTomato 
(561nm excitation), EGFP (488nm) and Hoechst (405nm) channels and used at the 
lowest possible intensities which produced a clear signal. Laser/LED intensities and 
gain were kept constant between all wells during an individual experiment. Depending 
on the aims of the experiment, a range of different magnifications was used. Generally, 
no environmental control, apart from heating the chamber to 37°C, was required for 
short imaging experiments (< 3 hours). 
In order to remove bias from imaging experiments which were to be quantified, several 
positions (usually 10) were chosen at random per well. These were programmed, 
including perfect-focus settings, prior to the experiment and saved on the relevant 
software. This allowed automated, un-biased capture on the experimental plate. 
2.15.1 Time-lapse Imaging 
Time-lapses were captured on the Dragonfly spinning disk confocal (Andor). One 
10µm Z-stack was captured at each position every 20 minutes. Positions were 
programmed prior to imaging and saved. Movement between positions was automated 
and the Nikon Perfect Focus System (PFS) was used to maintain focus. During 




2.16 Image Processing & Analysis 
Images were processed using the appropriate software for each imaging platform, that 
being Fiji/ImageJ (Schindelin, Arganda-Carreras et al. 2012, Rueden, Schindelin et al. 
2017) for Nikon platforms, Imaris (Bitplane) for Dragonfly and Zen (Zeiss) for the 
Celldiscoverer 7. Where post-processing was applied, such as changes in brightness or 
contrast, it was applied equally to all images in the experiment. 
2.16.1 Cell Counter and Nucleus Counter (Fiji) 
To calculate the number of cells in an image, the Nucleus Counter plugin in Fiji was 
employed. Settings were optimised for the Hoechst stain levels in each experiment and 
were validated by manually counting three images and ensuring Nucleus Counter 
results were within 15% of the manual counts. GFP-positive nuclei were manually 
counted using the Cell Counter plugin in Fiji. 
2.16.2 Imaris Time-lapse Analysis Settings 
Imaris (Bitplane) was used with the ‘Track’ module enabled to measure changes in 
fluorescence intensity over time. The Track module settings used to measure and track 
EGFP, tdTomato and background intensities are included on the attached media CD 
(ImarisTrackAnalysisSettings.rtf). ‘Tomato Removal’ settings were applied prior to 
measuring the background intensity, to ‘remove’ cells from an image, leaving 
background regions. 
2.16.3 CellProfiler & CellProfiler Analyst 
CellProfiler (Carpenter, Jones et al. 2006) and CellProfiler Analyst (Jones, Kang et al. 
2008) were used to count nuclei and GFP-positive nuclei in images. CellProfiler was 
programmed to identify nuclei, in the Hoechst channel. Following this, the ‘machine-
learning’ tool, CellProfiler Analyst, was ‘taught’ on an image-by-image basis to 
identify GFP-positive nuclei by manually selecting several positive cells. CellProfiler 




2.17 Fluorescence-Activated Cell Sorting 
Cells were prepared for flow cytometry (FC) or fluorescence-activated cell sorting 
(FACS) by rinsing in PBS and dissociating thoroughly in Trypsin/Versene (Section 
2.22.3) at 37°C for 5-10 minutes. Cells were aspirated by pipette several times to 
ensure a single cell suspension had been created. Following this, an equal volume of 
growth media was added and cells were transferred to 15ml Falcon tubes. These were 
centrifuged at 150 x g for 5 minutes, and the cell pellet was resuspended in PBS, 
generally 200-500µl. This cell suspension was transferred into a 4.5ml FACS tube (BD 
Falcon). 
To provide cell counts, a BD LSRFortessa or BD Accuri C6 was used, whereas to sort 
cells a BD FACSJazz or BD FACSAria were used (All BD Biosciences). Sorting gates 
were manually set on all machines. For EGFP an excitation filter of 488/50 was used 
with an emission filter of 525/50 (488-525/50). For Tomato, 561-610/20, 561-586/15 
or 561-582/15 were used depending on the machine. Within an experiment gates were 
kept constant between samples to allow comparison. For population counts, generally 
100,000 cells were sorted per sample. 
2.18 Next-generation Sequencing 
Next-generation sequencing (NGS) was carried out on two platforms, the Ion Torrent 
Personal Genome Machine (PGM) System (Thermo Fisher) using the Ion Torrent 314 
v2 chip (400bp reads), or the Oxford Nanopore MinION. 
2.18.1 Ion Torrent 
Samples were prepared for Ion Torrent sequencing either by myself or by the 
Edinburgh Wellcome Trust Clinical Research Facility (WTCRF). Sample preparation 
for MinION runs was performed by the WTCRF. 
2.18.1.1 Ion Torrent In-house Sample Processing 
For the Zmynd10 Ion Torrent sequencing run (Section 5.5), PCR samples were 
prepared for sequencing by myself and then sequenced at the IGMM. PCR products 
were purified twice using Agencourt AMPure XP beads (Beckman Coulter) as per the 
manufacturer’s instructions. Purified PCR products were analysed on an Agilent 
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Bioanalyzer 2100 using a high sensitivity DNA assay. Following this, an equimolar 
pool of all samples was prepared and submitted to the IGMM technical services for 
sequencing. 
2.18.1.2 Ion Torrent Processing by the WTCRF 
PCR Products were purified (Section 2.4.2) and eluted in TE-buffer before being 
transferred to the WTCRF. Samples were then processed by the facility. Amplicons 
were quantified using a Qubit dsDNA HS kit (Thermo Fisher, catalogue number 
Q32851) and then sheared using a Covaris E220 Evolution Focused Ultrasonicator 
(Thermo Fisher). Sheared samples were quantified, and Ion-compatible barcoded 
adapters (Thermo Fisher) were attached. The library was then amplified (10 cycles) 
and size selected using AMPure XP beads (Beckman Coulter) for fragments 
approximately 300bp in length. Barcoded libraries were checked for purity and 
quantified, and an equimolar stock was prepared and sequenced.  
2.18.2 MinION Processing by the WTCRF 
Amplicons were quantified using a Qubit dsDNA BR assay (Thermo Fisher, catalogue 
number: Q32850) and 50ng of each amplicon was end-repaired and adenylated using 
an NEBNext Ultra End Repair/dA-Tailing Module kit (NEB, catalogue number: 
E7442S) and purified using AMPpure XP beads (Beckman Coulter). Barcode adapters 
from the PCR Barcoding Kit 96 (Oxford Nanopore Technologies, catalogue number: 
EXP-PBC096) were ligated to the end-repaired, dA-tailed DNA during 18 cycles of 
PCR. Excess barcode adapters were removed using AMPure XP beads, and barcoded 
DNA was quantified using a Qubit dsDNA HS assay (Thermo Fisher, catalogue 
number Q32851). Equal quantities of each barcoded amplicon were pooled before 
being end-repaired and adenylated to allow ligation of sequencing adapters and tethers 
from the Nanopore 1D2 Sequencing Kit (Oxford Nanopore Technologies, catalogue 
number: SQK-LSK308). Libraries were purified with AMPure XP beads before 
elution in a proprietary Running buffer. The sequencing library was quantified using 
a Qubit dsDNA HS assay and an equimolar stock was prepared and sequenced. 
2.19 Sequencing Analysis Pipelines 
Pipelines were designed in-house to analyse the resulting data from NGS and were 
created as shell scripts in Unix which call on various software packages to perform 
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tasks such as alignments and quality control. The pipeline was initially designed for 
Ion Torrent data, and then adapted to process MinION data. The scripts used are 
provided on the attached media CD (IonTorrent_Editing_Analysis.sh and 
MinION_Editing_Analysis.sh). 
2.19.1 Ion Torrent Analysis Pipeline 
The Ion Torrent script takes as input a fastq file, as is output from an Ion Torrent run, 
and uses Bowtie 2 (Langmead and Salzberg 2012) to align reads against a custom 
reference sequence which is also supplied by the user. BamQC (Simon Andrews, 
https://github.com/s-andrews/BamQC) is called to provide quality control metrics on 
the input data. Following this, samtools (Li, Handsaker et al. 2009), bam-readcount 
(https://github.com/genome/bam-readcount) and the Genome Analysis Toolkit 
(McKenna, Hanna et al. 2010) packages are used to generate alignment statistics. Two 
different variant callers are invoked for comparison, VarScan 2 (Koboldt, Zhang et al. 
2012) and the Bcftools package by samtools. Bowtie 2 alignments were visualised 
using the Integrative Genomics Viewer (Robinson, Thorvaldsdóttir et al. 2011, 
Thorvaldsdottir, Robinson et al. 2013), which was also used to produce several figures. 
2.19.2 MinION Analysis Pipeline 
The MinION processing script was derived from the Ion Torrent script and is largely 
the same except that GraphMap (Sovic, Sikic et al. 2016) is used to align reads and 
that the following alignments are ‘cleaned up’ using Picard Tools 
(http://broadinstitute.github.io/picard). GraphMap contains a dedicated algorithm for 
aligning Oxford Nanopore data. Prior to running the MinION script, the .fast5 output 
was converted to .fastq using Poretools (Loman and Quinlan 2014), and then processed 
using Porechop (https://github.com/rrwick/Porechop) to split the file by barcode. A 
BBMap script, readlength.sh (https://github.com/BioInfoTools/BBMap), was used to 
generate read length histograms and calculate mean/median read lengths. 
2.20 De novo Genome Assembly 
SPAdes (Bankevich, Nurk et al. 2012) was used to assemble Ion Torrent data, whereas 
Canu (Koren, Walenz et al. 2017) was used to assemble MinION data. Settings in both 
93 
 
were tailored to expect a small, repetitive genome. The programme Bandage (Wick, 
Schultz et al. 2015) was used to visualise the resulting genome assemblies. 
2.21 Graphing & Statistical Analyses 
Counts from imaging and FACS/FC were plotted graphically and analysed using the 
Microsoft Excel package. Where biological replicates were performed, a Student’s 
t-test was performed to determine the statistical significance of any difference between 
populations. T-test results below p=0.05 were considered to be statistically significant. 
Furthermore, for experiments with biological replicates, graphs were plotted as the 
mean ± 1 SD to show variation in the results, unless otherwise stated. In cell culture 
experiments with the mTmG line, each batch of cells (biological replicate) was treated 
(generally transfected with or without drug), maintained and assayed separately for the 
entire experiment. 
2.22 List of Recipes 
2.22.1 General Recipes 
20x TBE (1000ml): 
216.0 g Tris base  
110.0 g Boric Acid  
80mL 0.5 M EDTA, pH 8.5 
Add ddH2O to 1000ml 
 
1x PBS (1000ml):  
 800ml ddH2O 
8.00g NaCl  
0.20g KCl  
1.44g Na2HPO4  
0.24g KH2PO4 
Adjust pH to 7.4 with HCl 





10x Orange G Loading Dye (50ml):  
30% Glycerol in ddH2O 
100mg Orange G 
 
1x Surveyor Buffer: 




2.22.2 Recipes for Bacterial Culture 
Luria-Bertani Broth (LB) (1000ml):  
 10.00g Tryptone 
5.00g Yeast Extract  
10.00g NaCl  
1.00g Glucose  
Add ddH2O to 1000ml 
Add Ampicillin (to 100µg/ml) or Kanamycin (to 50µg/ml) as required 
 
Freezing Media 
 70% Luria Broth 
 30% Glycerol 
 
LB-Agar (1000ml): 
 10.00g Tryptone 
5.00g Yeast Extract  
10.00g NaCl  
1.00g Glucose  
15.00g Agar 
Add ddH2O to 1000ml 




2.22.3 Recipes for Tissue Culture 
MEF Growth Media (500ml): 
 450ml Opti-MEM (Thermo Fisher, catalogue number: 31985070) 
 50ml FCS 
 5ml P/S 
 3.7µl β-mercaptoethanol 
 
MEF Freezing Media (50ml): 
 35ml MEF growth media 
 10ml FCS 
 5ml DMSO 
 
Hank’s Solution (100ml): 
 84ml Sterile, filtered tissue culture water 
 10ml HBSS + Ca + Mg (Thermo Fisher, catalogue number: 24020083) 
 5ml 1M HEPES (Thermo Fisher, catalogue number: 15630056) 
 1ml P/S 
 
Ependymal Growth Media (500ml): 
 450ml DMEM + GlutaMAX (Thermo Fisher, catalogue number: 10566016) 
 50ml FCS 
5ml P/S 
 
Ependymal Serum-Starvation Media (500ml): 
 495ml DMEM + GlutaMAX (Thermo Fisher, catalogue number: 10566016) 








1x Trypsin (1000ml): 
2.00g Trypsin 1:250 
0.06g Penicillin 
0.13g Streptomycin 
5.0ml 0.2% Phenol Red 
Add 1x PBS to 1000ml 
Adjust pH to 7.8 with NaHCO3 
 
1x Versene (1000ml): 
 0.40g Sodium EDTA 
 5.00ml 0.2% Phenol Red 
Add 1x PBS to 1000ml 
 
Trypsin/Versene (100ml): 
 50ml 1x Trypsin 
 50ml 1x Versene 
 
Quick Lysis Buffer (500ml): 
 25ml 2M Tris-HCl pH7.5 
 5ml 0.5M EDTA 
 10ml 10% SDS 
 20ml 5M NaCl 






Chapter 3 Repurposing of the mTmG Fluorescent 
Reporter System for CRISPR-mediated Genome Editing  
3.1 Introduction 
3.1.1 Repurposing of the Lineage-Tracing mTmG Fluorescent 
Transgenic Mouse 
Fluorescent reporters allow a rapid visual read-out of cellular events, both at a cellular 
and organismal level, which can be visualised and quantified using imaging or via flow 
cytometry (FC). Several fluorescent reporter systems have been made to track genome 
recombination events by Cre-recombinase, including the Z/EG reporter mouse 
(Novak, Guo et al. 2000). This is a random insertion transgenic mouse line, where a 
floxed LacZ is driven by the Cytomegalovirus (CMV) enhancer/chicken actin 
promoter (pCA); which while widely expressed is not ubiquitous, including in the 
airways. When crossed onto a Cre-deleter strain, lacZ expression is replaced with 
GFP. In another line from the Constantini group, the pCA promoter was used to drive 
a floxed CFP or YFP, this time targeted to the ubiquitously expressed Rosa26 locus, 
marking each cell type in the embryo and adult (Srinivas, Watanabe et al. 2001).  The 
mTmG mouse designed by Muzumdar, Tasic et al. (2007) contains a double 
fluorescence Cre-reporter cassette, which is also targeted to the Rosa26 locus. In the 
absence of Cre-mediated recombination, the ubiquitously expressed pCA promoter 
drives expression of a floxed membrane-tdTomato-polyA sequence. Upon Cre-
mediated recombination, the Tomato portion is excised, and the pCA promoter drives 




Figure 3.1: Cre-mediated recombination in the mTmG mouse leads to a specific 
transition from membrane-Tomato to membrane-GFP. A) Schematic of the 
mTmG locus. Grey triangles represent loxP sites. pA = polyadenylation signal. Not to 
scale. B–D) Following injection with tamoxifen at P7, actin-CreER mice display a 
complementary pattern of mTomato and mEGFP labeling in the liver (B-B’’), cerebral 
cortex (C), and retina (D). E-G) Following injection with tamoxifen, liver hepatocytes 
from adult mTmG;actin-CreER mice can be seen to grandually transition from 
mTomato to mEGFP. The persistence of membrane-Tomato is evidenced by the 
double-positive cells in (E) which can be seen to have largely disappeared in (F). A 
linear regression indicates a total elimination of mTomato after ~9 days (G). Scale bar: 
(B–F) 50 µm. Figure adapted from Muzumdar, Tasic et al. (2007). 
 
Given the nature of this dual reporter, we believed the mTmG system could be adapted 
to provide a visual read-out of genomic editing events. By targeting CRISPR/Cas9 to 
an identical sequence which surrounds the two loxP sites, we can distinguish non-
edited cells (membrane Tomato) from edited cells (other); allowing us to quantify 
editing efficiencies. Furthermore, by changing the localisation signal from a 
MARCKS membrane tag to a nuclear signal, we can separate both non-homologous 
end joining (NHEJ, membrane EGFP) and homology-directed repair (HDR, nuclear 
EGFP) driven by CRISPR/Cas9 by supplying a repair template. The Rosa26 mTmG 
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locus, along with our system for measuring rates of editing and repair, is illustrated in 
Figure 3.2: 
 
Figure 3.2: Schematic representation of the repurposed mTmG fluorescent 
reporter system, for measuring CRISPR-mediated genome editing (NHEJ) and 
repair (HDR) A) On the Rosa26 mTmG locus the target sequence for the guide-RNA 
(gRNA) is indicated with an orange bar, dashed lines Cas9 cleavage sites, the black 
arrow indicates the promoter, grey triangles loxP sites, boxes genomic elements and 
hexagons cells with oval nuclei inside. B) The resulting mixed population following 




3.2 Design Strategy for Repurposing the mTmG Locus to 
Report on Genome Editing Events 
3.2.1 Design of Guide-RNAs 
Two guides were designed in the laboratory to target the identical sequence 
surrounding the loxP sites in the Rosa26 mTmG locus (Section 2.1). Both guides were 
cloned into the Cas9 expression vector pX330 (Section 2.2). Using either of these 
guides, we would expect the creation of two double strand breaks (DSBs) resulting in 
the loss of the intervening 2.4kb fragment containing the membrane-tagged Tomato 
(Figure 3.3). The use of two different guides allows us to compare the efficiency of 
deletion at the same locus, with different target sequences. 
 
Figure 3.3: Schematic showing the location of the two guides used to target the 
loxP sites in the mTmG locus. Above: black arrow represents the promoter, grey 
triangles loxP sites and boxes genomic elements. Below: yellow indicates the target 
site while blue indicates the PAM. 
3.2.2 Repair Template Design 
As the ideal format for repair is not currently known, six different repair templates 
were designed in the lab (Section 2.13) and employed in the following work, to attempt 
to maximise rates of HDR. These repair templates have varying sized regions of 
homology, and were in various formats, such as single-stranded oligonucleotide 
(ssODN), plasmid and minicircle (a plasmid with the bacterial backbone removed). 
These repair templates were all designed to replace the MARCKS membrane tag with 
a nuclear signal; either an SV40 NLS sequence or the (well tolerated) human histone 
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H2B sequence, to determine which provides cleaner nuclear localisation. Whereas the 
NLS sequence requires active transport into the nucleus, proteins tagged with H2B are 
robustly incorporated into nucleosomes in cells from mice at all developmental stages 
(Kanda, Sullivan et al. 1998, Hadjantonakis and Papaioannou 2004). Furthermore, all 
but one of the repair templates harboured additional changes in that the PAM sites, 
necessary for Cas9 binding, in order to prevent cleavage of the template and repaired 
alleles. The repair templates used are summarised in Figure 3.4: 
 
Figure 3.4: Schematic representation of the repair templates used, displaying 
their regions of homology with respect to the pCA promoter and EGFP sequence. 
The size of the homology arms (in nt/bp) are indicated. Single basepair changes which 
abolish the PAM sites for LoxP#1 and LoxP#2 guides are indicated with yellow stars. 
H2Bv2 lacks the final ten codons of the EGFP sequence. Above: black arrow 






3.3 Derived mTmG MEFs and Ependymal Cells Display Stable 
Membrane-Tomato Fluorescence 
To test that the mTmG reporter system could be utilised to monitor genome editing 
events, we isolated primary cells from the mTmG mouse. Mouse embryonic fibroblasts 
(MEFs) and ependymal cells were derived from E11.5 and E18.5 mice, as described 
in Sections 2.10.1 and 2.11.1 respectively. Cells were cultured until a relatively 
homogenous population was obtained, 7 days for ependymal cells or passage 3 (P3) 
for MEFs. The ependymal radial glial progenitors were then serum-starved to induce 
terminal differentiation and multi-ciliation, forming motile ciliated ependymal cells. 
Both cell types were imaged following this process on a Nikon A1R confocal 
microscope at 20x, which confirmed that all cells display membrane-Tomato 
fluorescence with no cells displaying membrane-EGFP or loss of fluorescence. This 
indicates that there is no spontaneous conversion of the locus in the absence of Cas9 




Figure 3.5: Unedited mTmG MEFs (above) and mTmG ependymal cells (below) 
display only Tomato expression. Cells were imaged at 20x on a Nikon A1R confocal 
microscope. Scale bar 200µm. 
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3.4 Optimising Delivery of the Editing Machinery to Primary 
Cells 
In order to test that our system reports on genome editing, I transiently transfected our 
two cells lines; MEFs, with primary cilia only, and ependymal cells, a more clinically 
relevant motile-ciliated cell type, using a range of nucleofection platforms; including 
the Neon Transfection System (Thermo Fisher) and the 4D-Nucleofector System 
(Lonza). Furthermore, the lipid-based jetPRIME transfection reagent (Polyplus) was 
tested. All initial transfections were performed with the LoxP#1 pX330 plasmid alone. 
Further details on the transfection protocols can be found in Section 2.12. Following 
these trials, the Neon Transfection System, was found to be the most consistently 
efficient method of transfection, for both MEFs and ependymal cells. The 
4D-Nucleofector system resulted in a high amount of cell death, whereas transfection 
rates were very low with the jetPRIME transfection reagent (not quantified, images 
not shown). 
3.4.1 Neon Transfection System – MEFs 
mTmG MEFs were transfected with LoxP#1 pX330 using the Neon Transfection 
System as described in Section 2.12.1 with 10µl transfection tips. As controls a non-
electroporated and no DNA (electroporated) control were also prepared. 120-hours 
post-transfection, cells were imaged on a Nikon A1R confocal microscope. A large 
number of cells in the transfected population could be seen to have gained EGFP-
fluorescence, and many of the same cells appeared to have lost Tomato fluorescence. 
These cells were then analysed by FC at 144-hours post-transfection, at which time 
~20% of the cells appeared to be edited (Figure 3.6). The edited cells fell broadly into 
four populations; Tomato-positive (Q1), double-positive (Q2), double-negative (Q3) 
and GFP-positive (Q4). The double-positive (GFP+ Tomato+) population could 
potentially be explained by the ~4.5 day half-life of tdTomato (Muzumdar, Tasic et al. 





Figure 3.6:  The Neon Transfection System provides high transfection efficiency 
(~21%) and low cell death in mTmG MEFs. A, A’) Cells were imaged at 20x, 120-
hours post transfection, at which point GFP-positive cells could clearly be seen in the 
transfected sample. B, B’) Cells were analysed by FC 144-hours post-transfection, 
revealing all non-transfected cells are Tomato-positive, whereas there is a substantial 
shift in fluorescence in the transfected population. Scale bars 200µm. 
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3.4.2 Neon Transfection System – Ependymal Cells 
During the expansion phase, ependymal progenitor cells were transfected with LoxP#1 
pX330 using the Neon System (Section 2.12.1.2). A no DNA, electroporation control 
was also prepared. Transfected cells were allowed to proliferate for 5 days following 
transfection prior to serum-starvation. Approximately 14 days following serum-
starvation, cells began to form multicilia. 18 days following serum-starvation, wells 
were imaged on a Nikon A1R confocal microscope. Each well was imaged in 5 random 
positions, and images were quantified using the Nucleus Counter and Cell Counter 
plugins in Fiji (Figure 3.7). GFP-positive cells, which appeared by morphology to be 
ependymal cells, were present in every image, although the transfection efficiency was 




Figure 3.7: The Neon Transfection System transfects ependymal progenitor 
cells, albeit at low efficiency (~3.2%). A) Confocal images of non-transfected and 
LoxP#1 pX330 transfected ependymal cells captured at 20x, 18 days post-
transfection. Scale bar 200µm. B) Nucleus Counter and Cell Counter plugins in Fiji 
were used to quantify the images. 
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3.4.3 Plasmid Concentration is a Limiting Factor in Transfection 
Efficiencies 
Low transfection efficiencies associated with the Neon Transfection System could be 
due to excessive plasmid/DNA concentration and the following death of transfected 
cells. To test this I decided to perform a concentration curve with the LoxP#1 pX330 
plasmid. mTmG MEFs were transfected using the Neon system and 10µl tips (Section 
2.12.1). Three different concentrations of LoxP#1 pX330 were used, along with a 
Zmynd10 pX330 plasmid control (targets the endogenous Zmynd10 locus which is not 
expressed in MEFs), a no DNA electroporation control, and a cell only control. 3x105 
cells were transfected per well of a 6-well plate.  
Seventy-two hours post-transfection, each well was dissociated and cells were scored 
for GFP fluorescence using a BD FACSAccuri C6 flow cytometer (BD Biosciences). 
FC results showed a linear decrease in the number of GFP-positive cells upon 
decreasing plasmid concentration, suggesting this is a limiting factor. Cell survival did 
not appear to be affected by DNA concentrations in this range, but may have been 




Figure 3.8: There is a trend to higher transfection efficiencies with greater 
plasmid concentrations without cytotoxicity in mTmG MEFs.  A) FC plots of cell 
count versus GFP intensity. B) Summary of transfection conditions for each well along 
with the percentage of GFP+ cells and cell densities at 72 hours post-transfection. 
3.4.4 Scaling up Neon Transfections 
In order to mitigate the effect of buffer R on cell survival, while still transfecting a 
large number of cells, I tested whether similar transfection efficiencies could be 
achieved using 100µl Neon electroporation tips instead of the 10µl tips used 
previously. This would allow us to transfect 5x105 cells per reaction as opposed to 
0.5x105 (10x increase). 
Reagents were scaled up ten-fold for the 100µl tips; 5000ng pmaxGFP plasmid 
(Lonza) was used per reaction, and a range of voltages was assayed. At the same time, 
two controls were prepared: a well transfected using the 10µl tips as previously and a 
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no DNA control. Furthermore, in order to see whether plasmid concentrations could 
be increased further, a 750ng DNA/reaction well was prepared using the 10µl tips. 
Forty-eight hours post-transfection wells were imaged at 20x on the Nikon A1R 
(Figure 3.9A). The following day, wells were dissociated and the GFP-intensity of the 
cells was measured using a BD FACSAccuri C6 flow cytometer. Results indicated that 
the 100µl tips may even provide higher transfection efficiencies than the 10µl tips 
(91% vs. 86%), whereas the current voltage used appeared to be ideal (Figure 3.9C). 
There did not appear to be a substantial increase in transfection efficiency with the 
(50%) higher plasmid concentration. Based on this, it was decided to use the following 
transfection parameters for MEFs with the 100µl tips in all future experiments, unless 
otherwise stated: 
  1000ng of DNA per 1x105 cells, 1350V, 30ms, 1 pulse 
Furthermore, comparing the results of this experiment with the previous section, it is 
apparent that there is either a substantial difference in transfection efficiencies or cell 
survival following transfection with pX330 and pmaxGFP. Alternatively, these results 
could suggest that the majority of cells transfected with pX330 are not being edited. 









Figure 3.9: High rates of transfection (~90%) are seen with the 100µl Neon 
electroporation tips in MEFs A) Confocal images of each well taken at 20x, 48 hours 
post-transfection. Scale bar 200µm. B) FC plots of the wells showing cell count versus 
GFP intensity, taken at 60 hours post-transfection. C) Summary of transfection 
conditions used for each well along with the resulting percentage of GFP+ cells.  
3.4.5 Plasmid Size may be a Limiting Factor in Transfection Efficiencies 
In order to ascertain whether the size or associated cytotoxicity of the pX330 plasmid 
could account for the large difference in the number of GFP-positive cells between 
LoxP#1 pX330 and pmaxGFP, I decided to test the transfection efficiency of a larger 
(Cas9 containing) GFP expression vector. To do this, an empty pX458 plasmid was 
employed which is a similar size to pX330 (9.3kb and 8.5kb respectively). 
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Furthermore, a brighter variant of pX458 was included for comparison. This contained 
a membrane-tagged monomeric green fluorescent protein derived from mTFP1 
Wasabi, cloned into the pX458 plasmid, to create pX458-mWasabi (generated in our 
group by Peter Budd), These vectors, including pmaxGFP, were transfected into 
mTmG MEFs, 5x105 cells per well (Section 2.12.1.1). Twenty-four hours post-
transfection, each well was imaged on the Nikon A1R confocal, then following 
imaging the cells were dissociated and analysed on a BD FACSAccuri C6 flow 
cytometer. 
The results from this experiment (Figure 3.10) suggest that plasmid size may have a 
marked effect on transfection efficiencies. The pmaxGFP plasmid is approximately a 
third of the size of pX458 (3.5kb vs. 9.3kb) and drives 6-fold greater expression of 
GFP. The same difference is seen when using a brighter variant of GFP. Cell densities 
following transfection appeared largely the same in all transfected wells suggesting 
this is not due to cytotoxicity. This must be taken into consideration when quantifying 
editing rates with the LoxP pX330 plasmids as their size is large (8.5kb) and smaller 
expression vectors are not readily available. A transfection, and hence editing, rate of 




Figure 3.10: Substantially less GFP expression is seen on using a larger expression 
vector in mTmG MEFs. A) Confocal images of each well taken at 20x 24 hours post-
transfection. Scale bar 100µm. B) FC plots of cell count versus GFP intensity for each 
well at 28 hours post-transfection. C) Summary of transfection conditions for each 
well along with the resulting percentage of GFP+ cells. 
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3.5 Use of a Heterozygous mTmG Line Reduces but Does Not 
Eliminate the Double-Positive Population 
Whilst we initially hypothesised that a homozygous mTmG cell line could report on 
editing at both alleles, extrapolating editing from the fluorescence observed, namely 
yellow or double positive, as well as fluorescence intensity (i.e. lower green intensity 
could be due several editing events) was overly complicated for our analyses. To 
monitor mono-allelic editing of the mTmG locus, the homozygous Rosa26 mTmG 
mouse line was crossed onto a CD1 line in order to generate heterozygous mTmG mice. 
MEFs were generated from these mice as before (Section 2.10.1) and were imaged on 
a Nikon A1R once they had reached confluency at P3. As before, all the cells could be 
seen to display membrane-Tomato and none membrane-EGFP. Importantly, there did 
not appear to be a significant decrease in fluorescence intensity (Figure 3.11). 
 
Figure 3.11: Heterozygous mTmG MEFs display Tomato fluorescence without a 
significant decrease in fluorescence intensity. Images captured at 20x. Scale bar 
200µm. 
To verify that the heterozygous MEFs also report accurately on genomic editing, they 
were transfected with LoxP#1 pX330 using the Neon System and 100µl tips (Section 
2.12.1.1), 5x105 cells per well. Seventy-two hours post-transfection, the cells were 
imaged on a Nikon A1R confocal. The cells were then dissociated and analysed by FC 
on a BD FACSAria seven days post-transfection. FC results (Figure 3.12) indicated 
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there is still a significant double-positive population present, although it is much 
reduced compared to in the homozygous MEFs, from ~60% of the non-red population 
(Figure 3.6) to ~11% (Here the non-red or ‘edited’ population is the total of the cells 
which fall in quadrants 1 to 3 (Figure 3.6), that is the total of the double-negative, GFP-
positive and double-positive populations). The majority of edited cells are now found 
in the negative and GFP-positive quadrants (Q3 and Q4 respectively). This suggests 
that a large proportion of the double-positive cells were mono-allelically edited, 
however, another explanation must be found for the remaining double-positive cells. 
The long time between transfection and sorting (7 days), combined with the very 
minimal reduction in Tomato fluorescence intensity in this double-positive population 




Figure 3.12: The size of the double-positive population (Q2) is substantially 
reduced in heterozygous mTmG MEFs compared to homozygous mTmG MEFs. 
Above, wells were imaged at 20x on a confocal microscope 72 hours post-transfection. 




3.6 Improving Rates of Editing in mTmG Ependymal Cells – 
Further Optimisation of the Neon Protocol 
Given the reasonably low editing efficiencies seen in the initial Neon transfection 
experiment (Section 3.4.2), I decided to screen a range of conditions with the aim of 
increasing the transfection efficiency.  Using heterozygous mTmG progenitor cells, 6 
transfections were performed with the Neon 10µl tips as described in Section 2.12.1.2, 
except 2.4x105 cells were transfected per well. Here the voltage and plasmid 
concentration were varied (Figure 3.13C). Following electroporation these cells were 
successfully differentiated into ependymal cells (Section 2.11.2). Each well was then 
imaged 8 days post-transfection on a Nikon A1R confocal microscope at 20x. Twenty-
four hours after imaging, wells were dissociated using TrypLE Express (Thermo 
Fisher) at 37°C for thirty minutes. The long incubation time was required as these cells 
are strongly adherent. The dissociated cells were then re-suspended in PBS and 
analysed on a BD FACSAria. 
Imaging and FC results indicated that there were much higher editing efficiencies in 
this experiment compared to previously; editing rates approaching 16% were seen 
(Figure 3.13B). Partially, this may be due to the increased sensitivity of FC as opposed 
to imaging, although it may also be due to batch-to-batch variation between mTmG 
progenitors. Changing the voltage or plasmid concentration within the range assayed 




Figure 3.13: Voltage and plasmid concentration do not have a large effect on 
ependymal Neon transfection efficiencies in the ranges assayed. A) 20x confocal 
images of the wells were taken at 8 days post-transfection, following differentiation. 
Generally, highly clonal populations of edited cells could be seen. Scale bar 200µm. 
B) Cells were analysed by FC 9 days post-transfection and the results graphically 
plotted. FC plots included on attached CD in file ‘Figure 3_13’. C) Summary of 
transfection conditions for each well along with the resulting rate of total editing. Note: 
well 1 was imaged without a nuclear stain and was also not analysed by FC. Well 2 




3.7 Membrane-tagged Fluorescent Reporters Allow Easy 
Identification of Edited Cell Types 
The ependymal cells from the preceding section were imaged at higher magnifications; 
40x and 80x using oil immersion on a Nikon A1R confocal microscope, 24 hours prior 
to being analysed by FC. These images demonstrate that the membrane-tagged 
fluorescent reporters allow simple visual identification of the edited cell types based 
on morphology and motility; the ependymal cells can clearly be identified based on 
their size, shape and formation of tight junctions. Furthermore, both membrane-
Tomato and membrane-EGFP can be seen to be present in motile cilia, indicating we 





Figure 3.14: The membrane-tagged fluorescent reporters allow identification of 
the edited cell types (here: ependymal cells) based on morphology. A) 40x confocal 
images of the ependymal cells reveal that cell morphology is clearly delineated by the 
membrane-tagged reporters. B) 80x confocal images of the non-transfected sample 
reveal that membrane-Tomato is visible in the motile cilia. C) 80x confocal images of 
the LoxP#1 pX330 transfected sample reveal that membrane-EGFP is also visible in 
the motile cilia. White arrows: patches of multi-cilia. Scale bars 10µm 
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3.8 Combining Guides against LoxP may Modestly Improve 
Rates of Editing 
As mentioned previously, two guides were designed against the loxP locus (Section 
3.2.1). The second guide was designed subsequent to the first guide, in order to 
ascertain whether our guide choice was limiting editing efficiencies. We also 
hypothesised that by targeting multiple loci simultaneously we may be able to improve 
rates of editing. To test this, I performed four transfections in the heterozygous mTmG 
MEFs; a no DNA control, LoxP#1 pX330, LoxP#2 pX330 and LoxP#1 pX330 + 
LoxP#2 pX330. The Neon System and the 100µl electroporation tips were used as 
described in Section 2.12.1.1 with 5x105 cells per reaction. The total amount of DNA 
was kept the same for all transfections (that is 5000ng total per well). The transfected 
wells were imaged 4 days post-transfection on a Nikon A1R confocal microscope, and 
then analysed by FC the following day on a BD FACSAria. Both guides when used 
alone drove similar rates of editing, suggesting no significant sequence-based bias at 
this locus. Combining both guides may increase rates of editing, although only 
modestly (Figure 3.15C). Unexpectedly, in this experiment there was again a large 
proportion of double-positive cells (approximately 40% of non-red). Furthermore, a 
greater proportion of the non-transfected MEFs appeared to be losing fluorescence. 
This is likely a technical issue, such as a blockage or contamination during the FC 
analysis, as few single, live cells were detected (only ~6,000 vs. ~50,000 for wells 2-




Figure 3.15: Both guides (independently) targeting the loxP sites generate similar 
levels of editing in mTmG MEFs. Combining the two guides appeared to have 
little effect. A) Summary of experimental set-up. B) Confocal images of each well 
captured at 20x, 96 hours post-transfection. Scale bar 200µm. C) Each well was 
analysed by FC 120 hours post-transfection and the results were plotted graphically. 
FC plots included on attached CD in file ‘Figure 3_15’. 
123 
 
3.9 ssODNs Are Able to Drive HDR at Our Locus, Albeit at a 
Very Low Frequency 
As explained in Section 3.2.2, three ~200nt ssODN repair templates were designed to 
remove the MARCKS membrane tag and affix a nuclear localisation signal to the 
EGFP in the mTmG mice. The three ssODN repair templates are termed NLS EGFP 
1, NLS EGFP 2 and NLS EGFP 3, and are of varying designs (Figure 3.4). All three 
repair templates were synthesised by IDT. The three repair templates were transfected 
into heterozygous mTmG MEFs, together with LoxP#2 pX330, using the 100µl Neon 
electroporation tips as described in Section 2.12.1.1. Seventy-two hours post-
transfection each well was imaged on a Nikon A1R confocal microscope. Seven days 
post-transfection, the wells were then analysed by FC on a BD FACSAria. 
Confocal imaging revealed that the ssODN repair templates were very inefficient at 
driving HDR in this system. Wells were scanned manually for nuclear GFP and only 
two positive cells were observed (in a confluent 6 well plate); these were transfected 
with LoxP#2 pX330 and NLS EGFP 1. Promisingly, the GFP signal overlapped 
perfectly with the Hoechst signal. These cells also appeared to be Tomato-negative 
indicating correct repair (Figure 3.16C). FC results again revealed similar editing rates 
with either LoxP#1 pX330 or LoxP#2 pX330 (FC does not distinguish nuclear- from 
membrane-GFP, see Section 3.14). Interestingly, rates of editing appeared to be 






Figure 3.16 (on previous page): ssODN repair templates are inefficient at driving 
HDR in the mTmG MEFs. A) Summary of experimental set-up. B) Confocal images 
were taken of each well at 20x, 72 hours post-transfection. Scale bar 100µm. C) 40x 
image of the cells with nuclear-GFP, which also appear to be Tomato-negative. Scale 
bar 100µm. White arrows: nuclear-GFP. D) 7 days post-transfection cells were 
analysed by FC and the results were plotted graphically. FC plots included on attached 
CD in file ‘Figure 3_16’. 
3.10 Increasing Rates of Repair by Increasing Homology – 
Design of mTmG Repair Plasmids 
Whilst ssODN repair templates are very effective for introducing small changes by 
HDR (Ran, Hsu et al. 2013), editing in our reporter system is on the scale of several 
kilobases and the ~60nt homology arms may not be sufficient. In order to provide 
significantly larger regions of homology, we engineered 2 plasmids each containing 
~800bp homology arms extending into the pCA promoter at the 5’ end and the EGFP 
at the 3’ end. Each has both loxP PAM sites mutated to prevent re-cleavage. The 
designs of the two original repair plasmids, NLS Repair and H2B Repair, are shown 
in Figure 3.4.  
Both plasmids were transfected into heterozygous mTmG MEFs alongside LoxP#1 
pX330 or LoxP#2 pX330 using the Neon 100µl electroporation tips (Section 2.12.1.1). 
Furthermore, one well was prepared to test the effect of doubling the total plasmid 
concentration (Figure 3.17A). Seventy-two hours post-transfection wells were imaged 
in ten random positions at 20x on a Nikon A1R confocal. The resulting images were 
then quantified using the Nucleus Counter and Cell Counter plugins in Fiji to estimate 
the percentage of cells which have undergone NHEJ and HDR. 
Unexpectedly, the images revealed that both plasmids, especially the H2B repair 
plasmid, are able to drive expression of nuclear-GFP in the absence of editing and/or 
repair (Figure 3.17). It is unclear how this would arise at this frequency as the repair 
plasmids are promoterless; their 780bp 5’ homology arms contain only part of the 
Chicken β-Actin intron and the Rabbit β-Globin splice acceptor. However, these 
results did indicate that the histone H2B sequence results in brighter nuclear-GFP than 
the SV40 NLS sequence. It is unclear why there appeared to be ~6 fold more edited 
cells in well 4 with LoxP#1, as previously we had seen similar results with both 
plasmids. The results from this experiment also indicated that doubling the total 
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plasmid concentration (by adding an equal amount of repair plasmid) appears to be 
well tolerated and offers greater rates of editing (cf. well 5 and 6). Based on this, in all 
following experiments 1000ng of Cas9 plasmid(s) and 1000ng of repair plasmid 
(2000ng total) were used per 1x105 cells.  
 
Figure 3.17: Promoterless repair plasmids drive expression of nuclear-GFP in the 
absence of editing in mTmG MEFs. A) Summary of experimental set-up. B) 
Representative confocal images of each well taken at 20x 72-hours post-transfection. 
Scale bar 100µm. C) Confocal images were quantified using Nucleus Counter and Cell 
Counter plugins in Fiji and the results were plotted graphically. 
127 
 
3.11 Creation of Immortalised mTmG MEF Lines to Facilitate 
Experiments 
MEFs have a limited life-span and can only be propagated for approximately 8 
passages before becoming senescent. This significantly hinders our ability to expand 
cells following FACS for imaging and/or to extract a practical quantity of DNA for 
sequencing. In order to circumvent this problem, I immortalised the heterozygous 
mTmG MEFs with an SV40 large T antigen plasmid as described in Section 2.10.4. 
Following immortalisation, the MEFs appeared morphologically normal, although 
their doubling time was significantly reduced. The immortalised heterozygous mTmG 
MEFs were used in all following experiments, unless otherwise noted.  
3.12 Re-designing the H2B Repair Plasmid to Limit Aberrant 
Expression 
In order to attempt to eliminate transient expression, a new repair plasmid, termed 
H2Bv2, was designed in which the final 10 codons (including stop) were removed 
from EGFP, whilst maintaining ~740bp of 3’ homology. Without the final 10 codons, 
we hypothesised that the EGFP would be unstable in the absence of HDR.  I transfected 
this new repair plasmid into the immortalised heterozygous mTmG MEFs alongside 
LoxP#1 and/or LoxP#2 pX330 using the Neon 100µl tips: 
 
Forty-eight hours post-transfection the wells were imaged on a Nikon A1R confocal 
microscope at 40x. Unexpectedly, these images indicated that the new repair plasmid 
could still drive transient expression of nuclear-GFP (Figure 3.18A). To gauge the 
duration of the transient plasmid expression, I decided to maintain the cells further. 
The cells were imaged again at 144 hours post-transfection, after having been split 
1-in-2 twenty-four hours previously. At this time-point no nuclear-GFP signal could 
be seen in the H2Bv2 repair template alone well, whereas it was maintained in the 
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pX330 wells indicating repair. Critically, the cells with nuclear-GFP appeared to have 
lost Tomato fluorescence (Figure 3.18C). The results revealed HDR in approximately 




Figure 3.18 (on previous page): Plasmid-based nuclear-GFP expression from the 
H2Bv2 construct disappears after 144 hours in MEFs. A) 40x confocal images at 
48 hours post-transfection. Scale bar 100µm. Top right: well layout. B) 15x confocal 
images at 144 hours post-transfection. Scale bar 250µm. Top right: well layout. C) 40x 
close up of the GFP-positive nuclei seen in well 5. Scale bar 100µm. D) Cell Counter 
and Nucleus Counter quantification of the images taken at 144 hours post-transfection. 
3.13 Membrane- and Nuclear-EGFP are Not Distinguishable by 
FACS 
Given our confocal imaging capabilities are relatively low throughput, sampling only 
a small proportion of the cells in the well, it was hoped we could develop a 
FACS-based approach for counting cells with nuclear-GFP. We had envisioned that 
cells with nuclear-GFP would have a lower fluorescence intensity than cells with 
membrane-GFP and could be counted and isolated as a sub-population on a FACS 
plot. To test this directly, I performed a transfection with LoxP#1 pX330, LoxP#2 
pX330 and H2Bv2 as before, along with non-transfected and H2Bv2 only controls. 
These cells were maintained for 14 days prior to being sorted on a BD FACSAria, by 
which point no transient nuclear-GFP fluorescence could be seen in the H2Bv2 only 
control.  
The transfected cells then were sorted into five populations: Tomato-positive, double-
positive, bright GFP (i.e. membrane), dim GFP (i.e. nuclear) and double-negative. The 
sorted cells were then returned to glass-bottom plates and allowed to reach confluency. 
At this point, each well was imaged on a Nikon A1R confocal. Imaging revealed that 
both dim and bright GFP populations contained many cells with GFP-positive nuclei, 
as well as cells with membrane-GFP (Figure 3.19B), however, the dim GFP population 
appeared to be more similar to the double-positive population. This may be reflective 
of editing at the sequence level partially disrupting varying degrees of the surrounding 
sequence, such as the promoter, and therefore changing expression levels. Imaging 
also revealed that there was significant contamination from the Tomato-positive cells, 
which are the most prevalent, into all the sorted populations. These results suggest that 
our current FACS system (BD FACSAria) is unable to reliably separate and/or count 





Figure 3.19: FACS cannot reliably distinguish nuclear-GFP from membrane-
GFP in mTmG MEFs. A) Confocal image of the LoxP + H2Bv2 well captured at 20x 
prior to sorting by FACS. B) Confocal images of sorted populations captured at 20x. 
Scale bar 200µm. 
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3.14 Modulating Double-Stranded DNA Break Repair with 
Reported Enhancer Small Molecules BFA, L-755,507, RS-1 at 
the mTmG Locus 
Given our system provides a visual read-out of repair, we hypothesised it would be 
amenable to small molecule screening protocols; with the ultimate goal of identifying 
novel enhancers of HDR. In a small proof-of-principle experiment, I tested the effect 
of four small molecules which have been shown to improve rates of HDR in our 
system. Three separate experiments were carried out, varying different parameters, in 
order to identify the optimum concentration and time-point to use each molecule. In 
the first experiment (Figure 3.20), three concentrations of BFA, L-755,507 and SCR7 
were assayed. In the second (Figure 3.21), different time points for the addition of the 
same small molecules were tested. Finally, based on the most promising results from 
the previous two experiments, in the third (Figure 3.22), further concentrations of BFA 
and SCR7 were evaluated, along with five concentrations of another small molecule, 
RS-1. All small molecules were removed 24 hours after addition. The transfections 
were all performed using Neon 10µl tips and a combination of LoxP#1 pX330, LoxP#2 
pX330 and H2Bv2, as this had been seen previously to give the greatest rate of HDR: 
 
Five days post-transfection, the wells were split 1 in 2 to disrupt clonal populations 
and allowed to settle for 6 hours. Each well was then imaged 10 times at 20x in random 
positions on a Nikon A1R confocal microscope. Images were quantified using Cell 
Counter and Nucleus Counter (Section 2.16.1). Following imaging, plate 3 was also 
analysed on a BD LSRFortessa to determine total rates of editing. 
Generally, there appeared to be little effect on the rates of NHEJ seen with any of the 
treatments (Figure 3.22C), whereas the rates of HDR picked up by imaging were 
highly variable with no clear trend for any of the small molecules (Figure 3.22B). As 
none of the conditions assayed resulted in a significant improvement in the rates of 
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HDR over the control well (well 3A, ~0.5% HDR), while the current methodology 
employed was highly time-consuming and gave variable results, it was decided to not 
continue with further screening using this approach. Alternative platforms, which may 
provide more consistent results when detecting HDR in our system, were not available 
on-site at this time. 
  
Figure 3.20: The small molecules BFA, SCR7 and L-755,507 do not appear to 
have a significant effect on HDR at any concentration tested in mTmG MEFs. A) 
Summary of experimental set-up. B) Ten 20x images were taken of each well in 
random positions and then quantified using the Nucleus Counter and Cell Counter 




Figure 3.21: The highest rates of HDR appear to be achieved by adding the small 
molecules 24 hours post-transfection in mTmG MEFs. A) Summary of 
experimental set-up. B) Ten 20x images were taken of each well at random and then 




Figure 3.22: The small molecules BFA, SCR7 and RS-1 do not appear to have an 
effect on HDR or NHEJ at any concentration tested in mTmG MEFs. A) Summary 
of experimental set-up. B) Ten 20x images were taken of each well at random and then 
quantified using the Nucleus Counter and Cell Counter plugins in Fiji. C) Following 
imaging, each well was analysed by FC to quantify the total rate of editing. FC plots 
included on attached CD in file ‘Figure 3_22’. 
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3.15 Efficiency of Editing versus Efficiency of Transfection – 
Puromycin Selection Reveals the Majority of Transfected Cells 
are Edited 
Given the large discrepancy between the number of GFP-positive cells following 
pmaxGFP transfection and LoxP pX330 transfection, we needed to examine the 
relationship between the transfection rate and the editing rate in our system. In order 
to achieve this, I cloned both guides (Section 2.3.1) into an alternative expression 
vector, pX459 (Ran, Hsu et al. 2013), which contains a puromycin resistance cassette. 
Using pX459 one can isolate successfully transfected cells with puromycin treatment, 
allowing determination of the rates of editing in a transfected population.  
I therefore performed a series of transfections into non-immortalised heterozygous 
mTmG MEFs (as the immortalised MEFs are already puromycin resistant) using the 
pX459 LoxP plasmids and H2Bv2 with the Neon 100µl tips: 
 
Cells were imaged on a Nikon A1R confocal microscope 24 hours post-transfection, 
at which point GFP-positive cells could be seen, indicating the CRISPR plasmids had 
begun to be expressed (Figure 3.23A). Therefore, the growth media was changed to 
MEF growth media + 3µg/ml puromycin. Forty-eight hours later the control cells had 
died, and so the media was replaced with antibiotic-free media in the remaining wells 
to allow cells to recover. Six days later, nine days post-transfection, wells were imaged 
in ten random positions at 20x on the Nikon A1R confocal. Images were quantified 
using the Cell Counter and Nucleus Counter plugins in Fiji to estimate rates of NHEJ. 
Unfortunately, as the cells were not immortalised, the primary MEFs doubled a limited 
number of times following transfection and the signal from the H2Bv2 plasmid was 
not diluted out, preventing accurate quantification of HDR. The results of this 
experiment indicated that approximately 70% of the transfected cells are visibly edited, 






Figure 3.23 (on previous page): Following puromycin selection, the majority of 
transfected mTmG MEFs are visibly edited. A) Confocal images taken at 20x prior 
to puromycin selection. Scale bar 200µm. B) Confocal images taken at 20x post-
puromycin selection and recovery. Scale bar 200µm. C) Ten 20x images were taken 
of each well in random positions and then quantified using the Nucleus Counter and 
Cell Counter plugins in Fiji. 
3.16 Using Alternative Delivery Vectors to Improve Rates of 
Editing and Repair 
The Neon system, with a transient plasmid delivery approach, has given highly 
variable results with regards to rates of editing between experiments, from 5% to 
approaching 40%. In order to improve reproducibility and minimize variability, I 
tested three additional methods for delivering the CRISPR components and repair 
templates: 
a) viral transduction, taking advantage of the ability of lentivirus to deliver 
DNA into cells and adeno-associated virus (AAV) to stimulate repair; 
b)  RNP transfection, where ribonucleoprotein complexes consisting of 
ribonucleic acid and Cas9 protein are directly delivered, avoiding the need 
for transcription and translation; and 
c) minicircle transfection, where the bacterial backbone has been removed 
(from the repair plasmids), allowing for a greater payload of repair template 
to be delivered and circumventing the cell’s ability to recognise the repair 









3.16.1 Viral Transduction Provides Mixed Results 
A viral transduction was performed into heterozygous mTmG MEFs, using lentiviral 
delivery vectors (pseudotype: VSV-G) for Cas9 and guides, and an AAV vector to 
deliver the repair template (all received from Dr Peter Tennant, Section 2.12.4). I 
carried out eight separate transductions, using varying amounts of lentivirus (Lv) and 
AAV repair template: 
 
The MOI (multiplicity of infection) for each virus preparation was:  
LoxP#1 Lv  –  362,  
LoxP#2 Lv   –   355, and  
H2Bv2 AAV  –   3760. 
 
Following transduction, on day six, each well was imaged ten times at 20x 
magnification in random positions on a Dragonfly spinning disk confocal (Andor). 
Unfortunately, due to a software error, the images for control wells 1 and 2 were not 
saved, although no GFP-positive cells were observed in either well. Furthermore, few 
GFP-positive cells were seen in any of the LoxP Lv transduced wells (Figure 3.24), 
indicating a low rate of transduction. Further experiments using a viral transduction 
approach, performed by Dr. Peter Tennant, have since revealed highly variable rates 





Figure 3.24: Lentiviral transduction of the heterozygous mTmG MEFs appears 
highly inefficient. Confocal images captured following transduction at 20x 
magnification. Scale bar 200µm. 
3.16.2 High Editing Efficiencies can be Attained Using an RNP Approach 
I prepared RNP complexes for both guides (Section 2.2.3), and then performed 
transfections using the Neon system and the 10µl electroporation tips into 
heterozygous mTmG MEFs (Section 2.12.1.3): 
 
Six days post-transfection, each well was imaged on a Dragonfly spinning disk 
confocal. Twenty-four hours later, the cells in each well were dissociated and prepared 
for FC, which was performed on a BD FACSJazz. A high editing efficiency could be 
seen with LoxP#1 RNP (~27%), however editing rates were much lower with LoxP#2 
RNP (Figure 3.25); it is unclear why this would be the case, given the guides are the 
same between the plasmid, viral and RNP strategies.  The FC plots again surprisingly 
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indicated that the largest proportion of the heterozygous (but immortalised) edited cells 
were double positive (Figure 3.25C). 
 
Figure 3.25: RNPs drive high rates of editing in immortalised heterozygous 
mTmG MEFs. A) Confocal images taken at 20x magnification, six days post-
transfection. Scale bar 200µm. B) Each well was sorted seven days post-transfection 
on a BD FASCJazz and the total of the non-Tomato populations was plotted 
graphically. FC plots included on attached CD in file ‘Figure 3_25’. C) FC plot for 
LoxP#1 RNP (seven days post-transfection) which shows the large double-positive 
population, at 11.64% (Q2). 
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3.17 The Double-positive Population in Immortalised mTmG 
MEFs May Be an Artefact of Genome Instability 
Given the surprisingly large numbers of double-positive cells following an RNP 
transfection into heterozygous immortalised MEFs, it seems unlikely this population 
exists due to the half-life of the Tomato protein. A more plausible explanation is that 
several copies of the reporter emerge over time in our immortalised MEFs. We 
hypothesised that the process of immortalisation, in which we used SV40 large T-
antigen to inactivate the tumour suppressor protein p53, could lead to much greater 
genome instability and an abnormal karyotype, with the potential outcome that our 
reporter locus is lost or duplicated. Less frequently, this may also be observed in late 
passage (>P8) primary MEFs which bypass senescence, by gaining spontaneous 
inactivating mutations in p53. 
To test this hypothesis, I repeated the LoxP#1 RNP transfection in non-immortalised 
heterozygous mTmG MEFs at a low passage number (P3). In this iteration the 
minicircle repair template was also included. To ensure there were a large number of 
cells for the FC analysis, six transfections were performed (with the 10µl tips) for a 
total of 3x105 cells, and the cells were returned to a 6-well glass-bottomed plate: 
 
Four days post-transfection, each well was imaged in 10 random positions at 20x using 
the Dragonfly spinning disk confocal. Imaging again revealed high rates of editing 
with the LoxP#1 RNP complex, including several cells with GFP-positive nuclei. 
Critically, there were no cells visible with GFP-positive nuclei in the minicircle only 
control well (Figure 3.26A). Four days after imaging, wells were analysed using a BD 
FACSAria. FC results revealed, as expected, a very small proportion, 0.3%, of double-
positive cells following this transfection (Figure 3.26B); indicating immortalisation 
leads to genome instability affecting our reporter locus. Furthermore, editing rates 
were again very high (approaching 40%) and several cells with GFP-positive nuclei 
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could be seen (arrows, Figure 3.26A, C), suggesting that this approach may be more 
efficient and reliable than plasmid delivery. Despite the potential genome instability, 
given the ease of handling and scalability of the immortalised MEFs, I have continued 
to utilise them for specific applications. 
 
Figure 3.26: Double-positive cells are not detected in non-immortalised MEFs 
following RNP transfection. A) Cells were imaged at 20x on a confocal microscope 
four days post-transfection. Scale bar 200µm. B) Eight days post-transfection each 
well was analysed on a BD FACSJazz. Plots for the minicircle control and the LoxP#1 
RNP + minicircle wells are shown. C) Viewing the LoxP#1 + minicircle confocal 
images with split channels reveals the lack of Tomato fluorescence in several of the 
GFP-positive cells, although this is more evident on the FC plots due to the high 




3.18 Determining the Kinetics of Editing in the mTmG System 
Using Time-lapse Imaging 
In order to determine how quickly our system responds to editing events, via the 
production of EGFP and degradation of Tomato, I carried out a time lapse imaging 
experiment following transfection. In addition, time-lapse imaging will allow us to 
confirm that both proteins are present for the entirety of the cell cycle, especially 
during mitosis/cytokinesis. This will reveal whether the existence of a transient 
negative population could explain the mis-sorting we see by FACS. 
3.18.1 A 48-hour Time-Lapse Post-Transfection Reveals the Speed of the 
mTmG System 
Using the Dragonfly confocal microscope, a time-lapse was set up, this time for 48 
hours. Four wells of a 6-well plate were transfected using the Neon 100µl tips (Section 
2.12.1.1): 
 
2x105 heterozygous mTmG immortalised MEFs were transfected per well to ensure 
the cells were reasonably sparse for the duration of the time-lapse. Cells were imaged 
6 hours post-transfection. A multi-position programme was used to image each well 
in 10 positions, taking a 10µm Z-stack in all channels every 20 minutes. A maximum 
intensity projection was then taken, and the images were compiled to form videos (40 
in total). 
The resulting time-lapse videos revealed that editing is rapid in our system, even when 
using plasmids which would need to be transcribed and translated. Using these videos, 
I tracked three cells which began to show EGFP expression within ~24 hours post-
transfection and completed the transition from Tomato to EGFP within 48 hours 
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(Figure 3.27, 3.30, NB. similar kinetics can be seen in the videos in many other MEFs 
however it is only possible to cleanly perform this analysis on the very small 
proportion of MEFs which remain separate from all other cells for the entire time-lapse 
due to overlapping fluorescence). There appears to be a peak in editing, based on the 
number of cells beginning to express GFP, between 30 and 36 hours post-transfection. 
Unfortunately, as imaging positions were randomised, very few cells were captured 
which expressed nuclear-GFP thus it is difficult to comment on the kinetics of repair, 
although one would expect it to occur across a similar time-frame. Several of the 
resulting videos are included in the attached media CD (saved as Time-course XX.avi, 




Figure 3.27: Time-lapse imaging in MEFs reveals the kinetics of EGFP production following editing and Tomato degradation, 
often reaching completion within 48 hours post plasmid transfection.  Images were captured at 20x magnification every 20 minutes, 
beginning 6 hours post-transfection and continuing for 48 hours. Above: Tomato and Hoechst, below: merge. Two cells are highlighted 




3.18.2 Quantification of Kinetics Using Imaris 
In order to quantify the time-lapses captured, and to gain objective measurements of 
the change in fluorescence intensity, the Track (cells) module in Imaris was used, with 
the settings detailed in Section 2.16.2.  
3.18.2.1 Quantifying Background Fluorescence 
Firstly, I quantified background fluorescence by identifying regions with cells in the 
image, and then averaging the fluorescence intensity detected outside these regions. 
This analysis revealed a remarkably constant background fluorescence detected 
throughout the whole time-lapse, with a reading in both EGFP and Tomato channels 
of ~120 arbitrary units (AU) (Figure 3.28). 
 
Figure 3.28: Cell-free background fluorescence intensities in the GFP and 
Tomato channels are constant. The mean fluorescence intensities in regions outside 
cells was calculated at every time point during two time-lapse videos using Imaris. 
Axes were chosen for comparison with Figure 3.29. The videos for Time-course 03 
(above) and Time-course 15 (below) are included on the attached media CD. 
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3.18.2.2 GFP Fluorescence Does Not Rise Above Background Levels in 
Non-Transfected Cells 
As a second control, I analysed time-lapses from the non-transfected, electroporated 
sample (well 1) to gauge the variation in EGFP and Tomato fluorescence intensities 
during imaging. Imaris Track was again used to separate the videos into individual 
cells, and then the mean fluorescence intensity across the volume of each cell was 
measured. The variation in the mean fluorescence intensities was then plotted in Figure 
3.29. EGFP fluorescence could be seen to be constant and equal to the background 
fluoresce seen in the previous section; that is ~120 AU. Tomato fluorescence was more 
variable and averaged between 300 and 400 AU, with the mean intensity for any single 
cell not dropping below 200 AU. 
 
Figure 3.29: In non-transfected mTmg MEFs, GFP fluorescence remains at 
background levels with constant Tomato fluorescence. The mean fluorescence 
intensity across the volume of each cell was calculated by Imaris. The minimum, 
maximum and mean values for the population of detected cells was then plotted 
graphically. The videos for Time-course 34 (above) and Time-course 38 (below) are 
included on the attached media CD. 
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3.18.2.3 Transfected Cells Display a Rapid Switch in Fluorescence from 
Tomato to EGFP 
In order to measure the change in fluorescence in transfected cells, Imaris Track was 
again used, this time to identify cells based on their GFP fluorescence intensities. Once 
a cell was detected as being GFP-positive, the mean GFP and Tomato intensities across 
the volume of the cell were tracked for the duration of the time-course. The results 
revealed that edited cells display a rapid decrease in Tomato intensity across a period 
of 24 hours, from approximately 500 to 200 AU or below, while there is a simultaneous 
substantial increase in GFP intensities (Figure 3.30). 
Across the 40 videos there were many cells which appear to be double-positive 
following transfection (not quantified), in the time-frame of 54 hours post-transfection. 
Interestingly, a double-positive cell from Time-course 08 can be tracked as it 
undergoes a cell division following developing GFP fluorescence (Figure 3.31A). By 
tracking the mean Tomato and GFP intensities of this cell as it undergoes cell division, 
one can see that there is no period during the cell cycle in which fluorescence from 
either reporter is lost (Figure 3.31B). Other instances of Tomato- and GFP-positive 
cells dividing in the included time-courses confirm this finding; which indicates that 
the double-negative population seen following editing cannot be a cell cycle artefact. 
Furthermore, by tracking the sum intensities in both channels, one can clearly see when 





Figure 3.30: Edited mTmG MEFs display a rapid switch in fluorescence from 
Tomato to GFP within 24 hours. Imaris Track was used to identify cells based on 
GFP fluorescence, and then the mean GFP and Tomato intensity across the volume of 
the cells was calculated for each time-point. Here, Cell 01 and Cell 02 from Time-
course 08 correspond to the cells highlighted in Figure 3.27. Videos for Time-course 




Figure 3.31: Both Tomato and GFP fluorescence are maintained throughout the 
cell cycle in mTmG MEFs. A) One double-positive cell, Cell 03, was tracked for the 
duration of Time-course 08, as it undergoes cell division soon after gaining GFP 
fluorescence. The daughter cell produced is indicated with an arrow. B) Plotting the 
mean intensities of the cell as it undergoes cell division reveals that there is no phase 
of the cell cycle in which fluorescence is lost or drastically reduced. C) Plotting the 
sum intensities of the detected object clearly highlights several points during cell 





3.19 The Small Molecules NU-7441 and Mirin Provide 
Unexpected Results in the mTmG System 
Previous pilot trials with small molecules to improve rates of HDR have proven 
inconclusive (Section 3.14). This may be due to two reasons; our limited ability to 
capture a large, representative sample by imaging to get accurate counts; and/or due to 
inherent differences in the repair machinery employed between the cell types used in 
their respective published studies and in our MEF model. During the course of my 
PhD it became possible to partially address both of these questions.  
In terms of imaging, a novel platform became available, the Zeiss Celldiscoverer 7, 
which allows the quick, automated capture of the majority of a well in several 
channels. Following imaging, the associated Zen software is then able to detect and 
quantify various parameters, including the percentage of cells with GFP-positive 
nuclei. This platform allowed us to sample a vast number of cells, approximately 
140,000 per well in a short space of time, potentially providing a more reliable and 
consistent figure for HDR. This platform was used to test a recently described small 
molecule, NU-7441, which had been shown to specifically increase rates of HDR in 
MEFs (Robert, Barbeau et al. 2015). I carried out three separate transfections with the 
Neon 100µl tips (Section 2.12.1.1) for comparison: 
 
An optimised concentration of 2µM NU7741 was used following the protocol by 
Robert, Barbeau et al. (2015), where the small molecule was added immediately 
following transfection and maintained for 24 hours. Transfections were performed 
using the Neon 100µl tips (section 2.12.1.1), into immortalised heterozygous mTmG 
MEFs. Five days post-transfection, all three wells were split 1 in 2 in order to disrupt 
any clonal outgrowth. The following day, a 10x scan was taken of the central 25% of 
each well of the 6-well plate (Figure 3.32A). A bespoke automated analysis pipeline 
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was constructed in the Zen software which first applied a mask based on DAPI 
intensity (with a watershed) to provide a total cell count, and then a second mask based 
on GFP intensity, area and circularity to provide a count of the number of GFP-positive 
nuclei (Figure 3.32C). This allowed us to report the percentage of GFP-positive nuclei 
in each well. Following imaging, 24 hours later, each well was dissociated and 
analysed by FC to gain a read out of the total visible editing in each well (Figure 
3.32D). This was used to normalise for any difference in transfection efficiencies 
between the two wells. The results indicated that there was potentially a greater than 
2-fold increase in HDR when treating with NU-7441 (Figure 3.32E). 
Unfortunately, the Celldiscoverer 7 was only available on-site for a brief demo period. 
Therefore I decided to attempt to repeat and confirm the results using the Nikon A1R 
confocal microscope, taking advantage of a machine learning tool, CellProfiler 
Analyst (Jones, Kang et al. 2008), to quickly score a large number of images for 
nuclear-GFP.  As before, heterozygous mTmG immortalised MEFs were transfected 
with the LoxP pX330 plasmids and the H2Bv2 repair plasmid with or without 2µM 
NU-7441 for 24 hours, however this time three biological replicates were carried out 
for each condition (mTmG MEFs were split into three batches which were transfected, 
treated, maintained and assayed separately). Seventy-two hours post-transfection, each 
well was split 1 in 2. One half of the split was returned to the plate for imaging, and 
the other half was taken for analysis on a BD LSRFortessa to determine editing rates. 
Twenty-four hours later, four days post-transfection, each well was imaged at 20x on 
the A1R in a 10x10 grid array (for the equivalent of 100 fields at 20x, Figure 3.33A, 
B). CellProfiler Analyst (Section 2.16.3) was then used to calculate the rates of HDR 
seen in each image. Unfortunately, using this methodology, no significant difference 
could be seen in HDR rates upon NU-7441 treatment, however, there was a significant 







Figure 3.32 (on previous page): The small molecule NU-7441 appears to increase 
HDR in mTmG MEFs following plasmid transfection. A) A 10x scan was taken of 
the central 25% of each well of a six well plate using a Zeiss Celldiscoverer 7, five 
days post-transfection. Scale bar 5000µm. B) Enlargements of the above images reveal 
a high level of detail, including nuclei and GFP-positive nuclei. Scale bar 500µm. C) 
The Zen software is able to process the images to automatically identify nuclei (in 
yellow) and GFP-positive nuclei (in purple). D) Each well was analysed by FC 
following imaging to estimate transfection efficiencies as a proxy of editing rates 
(noted in the corner of the plots). E) The results of the automated counting of nuclei 
and GFP-positive nuclei produced by the Zen software, presented as rates of HDR with 




Figure 3.33: Using CellProfiler Analyst quantitation, the increase in HDR on 
NU-7441 treatment in mTmG MEFs failed to replicate, but FC did show a 
statistically significant increase in total editing. A) A 10x10 grid was imaged in 
each well at 20x using a Nikon A1R confocal microscope. Scale bar 2000µm. B) An 
enlargement of the image for NU-7441 well 3 displays a good level of detail, however 
significantly fewer cells have been captured than with the Celldiscoverer 7. Scale bar 
2000µm. C) CellProfiler results (left) and FC results (right) with the corresponding 
statistical significances from a Student’s t-test indicated (N=3 for each condition). FC 
plots included on attached CD in file ‘Figure 3_33’. 
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3.19.1 The Increase in Editing upon NU-7441 Treatment is Maintained 
in the Absence of a Repair Template 
In order to rule out the possibility that the increase in editing we are seeing with 
NU-7441 treatment is due to repair, I repeated the previous experiment with the 
omission of the H2Bv2 repair template. Three biological replicates were prepared for 
each condition, that being with or without NU-7441 treatment, and 72 hours 
post-transfection each well was dissociated and analysed on a BD LSRFortessa. The 
results again indicated a statistically significant increase in the percentage of edited 
cells, this time in all quadrants, following a 24-hour incubation with 2µM NU-7441 
(Figure 3.34). 
 
Figure 3.34: In the absence of a repair template, NU-7441 treatment is still able 
to drive a statistically significant increase in editing in mTmG MEFs. Error bars 
represent the standard deviation of three biological replicates and stars indicate the 
statistical significance from a Student’s t-test (N=3). FC plots included on attached CD 
in file ‘Figure 3_34’. 
3.19.2 The Increase in Editing Does Not Appear to be Driven by MMEJ 
As a potential explanation for the increase in editing seen with NU-7441 treatment, I 
noted that there would be small regions of homology remaining on either side of the 
loxP sites following cleavage with either guide (Figure 3.3). These regions may allow 
repair by the microhomology-mediated end joining pathway (MMEJ), as opposed to 
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NHEJ or HDR. Furthermore, it has been shown that blocking the canonical NHEJ 
pathway may promote the use of MMEJ (Sharma, Javadekar et al. 2015). To examine 
whether we are seeing increased rates of editing due to the promotion of the MMEJ 
pathway in our cells, I repeated the previous experiment with the addition of the small 
molecule Mirin, which inhibits MMEJ (and HDR) but has no effect on NHEJ (Sharma, 
Javadekar et al. 2015). Mirin was used at a concentration of 50µM as this concentration 
has previously been shown to result in 95% inhibition of MMEJ in HEK293 cells 
(Dupré, Boyer-Chatenet et al. 2008). 
The experiment was repeated as before with the addition of Mirin at 50µM to the wells 
with NU-7441, and an additional three wells with Mirin (50µM) alone. Cells were 
again allowed to proliferate for 72 hours post-transfection prior to being analysed on 
a BD LSRFortessa. The FC results indicated that Mirin treatment alone did not appear 
to be having a significant effect on editing, however there was still a significant 
increase in editing on treating with both NU-7441 and Mirin (Figure 3.35). 
 
Figure 3.35: The increase in editing in mTmG MEFs seen upon NU-7441 
treatment does not appear to be driven by MMEJ, as a potent MMEJ inhibitor, 
Mirin, fails to alter editing outcomes. Here, error bars represent the standard 
deviation of three biological replicates and stars indicate the statistical significance 
from a Student’s t-test. Upper bars indicate the statistical significance between 




3.19.3 Using RNPs to Limit the Duration of Editing Does Not Affect the 
Increase Seen upon NU-7441 Treatment 
As it is known that plasmid expression persists for several days (DeWitt, Corn et al. 
2017), it is possible that we are missing the window of editing when treating with the 
small molecules for twenty-four hours. To correct for this, I decided to repeat the 
experiments with RNP complexes instead of plasmids, as these will immediately be 
active once inside the cells, and thenceforth will be rapidly degraded. Indeed, Cas9 
RNPs have been shown to be almost entirely absent at 24 hours post-transfection, as 
opposed to plasmid-derived Cas9 which reaches its peak abundance at this time point 
(DeWitt, Corn et al. 2017). 
RNP transfections were performed using the Neon into heterozygous mTmG 
immortalised MEFs (Section 2.12.1.3), using a 1:1 mixture of the LoxP#1 RNP 
complex and the LoxP#2 RNP complex:  
 
Following transfection, the cells were immediately transferred into growth media 
containing the small molecules as before and incubated for a total of 24 hours. Within 
this window, a large amount of cell death was seen in the wells containing the small 
molecules, so the cells were allowed to proliferate for a further five days prior to being 
analysed by FC. In order to gauge the effect the small molecules are having on cell 
viability, each well was re-suspended in the same volume of PBS and then sorted for 
exactly 120 seconds. The total number of cells sorted from each well was then 
recorded. 
The FC results returned following RNP transfection were broadly similar to those 
following plasmid transfection (Figure 3.36). There was a significant increase in 
editing upon incubation with NU-7441 which was not reduced by the addition of 
Mirin. However, as opposed to the previous experiments, there appeared to be a small 
increase in editing when incubating with Mirin alone following the RNP transfections. 
Furthermore, both small molecules proved to be cytotoxic following a 24-hour 
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incubation at the concentrations employed and were very highly cytotoxic when 
combined (Figure 3.37). 
 
Figure 3.36: The increase in editing is also seen upon RNP transfection, following 
incubations with NU-7441 in mTmG MEFs. Error bars represent the standard 
deviation of three biological replicates and stars indicate the statistical significance 
from a Student’s t-test. NB. Total Non-Red in the above graph is the inverse of the 
graph below (red cells), which has been shown for clarity. FC plots included on 




Figure 3.37: Co-treatment with the small molecules Mirin and NU-7441 is 
cytotoxic to MEFs at the concentrations used, 50µM and 2µM respectively. There 
is a synergetic effect on cytotoxicity when combining the two small molecules. Bars 
indicate the mean number of cells from each condition which passed through the BD 
LSRFortessa in 120 seconds. Error bars represent the standard deviation of three 
biological replicates and stars indicate the statistical significance from a Student’s t-
test. NB. There was a statistically significant difference between DMSO, Mirin and 
NU-7441 + Mirin (p < 0.01). The difference between NU-7441 and other conditions 




3.20 Conclusions and Potential for Future Use of the mTmG 
System in vivo 
In the course of this chapter, I have shown that the mTmG fluorescent reporter system 
provides a reliable, rapid visual read-out of CRISPR-mediated editing which can be 
quantified both by FC/FACS and by image analysis. It is amenable to several different 
transfection methodologies and can also be used to probe the effect of small molecules 
on editing and repair within primary mouse cells, including motile-ciliated ependymal 
cells which are comparable to cells affected in PCD. Furthermore, preliminary work 
carried out by our group has shown that this system is functional in vivo and could be 
brought forward to test gene repair in embryos and live mice. Pronuclear injections in 
mouse embryos, using the same reagents as these cell studies, were performed by 
Margaret Keighren and cultured onto blastocysts. Briefly, pX330 reagents gave low-
level, mosaic editing in blastocysts, whereas RNPs provided efficient and uniform 
editing, including wholly HDR-derived embryos (Figure 3.38), using the minicircle 
repair template.  
 
Figure 3.38: Efficient editing can be detected in the mouse blastocyst following 
pronuclear injection of RNPs and a minicircle repair template in fertilised eggs. 
Injections were performed by Margaret Keighren and images were captured by Dr. 
Pleasantine Mill. 
In the future this system could feasibly be scaled up to perform small molecule screens 
for compounds which may improve repair in primary cells, both providing mechanistic 
insights and potentially identifying compounds which could be useful for gene therapy. 
While the techniques used here to measure HDR provided somewhat variable results, 
recent technological advancements such as the Celldiscoverer 7 and imaging-based 
162 
 
FC/FACS approaches should allow automated, rapid and accurate measurement of the 
rates of HDR across a range of treatments.  
The trials which I performed with the five small molecules all proved inconclusive, 
despite the fact that these small molecules have all been shown to improve rates of 
HDR in other systems (Leahy, Golding et al. 2004, Yu, Liu et al. 2015, Song, Yang et 
al. 2016, Li, Zhang et al. 2017). Far from invalidating the results from our system, I 
believe this highlights the inherent variability in the complexes and pathways which 
are employed to repair genomic legions. These are likely to vary between cell types, 
and even within cell types depending on the cell cycle. Furthermore, there is much 
work to be done on understanding when and where each repair pathway is 
preferentially employed, depending on the size of the generated break, whether there 
are regions of homology beside the break, and whether a repair template is available. 
3.20.1 Comparison of the mTmG System with other Methods Currently 
Used to Measure Editing and Repair 
Currently, the most common methods used to measure genomic editing are based 
around PCR, digestion and sequencing approaches, although these methods all involve 
processing a mixed population of cell types and may be subject to significant technical 
bias. The simplest methods, based on PCR and digestion, are the Surveyor assay and 
restriction-fragment length polymorphism (RFLP) assays. The Surveyor assay makes 
use of the T7 exonuclease which cleaves mismatched bases in dsDNA; small non-
homologous regions as a result of editing will therefore result in multiple bands being 
seen when the digestion product is run on a gel. By running an untreated PCR sample 
alongside the digested sample, relative intensities can be used to calculate an estimate 
of editing efficiencies (Figure 3.39A). However, this system cannot detect larger indels 
which prevent dsDNA annealing, as are created by CRISPR-mediated genome editing. 
Alternatively, in an RFLP assay, the presence or absence of a restriction site, as elicited 





Figure 3.39: A Schematic Representation of A) a Surveyor assay and B) an RFLP 
assay. Taken from Hendel, Fine et al. (2015). 
Recently, novel PCR-based approaches have been described which may be more 
accurate and flexible than Surveyor and RFLP assays. These include the use of ‘droplet 
digital PCR’, in which fluorescent probes are designed which bind specifically to the 
repair and wild-type sequence, and whose binding would be disrupted by editing 
(Figure 3.40). This assay has been shown to be able to detect HDR at a frequency of 
only 1 in 1000 cells (Miyaoka, Berman et al. 2016). Another alternative, termed high 
resolution melting analysis (HRMA), developed by Zaboikin, Zaboikina et al. (2017), 
is based on mismatches reducing the melting point of dsDNA, allowing sequence 
changes to be determined based on the melting curve. Furthermore, following PCR, 
there are a whole suite of potential next generation sequencing technologies which 
could be employed to elucidate rates of NHEJ and HDR, although these would all 
involve a significant outlay of time and capital, while the short reads returned may not 
allow confirmation of HDR if the repaired region is large. Recently described methods 
such as nanopore sequencing (Feng, Zhang et al. 2015) and single molecule real time 
sequencing (Hendel, Kildebeck et al. 2014), which provide much longer reads, may be 





Figure 3.40: Fluorescent probes allow the identification of NHEJ and HDR in a 
population of edited cells upon droplet digital PCR. A) Design of the experiment 
and placement of probes relative to editing. B) The outcomes of editing can be 
visualised by fluorescence intensities. Taken from Miyaoka, Berman et al. (2016). 
Alternatively, since starting this project several reporter systems have emerged which 
would allow a basic pre-clinical screening of compounds that may improve HDR and 
gene correction; mostly in cell lines such as HEK293 and U2OS. As very little is 
known on cell-type specific differences in DNA repair processes, this may limit the 
applicability of any results found, especially to therapeutically-relevant cell types.  
The most established system for measuring rates of NHEJ and HDR is the Traffic 
Light reporter system, which was developed by Certo, Ryu et al. (2011). Similar to our 
system, it is based on a dual fluorescence reporter cassette (mCherry and EGFP), 
however they have employed a (low MOI) lentivirus to randomly integrate the cassette 
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into HEK293T cells. In this system, the GFP is disrupted by an I-SceI nuclease target 
site and the following mCherry is out-of-frame. Indels created by NHEJ will restore 
the mCherry reading-frame in approximately 1/3 of cases; allowing the rate of NHEJ 
to be quantified. However, a repair template containing an unmodified GFP sequence 
can also be supplied with I-SceI, allowing the rate of HDR to be quantified by the 
number of cells with GFP fluorescence. This system is illustrated in Figure 3.41. Using 
this system, the authors demonstrate that editing can be biased towards repair both by 
using a nickase strategy and by inhibiting DNA-PKs (as does NU-7441, Robert, 
Barbeau et al. (2015)). The Traffic Light reporter system has since been modified to 
measure the effect of both single-strand annealing (SSA) and chromatin context on 
repair (Kuhar, Gwiazda et al. 2014). Interestingly, they found that the rate of HDR was 
reduced 10-fold in a transcriptionally-inactive chromatin context, whereas the rate of 
NHEJ only saw a 2-fold decrease. If validated in endogenous loci, these results suggest 





Figure 3.41: Summary of the Traffic Light reporter system. A) Schematic of the 
integrated fluorescence reporter cassette prior to B) editing by NHEJ or HDR. C) The 
resulting editing outcomes can be quantified by FC. Taken from Certo, Ryu et al. 
(2011). 
Two other fluorescence-based reporter systems for measuring HDR have also been 
described. The first employs a piggyBac transposon vector containing a puromycin 
resistance cassette followed by a poly-A sequence and H2B-GFP reporter (Wen, Liao 
et al. 2017). By inserting the target sequence for any guide of interest upstream of the 
poly-A sequence using a BstEII site and delivering this guide together with a repair 
template containing PuroR-T2A-H2B-GFP, the rate of HDR can be measured by the 
number of cells expressing H2B-GFP (Figure 3.42). It is proposed that this would be 
proportional to the rate of cleavage driven by this guide, although as the report by 
Kuhar, Gwiazda et al. (2014) indicates HDR is disproportionally inhibited by 
chromatin context, this may not be true at all loci. An alternative system, described by 
Glaser, McColl et al. (2016), simply involves the conversion of EGFP to BFP by 
changing three critical nucleotides in the sequence (in an 11bp window), using a 
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supplied repair template. In theory, this system can be employed in any cell or mouse 
line which expresses EGFP, and with it rates of NHEJ can be measured by loss of 
fluorescence whereas HDR can be detected by a change to blue fluorescence. Our 
mTmG system offers several advantages over this system, however: 
a) changes in fluorescence are easier to identify than a loss of fluorescence, 
b) a localisation tag allows the identification of the targeted cell types by 
morphology (Figure 3.14), and 
c) the UV illumination used for imaging BFP results in significant 
phototoxicity while BFP is also relatively dim (low quantum yield and 
brightness). 
 
Figure 3.42: Schematic representation of the piggyBac HDR reporter system. 
Homology-directed repair results in the expression of H2B-GFP in the correctly 
targeted cells. Taken from Wen, Liao et al. (2017). 
In the following chapter, I further validate our mTmG reporter system by performing 
next generation sequencing on non-edited mTmG cells, and all our edited sub-types. 
This sequencing reveals that the spectrally-distinct sub-populations we observe 
following transfection are indeed reflective of the outcomes we expect at a sequence-
based level, providing further evidence that our system is a valid tool for measuring, 
and optimising, rates of CRISPR-mediated genome editing in primary cells and in vivo. 
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Chapter 4 Sequencing of the mTmG Locus  
4.1 Introduction 
As I have demonstrated that the mTmG System provides a reliable, visual read-out of 
NHEJ and HDR, I wanted to confirm that the changes visually observed are the result 
of the expected editing at a sequence-based level. In order to survey the full range of 
editing events we are seeing in each of our spectrally distinct sub-populations, as well 
as to hopefully detect evidence of rare HDR events, it was decided to use a next 
generation sequencing approach. Next generation sequencing (NGS) should provide 
several thousand-fold coverage in each of our populations, allowing us to detect and 
quantitate even very rare events, while being much less labour-intensive than other 
manual sequencing approaches, such as TOPO-cloning.  
For this work, I took advantage of the services offered on-site by the Edinburgh 
Wellcome Trust Clinical Research Facility (WTCRF) in designing and carrying out 
NGS sequencing experiments on two complementary platforms. The first, the Ion 
Torrent Personal Genome Machine (PGM) system (Thermo Fisher), offers long reads, 
up to 400bp, as well as high coverage and a low error rate (1.71%, (Quail, Smith et al. 
2012)). This makes it highly suited for an experiment such as ours in which we want 
to detect editing in a repetitive locus. For longer reads across our 3kb locus, I also 
decided to test a novel sequencing technology, the Oxford Nanopore MinION. This 
platform can theoretically provide reads several thousand basepairs long, and so is 
highly suited to detect large deletions and insertions as I would expect in this 
experiment. The limitation of this system is its high error rate, around 10% in current 
iterations, and thus it is not the ideal system for detecting small indels and basepair 
changes. Therefore, I viewed these platforms as complementary; the Ion Torrent is 
able to provide us with accurate details of small edits at either cut site, while the 
MinION should provide evidence of larger deletions and insertions, such as of the H2B 
sequence. 
Following sequencing, I used two approaches to analyse changes at our locus. The first 
was variant calling, in which the resulting sequencing reads are mapped back onto the 
reference sequence and then any variants are detected, quantified and potentially 
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assigned a probability score. These variants can be viewed visually on a genome 
browser or called by a variant calling programme. This approach is generally more 
suitable when the variable regions in the supplied sequences are relatively small and 
few in number, as the presence of a very large indel or several smaller changes may 
result in the failure of the read to align back to the reference. Furthermore, one must 
consider that variant calling programmes are currently designed to detect discrete 
mutations, for example a +AG insertion at a single position, such as observed in 
disease mutation genetics, as opposed to the large genomic variation resulting from a 
CRISPR/Cas9 cut site.  
An alternative approach to variant calling, which may be particularly useful in our 
case, is de novo genome assembly. During de novo genome assembly, the reads from 
the sequencing experiment are aligned using their overhangs to attempt to form a new 
‘reference’ sequence or sequences. The number of reads which go to form each new 
reference sequence can then be quantified. This approach is useful for detecting large 
deletions, insertions and rearrangements, although it will ignore small, infrequent 
variants when forming a consensus sequence. However, if required, one could use the 
output reference sequences from a de novo genome assembly for further variant calling 
on the initial data, and potentially recover these smaller, less common variations. There 
are also a number of stand-alone tools designed to analyse NGS results from CRISPR 
experiments, such as CRISPResso (Pinello, Canver et al. 2016), however due to the 
unique nature of the editing expected in the mTmG reporter system, with two cut sites, 
a large deletion and potentially also a large insertion present, these ‘off-the-shelf’ 
analysis suites cannot currently be applied to our data. 
During this chapter I will detail the approaches I used to sequence the mTmG locus, 
including the initial design, and then refinement of the experiment, the laboratory work 
carried out prior to sequencing, and the various methods used to analyse the 
sequencing data. I show that while there are several challenges in sequencing this 
locus, and analysing the resulting data, I can demonstrate that the four populations we 
observe following transfection, that being Tomato-positive, GFP-positive, double-
positive and double-negative, are reflective of the edited sequences in these cells. 
Further work is required, however, to accurately detect and quantify cells containing 
the H2B repair sequence, for reasons I will discuss. 
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4.1.1 Experimental Design 
In order to sequence across the mTmG locus, I designed four sets of primers to attempt 
to capture all of the possible changes we may see following editing and repair in our 
system. These four sets of primers are listed in Section 2.5.1, and have been plotted 
visually onto the mTmG locus in Figure 4.1: 
 
Figure 4.1: Location of the sequencing primers on the mTmG locus. Primers are 
indicated by arrows with their respective numbers above. PCR products and their 
expected sizes are noted above primer pairs with brackets. The loxP sites are indicated 
with grey triangles, and the guide target sites either side are indicated with lightning 
bolt symbols. The sizes of the cleavage and repair products are approximate due to the 
variable sizes of indels generated by Cas9. NB. Product sizes are based on the 
sequencing of the locus in Section 4.3. Diagram not to scale. 
Primer choice was limited due to the repetitive nature of the mTmG locus, resulting in 
the use of primers with relatively large products which will need to be sheared prior to 
Ion Torrent sequencing. In design, PCR product 1 was chosen to allow me to quantify 
NHEJ at the first loxP site which hasn’t resulted in the excision of Tomato, while PCR 
products 2 and 3 should allow me to do the same at the second loxP site. PCR product 
4 can then be used to detect larger changes, such as the deletion of the region between 
the loxP sites to produce the ‘Cleavage Product’ and the incorporation of the H2B 
sequence to form the ‘H2B Repair Product’. Neither should be detected in the other 
PCR products due to the deletion of the binding sites for primers 2, 3 and 5. 
Using these primers, I performed PCR amplifications with the proof-reading 
polymerase, Phusion Hot Start II (Section 2.6). PCR amplifications were carried out 
on DNA extracts from the edited sub-populations (Tomato-positive, GFP-positive, 
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double-positive and double-negative), which were all isolated by FACS. Following 
PCR amplification, PCR products were purified (Section 2.4.2) and submitted for pre-
processing and sequencing by the WTCRF (Section 2.18 for details). 
4.2 Initial Ion Torrent Run 
4.2.1 CRISPR Genome Editing at the mTmG Locus Results in Four 
Spectrally Distinct Sub-Populations 
For the initial sequencing run on the Ion Torrent, I transfected immortalised 
heterozygous mTmG MEFs with the LoxP pX330 plasmids and the H2Bv2 repair 
plasmid, which had been shown to drive repair (Section 3.12). Three transfections 
were carried out on the Neon system (Section 2.12.1.1) using the 10µl electroporation 
tips and 1.5x105 cells per well (3 reactions): 
 
Ninety-six hours post-transfection, each well was split 1 in 2. Twenty-four hours later, 
each well was imaged seven times in random positions at 15x on a Nikon A1R 
confocal. These images were then quantified using the Cell Counter and Nucleus 
Counter plugins in Fiji (Section 2.16.1), which revealed that the transfections had been 
successful and that the transient expression from the H2Bv2 plasmid had mostly 
dissipated (Figure 4.2A, B). Based on this, each well was then dissociated and sorted 
on a BD FACSAria twenty-four hours later. As expected, the vast majority of cells in 
the control wells were Tomato-positive, whereas the cells in well 3 split into the four 
populations seen previously; Tomato-positive, GFP-positive, double-positive and 




Figure 4.2: Transfection and isolation of genome edited spectrally distinct sub-
populations of mTmG MEFs for NGS. A) Representative confocal images of each 
well taken at 15x, 96 hours post-transfection. Scale bar 200µm. B) The images from 
each well were quantified using Cell Counter and Nucleus Counter in Fiji in order to 
estimate rates of NHEJ and HDR. C) An example FACS plot from well 3 in which the 
cells can be seen to form four populations; Q1 – Tomato-positive, Q2 – double-
positive, Q3 – double-negative and Q4 – GFP-positive. NB. Results are only shown 
for the final 50,000 cells sorted. Other FACS plots included on attached CD in file 
‘Figure 4_2’. 
4.2.2 FACS Is Able to Sort Edited Cells into Their Sub-Populations with 
Reasonable Accuracy 
Following FACS, the two control populations and the four edited populations were 
returned to a 6-well plate and allowed to reach confluency. At this point, I imaged each 
well five times at 20x on a Nikon A1R confocal. Imaging revealed that there were no 
GFP-positive nuclei remaining in the H2Bv2 only control, as expected. As previously 
observed, there was significant contamination of the Tomato-positive population into 
the other wells (Figure 4.3). These images were quantified using the Cell Counter and 
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Nucleus Counter plugins, which indicated that ~10% of the GFP-positive sort 
comprised Tomato-positive cells along with ~3% of the double-negative sort. Later 
experiments have indicated that this appears to be unavoidable, see for example 
Section 3.14. This cross-over appears to be due to the abundance of the Tomato-
positive population, potentially combined with the adherent nature of MEFs. 
 
Figure 4.3: mTmG MEFs maintain their edited states over time, although there is 
an error rate of up to 10% in FACS. Representative confocal images captured at 
20x, 16 days post-FACS. Scale bar 200µM. 
4.2.3 PCR Optimisation for Sequencing 
Following imaging, I extracted DNA from each well using Quick Lysis Buffer 
(Section 2.4.1). DNA extractions were then quantified using a Nanodrop 
spectrophotometer. Dilutions of each DNA extraction were therefore made, at a 
concentration of 100ng/µl in NF-H2O. After several rounds of PCR optimisation, each 
primer set produced a single band of the predicted size (in samples where only one 
band was expected). The inclusion of betaine in the reaction mixes was found to be 
necessary to achieve amplification, indicating there may be strong secondary 
structures present. Furthermore, annealing temperatures had to be raised several 
degrees above their expected values to prevent non-specific binding. The final reaction 
compositions used for each primer set are detailed in Section 2.6.1, while the general 
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cycling parameters are detailed in Section 2.6.2. Following PCR, each amplification 
was purified using a QIAquick PCR Purification Kit (Section 2.4.2) and 5µl of each 
purified product was electrophoresed on a 2% agarose gel. This indicated that bands 
of the expected sizes had been produced for each PCR product (Figure 4.4). Each 
product was named with a letter representing the DNA template followed by the 
number of the PCR reaction: 
 A - NF-H2O 
 B - Cas9 Only Control 
 C - H2Bv2 Only Control 
 D - Tomato-positive 
 E - GFP-positive 
 F - Double-positive 
 G - Double-negative 
 
 
Figure 4.4: Purified PCR products for Ion Torrent sequencing. Products were 




4.2.4 Sequencing Design and Ion Torrent Run Reports 
Following PCR purification, each sample was transferred to the WTCRF for 
preparation and sequencing. Samples were prepared as detailed in Section 2.18. All 
PCR products were sheared to a mean length of 350bp and then six different barcodes 
were added to allow us to separate reads from each DNA template in silico. Run reports 
were automatically generated by the Ion Torrent software upon completion of 
sequencing.  The initial run report indicated that the mean read length was significantly 
shorter than we were expecting, at 218bp (Figure 4.5, quality filters on, top right box). 
Furthermore, ~24% of the reads were being discarded or trimmed due to their quality 
scores (Figure 4.5, quality filters on, middle right box).  It was decided to reanalyse 
the data with the quality filter relaxed, which increased the mean read length back up 
to its expected value at ~350bp (Figure 4.5, quality filters off, top right box).  
Therefore, this indicates many of the reads substantially declined in quality towards 
the 3’ end and as such have been trimmed by the software. As low-quality bases may 
complicate any analysis, it was decided to initially continue with the reads produced 
with the more stringent quality filter. Based on the number of reads per barcode, this 
should still leave several thousand reads per PCR product. The resulting reads, in fastq 
format, were aligned and analysed using the pipeline detailed in Section 2.19.1 to the 





Figure 4.5: Ion Torrent run reports indicate read quality is low after ~220bp (c.f. mean read length, top right, with quality filters 
on and off). However, after quality filtering, there are still a high number of reads returned per barcode (bottom table) for future analysis. 
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4.2.5 Sequencing Results 
4.2.5.1 Alignments and Variant Calling Prove Inconclusive Due to the 
Highly Repetitive Nature of the mTmG Locus 
Following alignment of the reads to the reference sequences, the mapping statistics 
were consulted. These revealed that the vast majority of the reads were mapped 
successfully back onto the references (Figure 4.6A), however there were a significant 
number of reads which could not be mapped uniquely to a single position (Figure 
4.6B). Taking PCR product 4 to demonstrate, the aligned reads were viewed using the 
Integrative Genomics Viewer (IGV, Figure 4.7). On this platform, grey bars indicate 
uniquely aligned reads, while white bars indicate reads which aligned to multiple 
positions and black bars indicate deletions. Furthermore, vertical purple bars indicate 
insertions while coloured bars indicate single nucleotide variants (SNVs). Viewing 
these alignments, it becomes clear that the software, with ~220bp reads, is unable to 
definitively separate reads which align around either of the two loxP sites, most likely 
due to the high sequence similarity and the presence of indels. Therefore, it is difficult 
to say whether the variants seen at these sites are real or simply errors of alignment.  
Aligning the samples against the expected cleavage product also produces somewhat 
ambiguous results. Many reads from the controls also align to this sequence, including 
over the loxP site, although there is a large increase (~20%) in the number of reads 
which align in the edited sub-populations (Figure 4.8A and 4.9). Furthermore, 
unexpectedly, there is no discernible enrichment in the number of reads which align to 
the H2B sequence between the edited sub-populations (Figure 4.8B), although very 
few reads align to this sequence from any of the samples (see coverage plots in Figure 
4.10). 
Considering these results, it was clear that we had underestimated the impact the 
repetitive nature of the mTmG locus would have on read alignment, although the 
problem may have been compounded by the unexpectedly short reads we received 





Figure 4.6: Mapping statistics following the alignment of Ion Torrent reads from 
each sample against the expected sequence for PCR product 4. A) The total 
percentage of reads which align to the reference sequence. B) The percentage of reads 




Figure 4.7:  With the current data it is not possible to unambiguously align reads to either loxP site. A screen capture from the IGV 
browser is shown of the alignments produced for each sample against the expected sequence for PCR product 4. Here, grey bars indicate 
uniquely aligned reads, white bars reads which aligned to multiple positions, black bars deletions and purple bars insertions. Furthermore, 
SNVs are indicated with coloured bars. A coverage plot, representing the number of reads which have aligned at each position, is displayed 




Figure 4.8: Mapping statistics showing the percentage of reads from each sample 
which aligned to A) the cleavage product and B) the H2B sequence. H2B is 




Figure 4.9: Screen capture from the IGV browser showing the alignments of Ion Torrent reads from each sample against the 






Figure 4.10: Screen capture from the IGV browser showing the alignments of Ion Torrent reads from each sample against the 
predicted sequence for the H2B repair product, with the associated coverage plots above. The loxP site, H2B sequence and EGFP 
are highlighted with red bars. 
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4.3 Sequencing Across the Locus Reveals Changes Relative to 
the Reference 
Prior to repeating the sequencing experiment, I decided to Sanger sequence across the 
locus to determine whether there are any differences between the reference sequence 
and the sequence present in our MEFs. Several variants, which appear to be present in 
all samples, can clearly be seen in Figure 4.7; and include a deletion before the first 
loxP site, an insertion following the second Tomato dimer and a larger variable region 
before the second loxP site.  
In order to sequence across the locus, I prepared a new PCR amplification with all four 
primer sets, using the Cas9 only control DNA and the same PCR conditions as 
previously. These PCR amplifications were visualised on a 2% agarose gel (Figure 
4.11A), before being submitted for sequencing by technical services. The sequences 
were aligned against the current reference using SnapGene. This revealed, as expected, 
that there were two differences between the reference sequence and the sequence in 
our MEFs (Figure 4.11B), as well as one 218bp fragment which was missing from the 
sequence we were using for alignment. This 218bp fragment may have reduced the 
number of reads from PCR product 2 which were able to align in Figure 4.7, although 
due to the trimming of reads into ~220bp fragments and the coverage from PCR 
product 3 over the second loxP site, it shouldn’t have significantly affected the overall 
results. Furthermore, none of the detected changes would significantly affect the 
functionality of our guides or repair template. These changes were added to our 




Figure 4.11: Sanger sequencing reveals two differences between the reference 
sequence and the sequence in the mTmG MEFs. A) PCR products generated using 
the Cas9 Only control template DNA were electrophoresed on a 2% agarose gel. L= 
1kb Plus DNA Ladder (Thermo Fisher). For expected product sizes see Figure 4.1. B) 
Cartoon showing the size and location of the three detected changes on the mTmG 
locus. 
4.4 Experimental Re-design – Barcoded Primers and A 
Potential Application for Nanopore Sequencing 
In order to circumvent the difficulties in aligning reads back to the repetitive reference, 
I decided to use a more sophisticated design for sequencing, in which all of the PCR 
products are individually barcoded, allowing separation in silico. This should 
significantly reduce the noise seen due to incorrect alignments. Furthermore, it was 
decided to sequence the products on both the original Ion Torrent PGM system, and 
the novel Oxford Nanopore MinION system. As explained in the introduction, the 
longer reads from the MinION should cover the entire length of the PCR products, 
avoiding the issues with aligning shorter reads. However, the high error rate of the 
MinION makes it unattractive as a sequencing approach to quantify editing on its own, 
hence why it is necessary to have the Ion Torrent for comparison. For this sequencing 
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experiment we also decided to take advantage of several newly developed reagents 
which had demonstrated high efficiencies in recent experiments; that being the use of 
RNP complexes to direct cleavage, and a minicircle repair template to drive higher 
rates of HDR. These are further investigated in Section 3.16.2. Furthermore, as we 
tend to see a large number of multi-nucleated cells following immortalisation (data not 
shown), it was decided to return to using non-immortalised MEFs since duplication of 
the locus may complicate the sequencing results. 
4.4.1 High Rates of Editing Are Seen Following RNP Transfection 
Early passage non-immortalised heterozygous mTmG MEFs (P3) were transfected 
using the Neon system (Section 2.12.1.3), however, for greater numbers I used 100µl 
tips with 3x105 cells per reaction/well, scaling up all reagents accordingly. Two wells 
of a 6-well plate were prepared: 
 
Ninety-six hours later, I imaged each well at 20x on a Dragonfly spinning disk 
confocal (Andor). Images revealed a high transfection efficiency, and several cells 
with GFP-positive nuclei could be seen (not quantified, Figure 4.12A), therefore I 
decided to continue with FACS. Twenty-four hours later, each well was dissociated 
and sorted on a BD FACSAria, separating each well into the four populations as before 
but with more constricted gates. This time, a small negative population was also 
captured from the control for inspection (Figure 4.12B). The rate of editing was found 
to be high in well 2 (~26%) and, as I had seen before, there was a low proportion of 
double-positive cells (1%) in the non-immortalised MEFs. FACS plots in Figure 4.13 
are shown for a proportion of the cells, the final numbers sorted from well 2 are 
approximately: 
  Tomato-positive - 400,000 cells 
  Negative  - 20,000 cells 
  GFP-positive  - 20,000 cells 




Figure 4.12: Joint transfection with RNP complexes and a minicircle repair 
template leads to a high rate of NHEJ and HDR in mTmG MEFs ahead of deep 
sequencing. A) 20x confocal images taken 96 hours post-transfection. Scale Bar 
200µm. B) Each well was sorted by FACS, 120 hours post-transfection. FACS plots 
for each well are shown, along with the gates used for sorting. 
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Each of the sorted populations was returned to a 24-well glass-bottomed plate for 
outgrowth. Forty-eight hours later, the majority of the wells were reasonably confluent, 
and each was imaged five times on a Dragonfly confocal at 20x. Images revealed that 
the sort had been largely successful, although again there was cross-over of cells into 
other populations. Interestingly, the ‘negative’ population from the control well 
appeared to be entirely Tomato-positive, if somewhat dimmer (Figure 4.13). 
Furthermore, several cells with nuclear-GFP could be seen in the GFP-positive and 
double-positive wells (not quantified). Based on these positive results, I extracted 
DNA from each well, at seven days post-transfection, following the protocol in Section 
2.4.1.1. DNA concentrations were reasonably low, between 10-20ng/µl, for several of 




Figure 4.13: Imaging reveals a small amount of cross-over between populations 
of edited mTmG MEFs during FACS. 20x confocal images taken of each well 48 
hours post-FACS. Scale bar 200µm. NB. There is some banding due to the intensity 
of the signal from nuclear-GFP, and to maintain laser power between wells. 
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4.4.2 PCR for Sequencing 
Using the DNA extractions from the previous section, I performed PCR amplifications 
as before (Section 4.2.3). Following amplification, each PCR product was purified and 
5µl was electrophoresed on a 2% agarose gel (Figure 4.14). Certain bands, e.g. D3 and 
E2, were very weak, although this may simply reflect that editing has removed the 
primer binding sites in these populations. DNA templates were coded as such: 
 A - NF-H2O 
B - Cas9 Only (Tomato-positive) 
 C - Tomato-positive 
 D - GFP-positive 
 E - Double-positive 
 F - Double-negative 
 
 
Figure 4.14: Purified PCR products for sequencing were electrophoresed on a 
2% agarose gel. L = 1kb Plus DNA Ladder (Thermo Fisher). 
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4.4.3 Sequencing Design and Run Report 
As before, purified PCR amplifications were transferred to the WTCRF for preparation 
and sequencing (Section 2.18). For MinION, amplicons were end repaired and 
adenylated, and then 16 barcode adapters were added during 18 cycles of PCR. For 
Ion Torrent, PCR products were sheared to a mean length of 300bp and then barcoded 
adapter sequences (16 in total) were added in a ligation step. Barcodes allow separation 
of reads by population and PCR product in silico. A run report was automatically 
generated by the Ion Torrent software upon completion of sequencing.  Again, this 
indicated that there was a substantial decrease in quality towards the ends of the reads, 
and that the mean read length was significantly below the input (189 vs. 300, Figure 
4.15). 
 
Figure 4.15: The Ion Torrent run report indicates there has been substantial 
trimming of the reads due to their low quality. 
Following sequencing, Ion Torrent reads were returned in files separated by barcode 
and aligned and analysed using the pipeline described in Section 2.19.1. The MinION 
reads were returned unsorted, and so initially were processed with the tool Porechop 
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(https://github.com/rrwick/Porechop) to sort them by barcode and then remove the 
adapter sequences. A modified version of the Ion Torrent pipeline was then used to 
align and analyse the reads (Section 2.19.2). Furthermore, a de novo genome assembly 
was attempted with both data sets (Section 2.20). 
4.5 Ion Torrent Sequencing Results 
4.5.1 The mTmG System Potentially Underestimates Rates of NHEJ – 
Deep Sequencing Reveals Greater Than 20% of the Tomato-only 
Population Is Edited 
I aligned the relevant barcoded reads against the reference sequences for PCR products 
1 and 2, which contain the first and second loxP sites respectively.  A high proportion 
of the reads were found to align in all cases (>90%) indicating the remaining reads 
were high quality and had been sorted by barcode correctly. On viewing the alignments 
in the IGV browser, I observed that a large proportion of the reads from the Tomato-
positive sub-population contained insertions and deletions across the loxP sites. I 
therefore quantified the percentage of reads containing indels across the loxP site ± 
10bp in each PCR product. The results showed that over 20% of the Tomato-positive 
reads contained indels or SNVs across the first loxP site (Figure 4.16), while ~8% of 
the reads were edited at the second loxP site (Figure 4.17). Unfortunately, as individual 
Ion Torrent reads do not span both loxP sites, it’s impossible to combine these two 
results. However, this still indicates that a significant proportion of the visually 
unedited cells have genomic evidence of editing. This could arise when there is editing 
at only one site, or where out-of-sync editing occurs at both sites such that the 
intervening fragment is not excised. Indeed, there is a large downward shift in Tomato 
intensity (Figure 4.12B) on editing, as opposed to the more tightly clustered population 
in controls. As the Tomato-positive cells comprised ~75% of the total following RNP 
transfection (Figure 4.12B), this would suggest that the rate of NHEJ was 15% higher 
than detected by FACS. Nevertheless, this underestimation was expected and is not a 
serious concern for a model which will mainly be used to optimise reagents for in vivo 




Figure 4.16: The alignments for PCR product 1 reveal a large proportion of the Tomato-positive population harbours small indels 
around the first loxP site. Screen capture from the IGV browser software. Regions of interest are highlighted in red. The black box 
indicates the region used to determine the rates of editing, which have been plotted graphically in the insert. NB. As we expect the binding 





Figure 4.17: The alignments for PCR product 2 reveal a smaller proportion of the Tomato-positive population harbours indels 
around the second loxP site. Screen capture from the IGV browser software. The loxP site is highlighted in red. The black box indicates 
the region used to determine the rates of editing, which have been plotted graphically in the insert. NB. As we expect the binding site for 




4.5.2 The Tomato-containing Fragment Between the LoxP Sites Has 
Been Excised in the GFP-Positive Population 
Next, I aligned the reads for PCR product 4 against the expected reference sequence 
and the predicted sequence of the cleavage product. These support two opposite 
hypotheses; in the first there has been no excision of the region between the loxP sites, 
whereas in the second this excision is total. On viewing the alignments against PCR 
product 4 in the IGV browser, almost no reads from the GFP-positive population were 
observed to contain the sequence between the two loxP sites (maximum coverage 11x 
vs. 1496x for Tomato-positive, Figure 4.18). These reads may be derived from the 
Tomato-positive contamination of the GFP sort. Furthermore, when considering the 
alternative hypothesis, the generation of the cleavage product, an alignment rate of 
approximately 85% is seen with the GFP-positive population (Figure 4.19, insert). 
These results are a clear demonstration that the GFP-fluorescence read-out is 
indicative of the expected cleavage and end-joining in our system. The range of 
‘indels’ which can be seen around the loxP site in the cleavage product are likely due 
to the different lengths of sequence which are left following cleavage by LoxP#1 or 
LoxP#2, along with varying amounts of end-resection. Indeed, the size of deletions 
which can be created by CRISPR/Cas9 is known to be highly variable (Kosicki, Rajan 
et al. 2017). 
This analysis provides no definitive answer into why the negative population has lost 
fluorescence, which is investigated further in Section 4.7.  However, the analysis does 
suggest that the double-positive population is a hybrid of events in between the 
Tomato-positive population and the GFP-positive population. Approximately 50% of 
the reads from the rare double-positive population (1%, or ~3,000 cells) align uniquely 
to the expected cleavage product. While less common in cultured primary cells, this 
could occur if the locus had been duplicated and only a single copy had been modified. 
Alternatively, editing at the second loxP site has occurred but has deleted back into the 
C-terminal end of the Tomato-cassette containing the polyadenylation sequence – this 
could result in a hybrid Tomato and GFP translation product. However, further 
experiments, such as fluorescence in situ hybridisation (FISH), would need to be 




Figure 4.18: The sequences from PCR product 4 reveal that the region between the loxP sites is almost entirely absent in the GFP-
positive population. Screen capture from the IGV browser software. Alignments are displayed with coverage plots above. Regions of 





Figure 4.19: The majority of reads from the GFP-positive population align correctly to the expected cleavage product. Screen 
capture from the IGV browser software. Regions of interest are highlighted in red. Insert: The percentage of reads from PCR product 4 
which align uniquely to the cleavage product has been plotted graphically. 
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4.5.3 H2B Sequence can be Detected in All Transfected Samples 
Next, I aligned the reads from PCR product 4 against the predicted sequence for the 
H2B repair product. As expected, no reads from the Cas9 only control contained the 
H2B insert sequence (Figure 4.20, 4.21). This region, which contained no reads in the 
Cas9 only control, was then used for comparison (highlighted with a black box in 
Figure 21). I calculated the average read depth across this region and compared it with 
the total number of reads from PCR product 4 in each sample to derive the percentage 
of reads which include this H2B sequence (Figure 4.20). This analysis revealed that 
the percentage of the GFP-positive reads which contain H2B was approximately as 
expected, at 1.5%. However, unexpectedly, a greater number of reads from the other 
sub-populations contained the H2B sequence than did the GFP-positive sub-
population.  
Returning to the PCR products in Figure 4.14, it becomes clear that all the sub-
populations contain a band at ~850bp and its intensity is proportional to the results 
seen in Figure 4.20. It seems likely that the seven-day period post-transfection was not 
sufficient to ensure the minicircle was adequately degraded and/or diluted out, 
allowing PCR to prime off the repair template. Alternatively, one of the reagents used 
for PCR may have been contaminated with the repair template. Returning to the initial 
Ion Torrent experiment (Figure 4.4), bands at ~850bp can also be seen in most 
populations, including the Cas9 only control, although strangely not in the H2Bv2 only 
control. In this experiment the repair plasmid would have had to persist for 17 days in 
a fast dividing cell population, which seems unlikely, although it is also possible that 
the repair templates are integrating elsewhere in the genome. However, evidence of 
HDR can be seen in the GFP-positive population due to the 2bp deletion which is 
present in the locus but not in the repair template. Very few reads from the Tomato-
positive population contain this deletion, suggesting they are from the minicircle, 
whereas most reads from the GFP-positive cells do, indicating repair (Figure 4.22, red 
box).  
In future experiments, in order to ensure we only detect instances of H2B which are 
correctly integrated into the mTmG locus, it will be necessary to use primers which lie 
outside the regions of homology in the repair template. A downside of this approach 
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would be the large (up to 5kb) PCR products, which may be difficult to amplify from 
this locus, although this could be overcome with optimisation. 
 
Figure 4.20: The H2B sequence can be detected in all the samples transfected with 
the minicircle repair template. The percentages above are derived from the average 




Figure 4.21: In all edited sub-populations, reads can be seen to align to the H2B repair sequence. Screen capture from the IGV 
browser software. Regions of interest are highlighted in red. The black box indicates the approximate region used to calculate the 
percentages in Figure 20. The red box indicates the 2bp deletion which is present in our locus but not in the minicircle repair template. 
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4.5.4 De novo Genome Assembly is Unable to Reconstruct the mTmG 
Locus from Ion Torrent Reads 
I also attempted to carry out a de novo genome assembly with the Ion Torrent data 
using the SPAdes software (Bankevich, Nurk et al. 2012). De novo genome assembly 
allows me to take a hypothesis-free approach, and let the algorithm assemble the reads 
through their overlapping regions into the DNA sequences from which they originate. 
Unfortunately, with our ~190bp reads, it was unable to produce any sequences which 
resembled the reference mTmG locus. Given the repetitive nature of the mTmG 
sequence, it would be difficult or impossible to assemble short reads unambiguously; 
alone, the tdTomato gene alone contains a tandem repeat which is much larger than 
our mean read length (~700bp vs ~200bp). 
4.6 MinION Sequencing Results 
The software used to align the MinION reads, Graphmap (Sovic, Sikic et al. 2016), 
offers three different approaches for aligning reads; global, local and semi-global or 
‘glocal’. In a global alignment, an attempt is made to align all the bases in the sequence 
and the reference, whereas in a local alignment, regions can be trimmed from the 5’ 
and 3’ ends to form a substring prior to performing the alignment. A global alignment 
therefore performs best when the input sequences are of a similar length to the 
reference sequence and have the same 5’ and 3’ ends. A local alignment, however, 
may substantially trim back reads or the reference to find the best matching portion. 
The hybrid method, glocal alignment, allows trimming of the reference sequence but 
not of the reads. It is particularly useful when one expects insertions, deletions and/or 
rearrangements in the reads relative to the reference. Based on this, I decided to align 
the reads using a ‘glocal’ algorithm, however, in practice, all three algorithms were 
found to produce similar results when tested (data not shown). 
4.6.1 MinION Sequences Carry a High Error Rate 
As mentioned previously, the MinION data was received unsorted by barcode, and so 
I initially processed it with Porechop to separate the reads by barcode and remove 
adapter sequences. Unexpectedly, after running this programme, the majority of reads 
were found to contain no identifiable barcode sequence, although there was a generally 
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even amount of data from the sequences with barcodes (Figure 4.22A). I analysed the 
sequences with no barcode further, which revealed that they had markedly reduced 
quality scores compared to the sequences with barcodes (Figure 4.22B). I  
hypothesised that this may be because these are much longer reads, however, on 
plotting the read distribution within the no barcode population this was not observed 
(Figure 4.22C). Therefore, it appears as if a large proportion of the reads from the 
MinION are simply too low quality for the barcodes to be identified correctly (a 





Figure 4.22: The high error rate in MinION data prevents the identification of 
barcode sequences.  A) The amount of data generated per barcode was largely the 
same, although most reads had no identifiable barcode. B) Quality score plots 
generated by FastQC for the no barcode population and B1. C) Comparing the mean 
read length of each PCR product with the read length distribution of the no barcode 





4.6.2 The MinION Sequencing Protocol is Biased towards Sequencing 
Shorter Products 
After sorting by barcode, I examined the mean read length (Figure 4.22C) and read 
length distributions of each PCR product. All of the PCR products from PCRs 1 
through 3 were of the expected size and had a single peak in their read length 
distributions. In PCR product 4, which is ~3kb as opposed to 900bp for 1 and 2, there 
were a range of peaks in the read length distribution, as expected based on the gel 
picture. However, there was a strong bias in the read length distributions towards the 
shorter PCR products. In several cases, the shorter PCR products were of a very low 
abundance on the gel and yet comprised the majority of the sequences returned (Figure 
4.23). This indicates that, given a population of mixed size, the MinION will 
preferentially sequence the shorter products present. Based on this, it suggests that 
currently use the MinION to quantify editing events where one expects products to be 




Figure 4.23: When given a population of DNA products of mixed sizes, the MinION exhibits a strong preference towards 
sequencing the shorter fragments. Top left: Products from PCR 4 were visualised on a 2% agarose gel, revealing bands with a range of 
sizes. Comparing the read length distributions with the gel picture, there is a significant discrepancy between band intensities and the 
frequency of sequenced products seen. 
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4.6.3 MinION Sequencing Confirms the Results from Ion Torrent 
Next, I aligned the processed MinION sequences, with their barcodes and adapters 
removed, against the expected/predicted sequences as before. The alignments largely 
confirmed what was seen in the Ion Torrent data; in that the region between the loxP 
sites was excised in the GFP-positive population (Figure 4.24) to form the expected 
cleavage product (Figure 4.25), with the double-positive population appearing to be a 
hybrid between the GFP-positive and Tomato-positive populations. However, 
compared to the Ion Torrent data, the high error rate of the MinION was clearly evident 
in the alignments. These errors were evenly distributed across the reads and make it 
impossible to discern whether there has been editing at the loxP sites, as was done with 




Figure 4.24: The MinION data confirms that the region between the loxP sites in 
the GFP-positive population is removed. A) Screen capture from the IGV browser 
showing the alignments and coverage plots for each population. Regions of interest 
are highlighted above in red. B) The percentage of reads from each population which 




Figure 4.25: The expected cleavage product is present in the GFP-positive 
population, and the double-positive population. A) Screen capture from the IGV 
browser showing the alignments and coverage plots for each population. Regions of 
interest are highlighted above in red. B) The percentage of reads from each population 
which align to the expected cleavage product. 
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4.6.4 De Novo Genome Assembly Is Successful with Longer MinION 
Reads 
As the MinION sequencing platform produces much longer reads than the Ion Torrent, 
it should be highly suited to performing de novo genome assemblies. MinION reads 
should extend beyond any repetitive regions, allowing them to be correctly ordered 
and assembled. Considering this, I attempted a de novo genome assembly with the 
reads from PCR product 4 for each of the samples using an algorithm, Canu (Koren, 
Walenz et al. 2017), which is optimised for MinION data. 
The results revealed that the MinION reads can be successfully assembled in order to 
form the major sequences which are present in the input. Aligning the resulting 
sequences on SnapGene to the reference, it could be seen that Canu had assembled the 
reference sequence from the Cas9 only control with very little error (Figure 4.26A). 
Furthermore, the three sequences assembled from the GFP-positive data were all 
lacking the tdTomato. Interestingly, Canu identified that the double-positive 
population consists of a mixture of sequences with Tomato (88%) and without (12%), 
while the double-negative population was also seen to be a mixture, with some 
sequences missing segments of the Tomato reporter; which could explain their loss of 
fluorescence. 
From the SnapGene alignments, I noticed that a large proportion of the edited 
sequences contained an insertion just upstream of the GFP in place of the MARCKS 
tag (noted by a small blue arrowhead). I hypothesised that this might be indicative of 
the H2B sequence being present, and so the assembled sequences were aligned again, 
this time to the expected repair product. This analysis revealed that the insertion was 
indeed H2B, although again it was detected in all the samples transfected with the 
minicircle repair template (Figure 4.26B), indicating possible sequencing off the repair 




Figure 4.26: A de novo genome assembly was performed on the MinION data for 
PCR 4 using the Canu software. The resulting assemblies were aligned against the 
expected sequences using SnapGene, and alignments are shown above for PCR 4 (A) 
and the H2B repair sequence (B). Assembled sequences are ordered based on the 
number of reads which went to form them, with the assembled sequence which 
represents the largest number of reads uppermost. 
4.6.5 H2B Sequence Is Again Detected in All Minicircle Transfected 
Samples 
Following on from the detection of H2B in all samples by de novo genome assembly, 
alignments of the reads from PCR 4 against the expected repair product produced a 
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similar result. H2B was detected in a large and reasonably equal percentage of all the 
populations transfected with the minicircle (Figure 4.27).  
 
Figure 4.27: The H2B repair sequence is detected in all samples transfected with 
the minicircle repair template. A) Screen capture from the IGV browser showing the 
alignments and coverage plots for each population. Regions of interest are highlighted 
above in red. B) The percentage of reads from each population which contain the H2B 




4.7 TOPO-Cloning of the Double-Negative Population 
Reveals Large Deletions across the Promoter and/or GFP 
As next-generation sequencing had provided no definitive explanation for the negative 
population, it was hypothesised that this group must contain larger deletions which 
extend beyond the binding sites for our current sequencing primers. Based on this, I 
designed new sequencing primers which lie within the pCA promoter and further into 
the GFP (Section 2.5.2 for sequences). PCR amplifications were then performed using 
these primers with DNA from both the Cas9 only control and double-negative 
populations. Amplifications were visualised on a 2% agarose gel, which revealed the 
presence of multiple bands in the negative population (data not shown). Following 
this, each PCR product was TOPO-cloned (Section 2.8) and 96 clones were submitted 
for Sanger sequencing. The returned sequences revealed that almost all negative cells 
harbour deletions that extend into the GFP sequence and/or the promoter, which would 
be expected to result in a loss of fluorescence. Furthermore, all sequences from the 




Figure 4.28: The negative population contains larger deletions which extend into 
the promoter and/or GFP. A) Example sequences aligned using SnapGene which 
show large deletions in the negative population relative to the control. B) Based on the 
SnapGene alignments, the number of sequences in each population which contained 
deletions was counted and plotted graphically. 
4.8 Conclusions 
With these sequencing results, it is possible to explain how the four spectrally distinct 
populations have arisen based on the editing they have seen at a genomic level. The 
GFP-positive population has undergone the expected cleavage at both loxP sites, 
removing the Tomato reporter, while the negative population appears to have 
undergone a similar process except larger deletions have been created at the loxP sites; 
disrupting the GFP and/or pCA promoter. It is also important to note that over 20% of 
the Tomato-positive cells contained indels around the cut sites, indicating that we are 
achieving a much higher rate of NHEJ than we can visually track. Furthermore, as a 
working model, I would suggest that the rare double-positive population contains more 
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than one copy of the mTmG locus, which are not equally edited. My data supports this 
model as the double-positive population is much reduced in non-immortalised cells 
which are more karyotypically stable. Nevertheless, some genome instability is 
expected when culturing even non-immortalised cells over large periods of time. In 
future work this could be tested by sequencing the mRNA transcripts from the double-
positive cells; if both pCA-Tomato and pCA-EGFP transcripts are detected this would 
support this hypothesis. Alternatively, we may detect hybrid pCA-Tomato-EGFP 
fusion transcripts as a result of more complex genomic editing at the (non-duplicated) 
original locus. 
The data presented in this chapter also allows us to draw comparisons between the two 
sequencing technologies employed, Ion Torrent and nanopore sequencing. Both can 
be seen to have their advantages and disadvantages. Strikingly, the error rate is still 
very high in MinION data, which can significantly hamper any further processing and 
analysis. However, due to the volume of data one receives from a MinION run, it is 
possible to filter out the lower quality reads and still be left with a large number of 
long, reasonably high-quality reads, which seem particularly suited to de novo genome 
assembly. Nevertheless, the error rate in the filtered reads is still higher than in Ion 
Torrent data, and the platform also displayed a strong preference to sequencing shorter 
fragments. These two factors currently mean it is ill-advisable to solely use the 
MinION when quantifying an editing experiment. In these cases, the Ion Torrent 
should give a much more representative picture of the input, as the DNA is sheared to 
the same size prior to being sequenced. Alternatively, TOPO-cloning is a valid 
approach if one expects there will be a high proportion of edited cells in the input 
(>1%, or ideally >10%), although it can be laborious and time-intensive if many 
samples are to be sequenced. It is therefore prudent to think carefully about the 
variables of the experiment prior to deciding upon a sequencing methodology, to 




Chapter 5 Correcting Pathogenic Indels in Zmynd10 in a 
Mouse Model of Primary Ciliary Dyskinesia 
5.1 Introduction 
As detailed in the previous two chapters, I have developed a system which will allow 
us to develop and optimise reagents and protocols for gene editing by CRISPR in cells 
and in vivo. Given that rates of gene editing and repair have been shown to be 
influenced by sequence, chromatin configuration and expression level (Chen, Rinsma 
et al. 2016, Tsouroula, Furst et al. 2016, Jensen, Floe et al. 2017), I next had to confirm 
that methods which achieve high rates of NHEJ and HDR in the exogenous mTmG 
cassette in the Rosa26 locus are also effective when targeting a disease-causing 
mutation in a gene of interest. Once we have developed methodologies for testing gene 
editing in organotypic cultures and in vivo, it will also be important to demonstrate an 
ability to edit clinically relevant cell types for our disease of interest in the reporter, at 
levels that would be therapeutically beneficial. As a proof-of-principle, I began to 
address these issues using a mouse model of the rare, highly polygenic, respiratory 
disease, primary ciliary dyskinesia (PCD). 
Primary ciliary dyskinesia (OMIM: 244400), is a genetically heterogeneous, 
autosomal recessive condition which affects approximately 1 in 10,000 to 1 in 20,000 
individuals world-wide (Mirra, Werner et al. 2017). PCD presents with a range of 
adverse symptoms, including respiratory distress, impaired mucociliary clearance, 
hydrocephaly, sinusitis and male infertility, due to a lack of correctly functioning 
motile cilia (Daniels and Noone 2015). Motile cilia are found on many of the body’s 
epithelial surfaces, such as the airways and the brain ependyma, where they are crucial 
for fluid and/or mucus clearance (Horani, Ferkol et al. 2016). Furthermore, motile cilia 
are present on the embryonic node where they are necessary to generate the fluid flow 
which establishes left-right asymmetry. Because of this, approximately half of PCR 
patients also present with laterality defects, most commonly situs inversus, in which 
organs are mis-placed in their mirror-image (Damseh, Quercia et al. 2017, Mirra, 
Werner et al. 2017). 
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Cilia are complex, microtubule-based organelles which project out from the cell, to 
which they are linked by the basal body. In mammals, there are two varieties: a) 
sensory, or primary, cilia which are immotile; and b) motile cilia which are involved 
in generating fluid flow or propelling sperm. The cilium is a dynamic structure, and its 
formation and maintenance are dependent on the bi-directional trafficking of many 
proteins in and out of the organelle via the specialised intraflagellar transport (IFT) 
system. Enclosed by the ciliary membrane, the axoneme of the motile cilia consists of 
an array of microtubules with a ring of 9 microtubule doublets and 2 central singlets, 
a (9 + 2) arrangement (Mitchison and Valente 2017) . Movement is generated by outer 
and inner dynein arms (ODA and IDA) which periodically decorate the A-tubule of 
each microtubule doublet ring (Figure 5.1). ODAs control beat frequency while IDAs 
control waveform in an ATP-dependent dynein-powered stroke whereby the dynein 
“walks” along the B-tubule, allowing the axoneme to bend (Bustamante-Marin and 
Ostrowski 2017). 
 
Figure 5.1: Diagrammatic representation of a motile cilium, as found on the brain 
ependyma and respiratory epithelium. Embryonic nodal cilia lack the central pair. 
Adapted from Reiter and Leroux (2017). 
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Immotile cilia, and hence PCD, can be the result of defects in a range of proteins, 
including structural elements of the cilium itself or factors involved in the assembly 
and transport of complexes to the cilia (Horani, Ferkol et al. 2016, Mitchison and 
Valente 2017). Indeed, mutations causative of PCD have currently been described in 
33 separate genes (Mirra, Werner et al. 2017), a number which is continuously rising.  
This genetic heterogeneity, combined with the rareness of the disease, means treatment 
options for PCD are severely limited, and largely only symptomatic (Polineni, Davis 
et al. 2015). While PCD may be amenable to a gene therapy by gene transfer approach, 
it is a much less attractive target than other, less rare, diseases, such as cystic fibrosis 
(CF), which are caused by mutations in a single gene. Furthermore, the very large size 
of genes commonly mutated in PCD (e.g. DNAH5 at ~14.6kb) impedes packaging in 
the viral vectors commonly employed for gene replacement, which have a maximum 
capacity of ~8kb (Dunbar, High et al. 2018).  Therefore, the treatment of PCD and 
other rare genetic diseases may particularly stand to gain from the development of 
CRISPR for gene therapy, as it will allow mutations virtually anywhere in the genome 
to be corrected with the same machinery in a “personalised” manner; potentially 
obviating the need for individual mutation-by-mutation clinical testing. Furthermore, 
if efficient, a genome editing approach allows the correction of the gene at its 
endogenous locus, ensuring correct regulation. 
5.1.1 ZMYND10 and Ciliary Assembly 
As our proof-of-principle model for PCD, we chose a Zmynd10 mutant mouse. The 
disrupted gene, Zmynd10, codes for an essential cytoplasmic dynein assembly factor 
(DNAAF), required for the formation and stability of both outer- and inner dynein 
arms. If we can restore ZMYND10 function by genome editing to rescue axonemal 
dynein stability in a DNAAF model, we would likely be able to rescue all other classes 
of mutants. This mouse model of PCD contains a -7bp deletion in the fourth, critical 
exon of Zmynd10 (Zmynd10 c.695_701 p.Met178Ilefs*183) which creates a null allele 
(Figure 5.2A, B). This mouse line is part of an allelic series generated by three separate 
gRNAs targeting this exon in a CRISPR-mediated mutagenesis strategy which all 
display PCD-like symptoms, indicating that the phenotype is not due to off-target 
mutations. Zmynd10 mutant mice were shown to lack ODA and IDA, and have 
immotile cilia (Figure 5.2) (Mali, Yeyati et al. 2017). A similar ciliopathy phenotype 
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in Zmynd10 nulls has been described in several other organisms, including in human 
patients (Moore, Onoufriadis et al. 2013, Zariwala, Gee et al. 2013, Kurkowiak, 
Zietkiewicz et al. 2016), in Drosophila melanogaster (Moore, Onoufriadis et al. 2013), 
and in zebrafish (Danio rerio) (Zariwala, Gee et al. 2013).  
 
Figure 5.2: Zmynd10 null mice display a characteristic PCD phenotype. A) Gene 
and protein sequence of the Zmynd10-/- mice which harbour a -7bp deletion creating a 
premature termination codon (PTC). B) Immunoblots from testes extracts show loss 
of ZMYND10. C-E) Zmynd10 null mice display characteristic PCD phenotypes, such 
as C) hydrocephaly (doming of the skull, white arrowhead), D) lack of ODA (white 
arrowhead) and IDA (black arrowhead), and E) situs inversus (arrowhead indicates 
heart, numbers indicate lobes of the lung). Adapted from Mali, Yeyati et al. (2017). 
The gene ZMYND10 (GRCh38: ENSG00000004838), or BLU, was initially described 
as a tumour suppressor which was particularly prone to silencing by promoter 
hypermethylation in lung cancer (Marsit, Kim et al. 2005, Yau, Lung et al. 2006). 
Later, whole exome sequencing of families affected by PCD revealed ZMYND10 
mutations to be causative in several unexplained cases. Further immunofluorescence 
experiments demonstrated that the light- and heavy-chain axonemal components 
DNALI1 and DNAH5 were absent in ZMYND10 mutants (Moore, Onoufriadis et al. 
2013, Zariwala, Gee et al. 2013, Mali, Yeyati et al. 2017). Moreover, Zmynd10 
expression was found to be controlled by RFX and FOXJ1, transcription factors known 
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to be required for ciliogenesis (Moore, Onoufriadis et al. 2013). These two initial 
studies also used overexpression of Zmynd10 to identify a potential interaction partner, 
LRRC6, itself another PCD gene, with which ZMYND10 was found to co-localise in 
the cytoplasm, forming a putative cytoplasmic assembly complex for dyneins (Moore, 
Onoufriadis et al. 2013, Zariwala, Gee et al. 2013).  
In order to better understand the disease mechanisms underlying Zmynd10 mutations, 
our group has undertaken a variety of candidate protein-affinity purification 
approaches, as well as unbiased label-free quantitative mass spectrometry, to establish 
that ZMYND10 acts as a specificity factor for the ubiquitous chaperone protein HSP90 
and co-chaperone peptidylprolyl isomerase FKBP8 for the ‘client’ axonemal dynein 
heavy chains. Interestingly, these two chaperones are critical for the folding of several 
proteins, such as the cystic fibrosis transmembrane receptor (CFTR) (Banasavadi-
Siddegowda, Mai et al. 2011, Hutt, Roth et al. 2012), on the cytosolic face of the 
endoplasmic reticulum. This suggests that biosynthesis and/or folding of the large and 
structurally complex axonemal dynein heavy chains may be spatially restricted within 
the cell to regions with high density chaperones and protein quality control 
mechanisms by ZMYND10.  
ZMYND10 appears to function in a sequential chaperone relay wherein the ‘client’, 
the heavy-chain dynein DNAH5, was found by endogenous affinity purification to 
initially associate with ZMYND10 and FKBP8, whereas when the ‘client’ was 
assembled into its final macromolecular complex with the dynein intermediate chain 
DNAI1, interactions with ZMYND10 and the chaperones were no longer detected  
(Mali, Yeyati et al. 2017). Moreover, once axonenal dynein arms are trafficked and 
docked into growing axonemes, during differentiation, the cytoplasmic levels of the 
dynein subunits and the assembly factors drop below the level of detection in mature 
cells. These findings suggest that there is a series of transient interactions, separated 
in time and space, during axonemal dynein assembly. As such, it will be important to 
test whether correcting Zmynd10 in mature ciliated cells, the predominant cell type in 
the conducting airways (Bustamante-Marin and Ostrowski 2017), can restore ciliary 
motility. Based on these findings, I would hypothesise that successful and long-lasting 
functional gene correction will require targeting the basal stem cells, where 
cytoplasmic dynein assembly is occurring upon differentiation (Spassky and Meunier 
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2017). Considering this, the mTmG system we have developed should provide 
invaluable preliminary results regarding which cell types we are able to edit with 
various protocols. 
5.2 Zmynd10 Guide and Repair Template Design 
Guide-RNAs were designed using a suite of online tools (Section 2.1.2) and chosen 
based on their high scores and low number of potential off-target sites. Three guides 
were chosen to target the -7bp deletion locus, one on the forward strand and two on 
the reverse strand (Figure 5.3A). All guides were initially cloned (Section 2.2) into the 
pX458 Cas9-GFP expression vector (Section 2.2.2), to allow for selection. 
Repair templates were designed for each guide and synthesised by IDT in ssODN 
format. For the ‘Z10 R’ guide, two alternative repair template designs were tested, one 
with approximately symmetrical regions of homology on either side of the Cas9 cut 
site, and one with asymmetric regions of homology. For the other two guides only 
asymmetric repair templates were designed (Figure 5.3B), as asymmetric ssODN 
repair templates have been reported to drive higher rates of HDR (Richardson, Ray et 
al. 2016). All repair templates carried silent mutations across the PAM site in order to 








Figure 5.3: Schematic representation of the CRISPR-based repair strategy, 
showing guides (A) and repair templates (B) in relation to the -7bp deletion in 
Zmynd10. A) The -7bp deletion is indicated with a yellow box. Guide target sites are 
indicated below with orange arrows, their direction being 5’ to 3’ relative to the target 
sequence. B) ssODN repair templates specific to each guide were designed following 
a symmetric (Sym) or asymmetric (Asym) layout. All repair templates harbour a silent 
mutation which disrupts the PAM site (yellow star). Not to scale. 
5.3 Generation of Mouse Embryonic Fibroblasts and 
Ependymal Cells from Zmynd10 Mice 
In order to test the functionality and efficiency of our various guides and repair 
templates, I derived two primary cell lines from the heterozygous Zmynd10 c.695_701 
line intercross; mouse embryonic fibroblasts (MEFs) from E14.5 mice (Section 2.10.1) 
and motile ciliated ependymal cells from E18.5 mice (Section 2.11.1). During 
dissection of the embryos a tissue sample was collected for genotyping. DNA was 
extracted from the samples (Section 2.4.1.2) and a genotyping PCR was performed 
using DreamTaq Green PCR Master Mix (Section 2.6) using primers 766 and 767 
(Section 2.5.3). Following amplification, the PCR products were digested with MlucI 
(Section 2.4.4.1). As a result of the -7bp deletion, homozygous mutants lack this cut 
site and will show an uncleaved band at 311bp, whereas homozygous wild-type DNA 
will be cleaved into one 150bp and one 164bp fragment (which appears as one band 
on the gel). The digestion products were visualised on 2% agarose gels (Section 2.7), 
which indicated the presence of one homozygous mutant in the MEF E14.5 litter 
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(Figure 5.4A), and three homozygous mutants in the ependymal E18.5 litter (Figure 
5.4B). Ependymal progenitor cells were then allowed to proliferate for 5 days prior to 
being used for transfections. MEFs were expanded to passage number 4 before being 
tested for mycoplasma and frozen down for future work (Section 2.10.1). 
 
Figure 5.4: Example genotyping of MEF (A) and ependymal cell (B) progenitors, 
revealing the presence of homozygous -7bp deletion mutants. Genotyping PCR 
products were digested with MlucI and then visualised on 2% agarose gels. L = 1kb 
Plus DNA Ladder (Thermo Fisher). Homozygous mutants are highlighted with grey 
arrowheads. C) Example digestion products from a heterozygous, homozygous mutant 
and homozygous wild-type mouse. 
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5.4 Ependymal Progenitor Transfections with pX458 
Following dissection, the ependymal progenitor cells were allowed to proliferate for 
five days to reach confluency and dissociated with TrypLE Express (Thermo Fisher). 
Four transfections were then performed using the Neon 10µl tips (Section 2.12.1.2): 
 
Following transfection, the cells were returned to a 24-well plate, although all four 
wells appeared unexpectedly sparse. As the progenitor cells need to reach confluency 
to differentiate, additional non-transfected cells (of the respective genotypes) were 
added to wells 2 and 4. Six days post-transfection, wells 2 and 4 were observed to be 
confluent and had formed tight-junctions (Figure 5.5A), while wells 1 and 3 remained 
significantly sub-confluent (data not shown). Furthermore, GFP-positive cells could 
be seen in both wells (Figure 5.5B) indicating transfection had been successful. Wells 
2 and 4 were therefore serum-starved to induce differentiation and the production of 
multi-cilia. Six days post-serum-starvation, patches of cells with motile cilia could 
clearly be seen in the heterozygous cells, although none overlapped with the GFP 
signal. GFP-positive cells, which appeared by morphology to be ependymal, were 
observed in the homozygous mutant well, although no cells with motile cilia were 
observed (Figure 5.5C).  
Given these results, it was apparent that this was not the optimum system for testing 
guide and repair template combinations, based on the low cell numbers obtained from 
ependymal dissections, combined with low transfection efficiencies (Figure 5.5B, 
number of GFP-positive cells, not quantified) and time required for differentiation. 
Therefore, I decided to move onto using the Zmynd10 mutant MEFs which are more 
scalable, whereupon I could assay editing at a sequence-based level (as MEFs do not 




Figure 5.5: No motile cilia were observed in Zmynd10-/- ependymal cells following 
pX458 and ssODN repair transfection. A) Prior to serum-starvation, each well was 
imaged at 20x on a Nikon T-iS inverted microscope which revealed the presence of 
tight-junctions. Scale bar 200µm. B) Six days post-transfection, each well was imaged 
at 20x on a Nikon A1R confocal which revealed the presence of GFP-positive, 
transfected cells. C) Six days post-serum-starvation, each well was imaged at 40x on 
a Nikon A1R confocal which revealed the presence of motile cilia in the heterozygous 
population (white arrow), but not in the homozygous, transfected population. A) 
Brightfield, B-C) GFP + Brightfield composite. 
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5.5 Can Use of a Selectable GFP Transfection Marker Enrich 
for Editing and Repair? 
As MEFs can be readily dissociated and re-plated, and can be propagated for several 
passages following transfection, this allows me to quantify rates of editing and repair, 
as opposed to transfection efficiencies, by isolating GFP-positive cells following 
transfection with pX458 (a similar construct to the pX330 used to generate the 
Zmynd10 mice but with a GFP marker, Section 2.2.2), and then expanding and 
sequencing. Furthermore, as in the mTmG sequencing experiment, I decided to 
sequence the samples on the Ion Torrent Personal Genome Machine (PGM) due to its 
low error rate and high coverage (Quail, Smith et al. 2012), which should allow me to 
detect potentially rare events, such as HDR from the ssODN repair template. 
5.5.1 MEF Transfections with pX458 
Heterozygous and homozygous Zmynd10 -7bp deletion MEFs were transfected using 
the Neon 100µl tips (Section 2.12.1.1). Two small molecules which have been reported 
to increase rates of HDR, BFA and L-755,507 (Yu, Liu et al. 2015), were included to 
test their effect in this system. Eight wells were transfected with varying conditions: 
 
Twenty-four hours post-transfection each well was sorted by FACS on a BD 
FACSJazz. No GFP-positive cells were found in well 1, as expected. Between 15,000 
and 38,000 GFP-positive cells were recovered from the remaining wells, which were 
returned to a 24-well plate. 300,000 GFP-negative cells were also recovered from each 
well and returned to a 6-well plate. Seven days later, all wells were confluent and so 
DNA was extracted (Section 2.4.1.1) and quantified on a Nanodrop spectrophotometer 
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(Section 2.4.3). The DNA extractions were then named based on the well they came 
from, and whether they were GFP-positive/green (Gr) or GFP-negative/blank (Bl) (i.e. 
5Bl represents the GFP-negative population from well 5). 
5.5.2 Monitoring Genome Editing by Deep Sequencing on an Ion 
Torrent Platform: PCR Amplification 
Sixteen barcoded Ion Torrent sequencing primers were designed to amplify the sorted 
populations plus a B6 (C57BL/6J) parental wild-type control (Section 2.5.4), allowing 
later separation of the reads by sample in silico. Each sample was amplified using 





Figure 5.6: Zmynd10 PCR amplifications for Ion Torrent sequencing. 
Amplifications were electrophoresed on a 1.5% agarose gel. L= 1kb Plus DNA Ladder 
(Thermo Fisher). Slight band blurring potentially due to issues with the buffer. Insert: 
amplification of 5BL initially failed due to evaporation and was repeated. 
5.5.2.1 Monitoring Genome Editing by Deep Sequencing on an Ion 
Torrent Platform: AMPure Purification and Purity Analysis 
PCR amplifications were subjected to two rounds of purification using Agencourt 
AMPure XP beads (Beckman Coulter) in order to remove any primer dimers present. 
Samples were visualised on a 1.5% agarose gel (Section 2.7) following purification 
which revealed that primer dimers appeared to be absent, although DNA concentration 
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was markedly reduced (Figure 5.7A). The purified samples were then analysed on an 
Agilent Bioanalyzer 2100 using a high sensitivity DNA assay which confirmed that 
the primer dimers had been largely removed (Figure 5.7B). 
 
Figure 5.7: Zmynd10 PCR products were purified with AMPure XP beads prior 
to Ion Torrent sequencing. AMPure XP purification leads to a substantial loss of 
product, although primer    is also reduced. A) PCR products were electrophoresed 
on a 1.5% gel following one and two rounds of purification. B) Following two rounds 
of purification, samples were analysed on an Agilent Bioanalyzer 2100 which revealed 
primer dimers had been largely removed (black arrows). 
5.5.3 Monitoring Genome Editing by Deep Sequencing on an Ion 
Torrent Platform: Ion Torrent Sequencing Results 
Following purification, the samples were transferred to the IGMM technical services 
for sequencing on an Ion Torrent PGM, using a 314 v2 chip to obtain reads up to 400bp 
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in length. After sequencing was complete, a run report was generated by the PGM, 
which revealed that the majority of reads returned were substantially smaller than 
400bp, although there was a small group of reads at this size. Unexpectedly, the run 
report indicated that these shorter reads were not primer dimers and did not contain 
any barcode sequences (Figure 5.8).  
 
Figure 5.8: Run report generated by the Ion Torrent PGM following sequencing 
of MEF pX458 transfections. Not all barcodes shown. Red arrow indicates a small 
group of reads which are of the expected size. 
 
5.5.3.1 The Zmynd10 Ion Torrent Reads Have a High Error Rate which 
Precludes Analysis 
The reads which were generated were aligned and analysed using my proprietary 
pipeline (Section 2.19.1). For all samples, less than 10% of the reads were found to 
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align to the wild-type Zmynd10 reference sequence (ENSMUST00000010188). When 
viewed in the IGV browser, the reads which did align were found to have a high error 
rate but generally provided ~400x coverage across the -7bp deletion region. Given this 
error rate, however, there does not appear to be any significant enrichment in editing 
around the guide target site in the homozygous samples, when comparing GFP-
negative (potentially non-transfected) to GFP-positive (transfected) cells. 
Furthermore, no reads were seen which convincingly demonstrated HDR, as all reads 
which lacked the deletion contained a high number of ‘SNVs’ (single nucleotide 
variants), most likely due to deteriorating quality towards the end of the reads (Figure 
5.9). This high error rate appears to be due to some aspect of the in-house, IGMM Ion 
Torrent processing pipeline as it was not seen when mTmG samples were processed 




Figure 5.9: Screen capture from the IGV browser showing the alignments of Ion Torrent reads from the B6 control and a GFP-
negative and GFP-positive sample against the reference, wild-type sequence for Zmynd10. Here, grey bars indicate uniquely aligned 
reads, white bars reads which aligned to multiple positions, black bars deletions and purple bars insertions. Furthermore, SNVs are 
indicated with coloured bars. Regions of interest have then been highlighted in red. 
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5.5.3.2 A Low Rate of Editing is evident in the Heterozygous, GFP-
Positive Populations 
Alignments of the heterozygous samples to the reference revealed several potential 
variants which appeared to be almost exclusively present on the wild-type, non-
deletion allele, one of which (a G to C transition) may affect Z10 R guide binding 
(blue, Figure 5.10). Despite this, the cleaner signal in the heterozygous control sample 
(1Bl) allowed comparisons to be made between the editing rates in the transfected, 
sorted samples. This revealed that limited rates of editing above background could be 
detected in the GFP-positive cells, ~8%, whereas no editing could be detected in the 
GFP-negative cells (Figure 5.11). However, this rate of editing, post-selection, was 
substantially lower than expected, indicating that either the vector or the guide are 
highly inefficient. 
 
Figure 5.10: Ion Torrent alignments against the Zmynd10 reference sequence 
reveal several potential variants in the heterozygous line. Screen capture from the 




Figure 5.11: A limited rate of editing can be detected in Zmynd10 -7bp deletion heterozygous MEFs following Z10 R pX458 
transfection and sorting for GFP-positive cells. Screen capture from the IGV browser. Regions of interest are highlighted above in red.  
Insertions, deletions and SNVs in reads at the cut site of guide Z10 R (black box) were used to calculate an overall variant rate for each 
sample.  The corresponding values for 4Bl and 4Gr are 8.7% and 19.1% respectively. 
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5.6 Sanger Sequencing of the Locus Reveals No Variants 
Given the low efficiency of editing (~8%), I decided to verify that the sequence in our 
mouse lines matched the reference sequence (ENSMUST00000010188) which was 
used for guide and repair template design, as several potential variants could be seen 
in the Ion Torrent data. Two sets of primers were designed to sequence an ~1000bp 
region around the -7bp deletion (Section 2.5.5). With them, a PCR amplification was 
performed using Phusion HSII polymerase (Section 2.6) on three genomic DNA 
samples from C57BL/6J mice, BALB/cJ x C57BL/6J F1 hybrids and Zmynd10 -7bp 
deletion homozygous mice. Gel electrophoresis revealed that each PCR amplification 
had produced a single, strong band (data not shown). The resulting PCR products were 
therefore submitted for Sanger sequencing by the IGMM technical services (Section 
2.9). The returned sequences were aligned against the Ensembl reference sequence 
using the NCBI nucleotide BLAST server (https://blast.ncbi.nlm.nih.gov/Blast.cgi). 
Unexpectedly, given the variability in the Ion Torrent results, Sanger sequencing 
revealed that all three mouse lines contain the reference sequence from Ensembl with 
no changes (besides the -7bp deletion), indicating our guides and repair templates 
should be functional. 
5.7 Low Rates of Editing are Detected Post-Puromycin 
Selection with pX459 
Given the low rates of editing seen in the Ion Torrent sequencing (~8%), along with 
the results of Sanger sequencing in the previous section, I concluded that the limiting 
factor was most likely the pX458 plasmid. Therefore, I decided to clone (Section 2.2.1) 
the three guides into an alternative expression vector, pX459, which is derived from 
the same backbone as pX330 (Section 2.2.2.3). As pX459 contains a puromycin 
resistance cassette, it also allows selection of successfully transfected cells, allowing 
us to circumvent the variable transfection efficiencies seen with pX330 (Chapter 3).  
5.7.1 Puromycin Kill Curve Optimisation in MEFs 
Prior to undertaking any transfections with the pX459 plasmids, I carried out a 
puromycin kill curve using (non-transfected) Zmynd10 -7bp deletion homozygous and 
heterozygous MEFs. The results of this experiment revealed that a concentration of 
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6µg/ml puromycin was required to achieve 100% cell death in a non-transfected 
population of MEFs within 24 hours (data not shown). 
5.7.2 Zmynd10-/- MEF Transfections with pX459 
Six transfections were performed using the Neon 100µl tips (Section 2.12.1.1) into 
Zmynd10 -7bp deletion homozygous MEFs: 
 
The cells were allowed to proliferate for 24 hours post-transfection, at which point all 
wells had reached confluency. The media was then replaced with puromycin selection 
media (6µg/ml). At this time-point plasmid expression should be at its highest 
(DeWitt, Corn et al. 2017). After twenty-four hours incubation, the selection media 
was removed, at which point a small number of cells remained in the control well (well 
6), although substantially less than in the other wells. All wells were then allowed to 
recover and proliferate for 96 hours, before DNA was extracted (Section 2.4.1.1). 
DNA extractions were quantified on a Nanodrop spectrophotometer (Section 2.4.3) 
and then diluted to ~100ng/µl. PCR amplifications were carried out (Section 2.6) using 
the Zmynd10 genotyping primers (Section 2.5.3). Gel electrophoresis indicated PCR 
amplification had been successful, with clear bands of the expected size produced for 
each sample (data not shown), therefore PCR products were submitted for Sanger 
sequencing (Section 2.9).  
5.7.3 Sanger Sequencing Reveals Negligible Rates of Editing with pX459 
in MEFs 
Sequence traces were inspected using the FinchTV software (Geospiza Inc.). pX459-
transfected samples were compared against the no DNA, electroporation control (well 
6). Sequencing revealed very limited editing with the Z10 R guide, even following 
puromycin selection. Z10 R2 and Z10 F appeared to elicit somewhat higher rates of 
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editing, although the edited sequence traces were still substantially weaker than the 
wild-type trace (Figure 5.12). Given the very low editing efficiencies seen, I decided 
not to continue with deep sequencing to attempt to identify HDR. 
 
Figure 5.12: Sanger sequencing reveals very low rates of editing following pX459 
transfection and puromycin selection in Zmynd10 MEFs. Sequence traces were 
visualised using the Finch TV software (Geospiza Inc.). For each guide the first base 
of the PAM site has been highlighted in blue. 
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5.8 Bypassing Transcription – RNPs are Able to Drive High 
Rates of Editing 
In this work, we have observed a significant discrepancy between the pX330 plasmids 
used to efficiently generate the Zmynd10 mutant mice and the pX458/pX459 plasmids 
used to elicit a repair editing event, despite both containing the same editing machinery 
and gRNA sequences driven by the same promoter. We are unable to explain the very 
low efficiency of editing in positively selected cells via the pX458 or pX459 plasmids, 
as each clone contained sequence identical to that deposited in AddGene 
(www.addgene.org/). We also tested using the pX458 plasmid with different gRNAs 
to target another PCD candidate gene, Wdr92, by pronuclear injection in mice and 
these injections also showed no evidence of editing in any of the founders screened 
(data not shown). One possibility is that the P2A self-cleaving peptide between the 
Cas9 and selection marker leaves a small peptide fragment on Cas9 which significantly 
decreases its activity, particularly in mouse cells. To bypass these technical limitations, 
I directly delivered the same guide-RNAs together with the Cas9 nuclease protein in 
ribonucleotide protein complexes (RNPs). As this circumvents tissue-specific 
limitations on transcription and translation, it may be more efficient and comparable 
between cell types. Furthermore, I had previously seen high rates of editing (>30%) in 
my own hands using RNP complexes in the mTmG MEFs (Figures 3.36, 3.37). 
5.8.1 Zmynd10-/- MEF RNP and ssODN Repair Transfection 
Guide-RNAs were synthesised for each target sequence (Section 2.2.3), complexed 
with GeneArt Platinum Cas9 Nuclease (Thermo Fisher), and electroporated into 





I decided to focus on guides Z10 R2 and Z10 F as they had shown clearer evidence of 
editing with the pX459 plasmid (Figure 5.12).  Forty-eight hours post-transfection 
DNA was extracted from all wells (Section 2.4.1.1) and PCR amplifications were 
performed (Section 2.6) using the Zmynd10 genotyping primers (Section 2.5.3). PCR 
amplifications were then purified (Section 2.4.2). 
5.8.2 Surveyor and Restriction Enzyme Digest Results Are Inconclusive 
The purified PCR products were digested with MlucI (Section 2.4.4.1) to attempt to 
detect repair. The -7bp deletion removes this cut site, which is exactly mid-way 
through the PCR product, and hence homozygous mutants will show a single, 314bp 
band. Repaired alleles will then be detected by their smaller size post-digestion, at 
150bp and 164bp. Furthermore, a Surveyor assay was carried out (Section 2.4.4.2) to 
estimate overall rates of mutagenesis. Purified PCR products, MlucI digests and 
Surveyor products were visualised on a 2% agarose gel (Figure 5.13). The gel revealed 
that the PCR and purification were successful, although no bands indicative of HDR 
could be seen. The Surveyor assay indicated that mutagenesis may have occurred via 
the reduced intensity of the main band at ~310bp in wells 2 and 3, although any lower 
bands were very faint, suggesting a large range of products may have been produced. 
In order to gain a better understanding of the rates of mutagenesis, all three PCR 




Figure 5.13: Surveyor and restriction enzyme digest results are inconclusive 
following RNP transfection into Zmynd10-/- MEFs. Products were electrophoresed 
on a 2% agarose gel. L= 1kb Plus DNA Ladder (Thermo Fisher). 
5.8.3 Sanger Sequencing Reveals a High Frequency of Editing 
Sequence traces were visually inspected using FinchTV (Geospiza Inc.), revealing a 
substantial decrease in wild-type signal 3’ of the cut sites for both guides, suggesting 
>50% rate of mutagenesis (Figure 5.14). Based on this, I decided to TOPO-clone 




Figure 5.14: Sanger sequencing reveals a high rate of editing following RNP 
transfection into Zmynd10-/- MEFs. Sequence traces were visualised using the 
FinchTV software (Geospiza Inc.). Cut sites for each guide have been indicated (black 
arrow). 
5.8.4 TOPO-Cloning Reveals a Very High Rate of NHEJ Following RNP 
Transfection with Evidence of Partial Repair 
The purified PCR products for Z10 R2 and Z10 F were TOPO-cloned (Section 2.8), 
and 96 clones from each were submitted for Sanger sequencing (Section 2.9). 
Sequences were then aligned against the Zmynd10 reference sequence using SnapGene 
(GSL Biotech LLC) and editing outcomes were manually quantified for each guide 
(Figure 5.15A). This analysis revealed very high rates of editing following RNP 
transfection with both guides, at ~80%. Furthermore, the alignments revealed one 
clone (transfected with Z10 R2 RNP and Z10 R2 Asym ssODN) which had undergone 
HDR, repairing the -7bp deletion and mutating the PAM site (Figure 5.15B, clone 31). 
Unexpectedly, however, this clone contained a novel deletion 3’ of the -7bp deletion 
site, despite the fact that the mutated PAM site should have abolished cleavage. We 
hypothesised that this may be due to microhomology at the locus or in the repair 
template, however microhomology prediction (Bae, Kweon et al. 2014) failed to 
identify the residues surrounding the novel deletion. The existence of errors following 
repair, even with PAM-blocking mutations, has been documented, although it is 
relatively infrequent (two- to ten-fold less than ‘scarless’ repair). It is hypothesised it 
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could be due to prior or concomitant use of the NHEJ pathway (Paquet, Kwart et al. 
2016). 
 
Figure 5.15: TOPO-cloning reveals an editing rate of ~80% following RNP 
transfection in Zmynd10-/- MEFs. A) Sequences from TOPO-cloning were aligned 
against the wild-type reference for Zmynd10 using SnapGene and alignments were 
manually quantified for editing. B) SnapGene alignments revealed one clone 
transfected with Z10 R2 (Reverse2) and ssODN repair (clone 31) which had undergone 




5.9 Is the mTmG System a Good Predictor of Editing at Other 
Loci? - Dual Transfections into mTmG MEFs 
As we had found a method, RNP transfection, which can generate high rates of editing 
at both the Zmynd10 -7bp deletion locus and visually in the mTmG system, we wanted 
to investigate whether there is a correlation between editing at the two loci. If so, this 
would provide preliminary evidence that an individual cell’s permissiveness for 
editing by CRISPR is similar across the genome, and thus that we can extrapolate 
results gained with the mTmG system to alternative, disease-causing loci. In order to 
test this, immortalised heterozygous mTmG MEFs were transfected with both LoxP#1 
RNP (Section 3.16.2) and Z10 R2 RNP complexes simultaneously using the Neon 
10µl tips (Section 2.12.1.3): 
 
Seven days post-transfection each well was imaged at 20x on a Nikon A1R confocal 
microscope, which revealed a high number of GFP-positive cells in both well 2 and 3 
(Figure 5.16A). Therefore, all three wells were sorted on a BD FACSJazz, separating 
the visually edited cells (Q2-Q4) from the Tomato-only population (Q1) (Figure 
5.16B). Furthermore, an unsorted population was kept for comparison. DNA 
extractions were then taken (Section 2.4.1.1) and PCR amplifications were performed 
(Section 2.6) using the Zmynd10 genotyping primers (Section 2.5.3) which produced 




Figure 5.16: Dual transfections with Zmynd10 and mTmG RNP complexes in 
heterozygous mTmG MEFs. A) Seven days post-transfection each well was imaged 
at 20x. Scale bar 200µm. B) Eight days post-transfection each well was sorted, 
separating Tomato-only cells in Q1 (top-left quadrant) from visually edited cells in 
Q2-4. C) PCR amplifications were performed across the Zmynd10 -7bp deletion locus 
in sorted and unsorted populations and products were visualised by gel electrophoresis 
on a 2% agarose gel. Here R = Q1 and O = Q2-4 on the FACS plot. L = 1kb Plus DNA 





PCR amplifications were submitted for Sanger sequencing (Section 2.9), and sequence 
traces were then visually inspected using FinchTV. Unexpectedly, no editing could be 
detected at the Zmynd10 locus in the visually edited mTmG MEFs (Figure 5.17A), 
however there appeared to be a SNV present which may affect guide binding. 
Therefore, the sequence from the non-transfected (heterozygous mTmG) control was 
aligned to the Zmynd10 reference sequence using nucleotide BLAST (NCBI). This 
revealed the presence of two variants in our mTmG line (Figure 5.17B), which is on 
an out-bred rather than B6 background. One of these variants is located proximal to 
the PAM site for Z10 R2 (Figure 5.17A, arrow) and also disrupts the PAM site for Z10 
F, therefore, cleavage rates would be expected to be substantially reduced with both 
guides. If cleavage did occur, the locus may be repaired based on the sequence of the 




Figure 5.17: No editing was detected at the Zmynd10 -7bp deletion locus in the 
heterozygous mTmG MEFs due to the presence of SNVs. A) Sequence traces were 
visualised using FinchTV (Geospiza Inc.). No editing could be seen at the Zmynd10 
locus in the samples transfected with Z10 R2, however a SNV (black arrow) may have 
affected binding. The predicted cut site for Z10 R2 has been highlighted in blue. B) A 
nucleotide BLAST (NCBI) alignment of the heterozygous mTmG sequence (Sbjct) 
against the reference sequence (Query) reveals two SNVs (red box) which will affect 
binding of both Zmynd10 guides. These two SNVs were also present and variable in 





5.10 Conclusions and Future Work 
The results of this chapter highlight the inherent variability in the genome, which can 
be substantial even within species. Therefore, it is prudent to sequence across the locus 
one wishes to target in one’s strain of interest prior to designing any reagents for 
genome editing. The implications of this also carry through to a therapeutic context, 
wherein it may be necessary to sequence each patient before designing a bespoke 
intervention. Furthermore, Cas9 expression vectors may have markedly different 
efficiencies in different cell types, potentially due to the promoter employed. 
Alternatively, the direct delivery of Cas9 in RNP complexes may offer high rates of 
editing in many cell types without need for such considerations. Moreover, the short 
~24 hour residency time of RNPs may reduce the frequency of off-target editing 
(DeWitt, Corn et al. 2017), which is critical in a therapeutic context. 
In the future, it will be necessary to repeat the Zmynd10 RNP and repair transfections 
in MEFs, potentially employing a plasmid repair template whose longer regions of 
homology may increase HDR (Hendel, Kildebeck et al. 2014, Li, Wang et al. 2014). 
If repair were detected, it would then be apt to employ the same conditions in a motile 
ciliated cell type such as ependymal cells, and assay whether a) the sequence can be 
corrected and b) whether repair at the Zmynd10 locus leads to functional correction in 
terms of restoring ciliary motility. If this is the case, it would be exciting to attempt to 
employ these reagents in vivo in the Zmynd10 mouse model at several different stages 
(e.g. blastocyst or post-natal) and determine whether the PCD phenotype can similarly 
be rectified. Furthermore, it will be necessary to repeat the experiment in the mTmG 
MEFs using novel guides which target regions unaffected by SNVs. If there is a 
correlation between editing at the mTmG locus and the Zmynd10 locus, this will have 
far-reaching implications about editing efficiencies between ubiquitously expressed 





Chapter 6 Concluding Remarks 
The allure of gene therapy lies in its potential, theoretically, to correct the underlying 
causes of all genetic diseases, whether inherited or acquired. However, despite being 
initially postulated as early as 1970, we still face many of the issues discussed in the 
first comprehensive review by Friedmann and Roblin (1972); such as efficient delivery 
of the DNA, targeting of the correct cell types, preventing an immune response, and 
ensuring correct regulation. Recent work with delivery vectors, in particular AAV 
(Baruteau, Waddington et al. 2017, Gray-Edwards, Randle et al. 2017, Guggino and 
Cebotaru 2017, Wells 2017, Yu, Mookherjee et al. 2017), is addressing the first three 
concerns, while SSN-mediated genome editing provides us with a novel, potentially 
safer, modality which, via HDR, should assist with ensuring correct regulation. To 
date, however, there remain no good models to test and optimise gene therapy by gene 
correction, in particular with the revolutionary CRISPR/Cas9 system (Stella and 
Montoya 2016).  
Given this, the mTmG reporter system we have developed should provide invaluable 
preclinical results regarding in vivo editing and repair driven by CRISPR/Cas9 and 
allow optimal reagents and protocols to be swiftly developed for the targeting of any 
tissue. To this end, I foresee that this system could also be repurposed, with appropriate 
imaging or FC/FACS technology, to undertake small molecule screens to identify 
novel enhancers of HDR, in various tissue-specific cell lines. However, further work 
needs to be done in comparing the editing seen at the mTmG locus with other loci, to 
determine how broadly applicable the results are. The advent of single cell sequencing 
(Huang, Ma et al. 2015) will allows us to comprehensively demonstrate simultaneous 
editing at the mTmG locus and disease-causing loci, while single cell RNA sequencing 
(Kolodziejczyk, Kim et al. 2015) will allow us to probe the effects of any editing 
achieved on a cell-by-cell basis, including, for example, the induction of DNA damage 
or repair proteins; providing important mechanistic insights. 
Before CRISPR/Cas9 can be applied therapeutically, however, certain concerns must 
be addressed. Chief of these is the prospect of off-target editing leading to adverse 
outcomes, in particular oncogenesis. Whilst it appears as if off-target mutagenesis can 
generally be predicted and occurs at low levels in cell lines (Section 1.5.1), due to 
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inherent genomic variability in a natural population it will be harder to predict the on- 
and off-target efficiencies of a certain guide sequence with accuracy. Indeed, each 
individual in the 1,000 genomes project contains 4 to 5 million variants relative to the 
reference (Lessard, Francioli et al. 2017). Prior to undertaking any work, it is therefore 
wise to carefully profile the off-target sites of chosen guides and discard any which 
have <5 mismatches in and around known oncogenes. Furthermore, with the reducing 
cost of NGS (Weymann, Laskin et al. 2017), it may become feasible to undertake WGS 
in each patient prior to designing a targeting strategy. Alternatively, novel methods of 
detecting and sequencing CRISPR/Cas9-mediated DSBs (Tsai, Zheng et al. 2014, 
Tsai, Nguyen et al. 2017) may allow a preclinical evaluation of each guide on a patient-
by-patient basis. However, given the incredibly high, and increasing, specificity of 
novel, engineered Cas9 variants (Chen, Dagdas et al. 2017, Casini, Olivieri et al. 
2018), worries of off-target mutagenesis may soon be laid to rest. 
Focussing specifically on gene therapy for PCD, several preliminary investigations 
have been made into both gene replacement approaches and gene editing/correction 
methodologies. In terms of conventional gene replacement, three studies have been 
carried out. Two of these studies were able to demonstrate at least partial restoration 
of ciliary function in cell culture assays; one used an SIV vector pseudotyped with 
VSV-G (vesicular stomatitis virus glycoprotein G) to transduce DNAI1 cDNA into 
human airway epithelial cells (Chhin, Negre et al. 2009) and the other used a novel 
lentiviral vector pseudotyped with avian influenza hemagglutinin to apically transduce 
mouse tracheal epithelial cells with Dnaic1 cDNA and achieving ~10% restoration of 
ciliary function (Ostrowski, Yin et al. 2014). Interestingly, this second study also used 
the same vector in vivo to transduce control and PCD mice by nasal inhalation and 
found a high level of gene transfer to control animals but little/no transfer to PCD 
mice; likely due to the inhibitory effect of mucus (Ostrowski, Yin et al. 2014). 
Conversely, a separate study has shown a significant improvement in the ciliopathy 
phenotype of ORPK (Oak Ridge Polycystic Kidney) mice, who display anosmia and 
a failure to thrive, following intranasal injection with IFT88–GFP adenovirus. 
Transduced ORPK mice displayed a restoration of ciliary structure on the olfactory 
neurons and an ~60% increase in weight at 3 weeks of age (McIntyre, Davis et al. 
2012); although in this model mucus plugs are likely not an issue.  
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Many of the genes which are currently known to cause PCD, however, are much too 
large to fit into commonly used gene replacement vectors (e.g. DNAH11 is ~14kb 
(Lai, Pifferi et al. 2016) versus a maximum packaging capacity of ~8kb for lentivirus 
and adenovirus (Boink and Robinson 2014)). Gene editing approaches therefore allow 
the field of PCD gene therapy to sidestep these packaging constraints by specifically 
correcting the mutated base(s) in the patient’s genome. One study has investigated this 
approach so far. In this study airway epithelial cells were collected from two patients 
with nonsense mutations in DNAH11. These cells form spheroids which do not rotate 
in culture. However, following transduction with vectors encoding left and right 
TALENs and a wild-type repair template, ~30% normalisation of ciliary activity was 
seen in spheroids from both patients (Lai, Pifferi et al. 2016); a potentially 
therapeutically relevant proportion of cells. To investigate the level of correction 
needed, a separate study, which utilised a floxed Dnaic1 gene to mosaically delete 
Dnaic1 in the airways of mice, demonstrated that mucociliary clearance began to be 
detected at low levels when Dnaic1 protein levels rose above 15% in some animals 
(Ostrowski, Yin et al. 2014); a seemingly achievable target.  
However, for gene therapy to progress to the clinic, several concerns must be 
addressed which are pertinent to both gene replacement and gene editing strategies. 
These concerns chiefly regard immunogenicity; of the delivery vector, of the nuclease 
employed (if any), and of the protein of interest which has been reintroduced. Much 
work has already been done on engineering delivery vectors to increase their 
specificity to their target cells and reduce any potential immune response (e.g. Martino, 
Basner-Tschakarjan et al. (2013), Lisowski, Dane et al. (2014)), while any immune 
response to the nuclease could be reduced by employing transient expression or 
inducible systems (Cao, Wu et al. (2016), Liu, Ramli et al. (2016), Lu, Zhao et al. 
(2018), Senturk, Shirole et al. (2017)) and/or tagging the nuclease for degradation (Tu, 
Yang et al. 2017). Regarding the potential for an immune response to the reintroduced 
protein (which may never have previously been present in its entire, correctly folded 
form), a recent study demonstrated expansion of corrected hepatocytes containing 
wild-type Fah protein in vivo following CRISPR-Cas9-mediated repair; indicating no 
substantial immune response to the protein which was only previously present in a 
severely truncated, and then degraded form (Yin, Xue et al. 2014). However, this may 
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need to be investigated on a gene-by-gene, and by tissue basis. Furthermore, 
oncogenesis is always a concern if an integrating vector (such as lentivirus) is 
employed, however, it is possible to profile via sequencing the integration sites of the 
vector thoroughly prior to moving into the clinic (Afzal, Wilkening et al. 2017), and it 
may also be possible to direct vectors specifically to safe-harbour sites (Rio, Banos et 
al. 2014). 
Finally, in order for any treatment to be of significant benefit, it has to be accessible to 
patients. The first commercialised gene therapy treatment, Glybera (alipogene 
tiparvovec), an AAV-mediated approach for the ultra-rare disorder lipoprotein lipase 
deficiency (European Biotechnology 2017), appears to have failed at the first hurdle. 
With its incredibly high cost, $1,000,000 per treatment, and limited efficacy, it was 
withdrawn from the market in the US after being given to only one patient, despite its 
safety profile. Furthermore, Glybera was not recommended for national 
reimbursement in any European country (Senior 2017). The second gene therapy 
treatment to be approved, Imlygic (talimogene laherparepvec), for melanoma, has 
currently fared little better. In the UK, the only country where it has currently been 
assessed, it was deemed not cost-effective and in need of greater supporting evidence 
(Touchot and Flume 2017).  
These initial forays into commercialising gene therapy highlight the need for a product 
which delivers substantial improvements in terms of its clinical end-points and a 
suitable pricing model. There is, however, a recent success story in Strimvelis 
(GlaxoSmithKline), an ex vivo, gammaretrovirus-based stem cell gene therapy for 
ADA-SCID (severe combined immunodeficiency due to adenosine deaminase 
deficiency). Since 2000, over 40 patients have been treated with a 100% survival rate, 
75% disease-free (Booth, Gaspar et al. 2016). It was approved in Europe in 2016, and 
the Italian Medicines Agency, AIFA, has agreed to reimburse the €594,000 cost. 
Critically, the cost of Strimvelis treatment is less than lifelong enzyme replacement 
therapy for ADA-SCID patients (Touchot and Flume 2017). Therefore, Strimvelis 
should provide a guiding light for the many gene therapies currently in clinical trials. 
Furthermore, the uptake of highly modular, ‘personalised’ gene correction strategies 
using CRISPR/Cas9 should only reduce costs in safety testing and increase 
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efficiencies, potentially bringing about the revolution of gene therapy first discussed 
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